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Effect of a maternal inflammatory challenge during the preimplantation period 
on offspring development and phenotype 
 
by Charlotte Lucy Williams 
The preimplantation mammalian embryo is sensitive to its immediate surroundings: 
alterations to its in vitro or in vivo environment can affect not only the immediate 
events of blastocyst formation, but can also give rise to long-term phenotypic 
consequences during fetal and/or postnatal life.  For example, rodent studies have 
shown that maternal under-nutrition during preimplantation gestation can lead to 
increased risk of cardiovascular, metabolic and behavioural abnormalities in the adult 
offspring.   
Do other types of maternal challenge similarly impact on the developmental 
programme with long-lasting consequences?  Infection and injury are common in 
everyday life and normally result in altered homeostasis and generation of an 
inflammatory response.  The aim of my thesis was to study the effects of an 
inflammatory environment during preimplantation development on the phenotype of 
the blastocyst, fetus and offspring postnatally.  In the first part of the study mouse 
embryos were cultured in vitro in the presence of medium only (control) or increasing 
concentrations (1-1000 pg/ml) of the inflammatory cytokine, interferon γ (IFN-γ).  The 
second part of the study focused on an in vivo model of maternal systemic 
inflammation where saline (control), 10, 50 or 150 μg/kg lipopolysaccharide (LPS) was 
administered intraperitoneally (i.p.) to female mice on gestational day 0.5 (GD 0.5).   
In vitro culture of mouse embryos with select higher concentrations of IFN-γ 
resulted in a greater proportion of cavitated embryos (1000 pg/ml) and reduced inner 
cell mass (ICM) cell number (10 and 1000 pg/ml) without affecting trophectoderm (TE) 
cell number.  In vivo, generation of a maternal systemic inflammatory response to LPS 
administration was confirmed initially.  LPS treatment induced sickness behaviour, 
weight loss and increased the serum concentration of several cytokines, e.g. 
interleukin-1β (IL-1β) and tumour necrosis factor-α (TNF-α).  Prenatally, the maternal 
inflammatory challenge resulted in reduced ICM cell number and reduced ICM:TE cell 
ratio in GD 3.5 blastocysts, but did not affect the number of embryos generated or GD 
17 litter size.  Furthermore, the GD 17 conceptus was normal in terms of weight of the 
extra-embryonic tissues and fetal organs.  Postnatally, the systemic maternal 
inflammatory challenge did not alter litter size, birth weight or growth, but did result in 
altered behaviour, organ/body weight ratios and immune status of adult offspring.  In 
particular, male offspring from 150 μg/kg LPS treated mothers displayed reduced 
levels of locomotor and exploratory related activity, increased mass of specific fat-pads 
and increased body mass index (BMI).  Furthermore, male offspring from 150 μg/kg 
LPS treated mothers displayed altered splenic T and B lymphocyte populations with the 
percentage of B lymphocytes reduced and the percentage of T lymphocytes increased.  
Both male and female offspring from LPS treated mothers had lower concentrations of   3 
a number of serum cytokines and chemokines, either basally or after directly receiving 
their own LPS challenge.   
My work using a mouse model has shown that maternal inflammation during 
preimplantation gestation can permanently change the developmental programme, 
leading to altered adult phenotype, affecting diverse physiological systems.  This study 
implicates maternal immune status during very early gestation as critical in the health 
of the next generation.   
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1  Introduction 
1.1  Preimplantation mouse embryo development 
1.1.1  Morphological aspects of preimplantation development 
The process of preimplantation development begins after fertilisation and culminates at 
gestational day (GD) 4.5 when implantation occurs (Johnson and McConnell, 2004).  
Thus, the primary morphological aim of preimplantation development is to produce an 
implantation-competent blastocyst comprising two distinct cell lineages; the extra-
embryonic trophectoderm (TE) that will eventually form the placanta; and the 
embryonic inner cell mass (ICM) that will give rise to the fetus.  The single-cell zygote 
undergoes a total of 7 cleavage divisions to become a blastocyst containing 128-
blastomeres (Fig. 1.1) and there is no net growth over this period, so each blastomere 
becomes progressively smaller with each cleavage division (Johnson and McConnell, 
2004).   
The first three cleavage divisions produce an embryo composed of 8 spherical, 
loosely-associated and non-polarised blastomeres (Fig. 1.1c).  The process of TE 
differentiation begins at the late 8-cell stage (approximately 10 hours after cleavage to 
the 8-cell stage) when the embryo becomes compact (Johnson and McConnell, 2004).  
At the time of compaction, all 8 blastomeres maximise cell-cell contact by flattening 
onto one another, and undergo both intercellular adhesion and apico-basal axis 
polarisation (Fig. 1.1d).  The outer apical surface of each blastomere has a stable 
population of microvilli and is non-adhesive, and the inner basolateral surfaces are 
adhesive and microvilli-free (Fleming et al., 2004b).  Flattening events co-ordinated by 
the calcium-dependent E-cadherin/catenin system (components of the adherens 
junction) seem to play a key role in correctly orientating the blastomeres for 
generation of inner- and outer-cells in subsequent rounds of division (Fleming et al., 
2004b; Johnson et al., 1986).  When cleavage stage embryos are incubated with anti-
E-cadherin antibodies, cellular polarisation still occurs but happens over a more 
protracted time course and along random axes.  In addition, junctional formation and 
blastocoel formation still take place but ICM is absent or greatly reduced (Johnson et 
al., 1986).   
Cell polarity attained at compaction provides blastomeres with the essential spatial 
organization to give rise to divergent cell lines at the fourth cell division.  Division of 
polarised 8-cell blastomeres gives rise to the 16-cell morula which is composed of two   22 
distinct cell types (Fig. 1.1e): the outer, polar cells of the TE lineage and the inner, 
non-polar cells of the ICM (Johnson and McConnell, 2004).  The polarised microvillus 
surface and cortical phenotype is maintained during mitotic cell division, but the 
cytoplasmic polarity is transiently lost; thus, the cytocotical pole effectively provides 
the cell with a memory of polarity (Johnson et al., 1988).  Cell division is either parallel 
or perpendicular to the axis of cell polarity: division parallel to the axis of cell polarity 
is a conservative division because the apical pole is bisected and inherited by both 
daughter cells; division perpendicular to the axis of cell polarity is a differentiative 
division since the apical region is not bisected (Johnson and McConnell, 2004).  
Therefore, one daughter cell is polar because it receives the microvillous apical region, 
whereas the other daughter cell is non-polar because it receives only the basolateral 
cell surface.  In a fifth cell cycle (16- to 32-cell transition) the outer, polar blastomeres 
engage in another round of differentiative or conservative division in order to complete 
the process of lineage segregation within the embryo.  If the first allocation (8- to 16-
cell transition) of cells to the ICM is relatively small then the embryo can compensate 
by a relatively large allocation in the second round (16- to 32-cell transition) and vice 
versa (Fleming, 1987; Johnson and McConnell, 2004).   
 
Figure 1.1  Diagram of preimplantation mouse embryo development from the 1-cell to the 
implantation-competent blastocyst stage (A-G).  Epi, epiblast; PE, primitive endoderm; Abemb.-
Emb., abembryonic-embryonic axis (Rossant and Tam, 2009). 
The embryo described thus far is a morula:  a densely clustered ball of 32-cells that 
does not have an internal cavity.  In order for the 32-cell morula to become a 
blastocyst, it must undergo the process of cavitation.  During cavitation the outer,   23 
polarized cells of the 32-cell embryo transport fluid transcellularly into the morula in 
order to create a fluid filled blastocoel cavity lying between the TE and ICM (Fig. 1.1f).  
Two major maturational events of the TE are essential for the success of cavitation and 
maintenance of the blastocoel.  Firstly, the tight junctions between the TE cells must 
be fully formed so that there is a stable permeability seal around the blastocoel to 
prevent leakage of the blastocoel fluid.  Secondly, the Na
+/K
+-ATPase in the 
basolateral membrane must be fully functioning, as it is this that is responsible for 
producing the ATP-dependent ion transport required to drive water down its osmotic 
gradient into the blastocoel.  The blastocoel cavity is fully expanded by the 64 cell 
stage and by the 128-cell stage (GD 4.5) a third cell lineage is apparent (Johnson and 
McConnell, 2004).  This cell lineage is the primitive endoderm (PE; Fig. 1.1g) and 
forms on the surface of the ICM adjacent to the blastocoel cavity and will form the 
extraembryonic parietal and visceral endoderm, which will eventually form the yolk sac 
(Rossant, 2004).  At this stage the embryo hatches from its zona pellucida, a 
glycoprotein-rich acellular coating, and begins the process of uterine attachment and 
implantation (Johnson and McConnell, 2004).   
1.1.2  Zygotic genome activation 
Zygotic genome activation (ZGA) is the first major developmental event that occurs 
following fertilization and is essential for development; 2-cell embryos do not cleave 
any further when cultured in the presence of the RNA polymerase II inhibitor, α-
amanitin (Zeng and Schultz, 2005).  During ZGA the developmental programme that is 
initially directed by maternally inherited components is replaced by the new 
programme that is coded for by the embryos own genome (Schultz, 2002).  ZGA has 
at least three functions that are essential for developmental progression.  The first is to 
destroy oocyte-derived mRNA transcripts.  The second is to replace maternal 
transcripts with zygotic ones for those common cellular components (e.g. actin) that, if 
not replaced, will result in developmental arrest due to the inability to execute basic 
cellular functions.  The third is to promote the reprogramming of gene expression that 
is coupled with generation of novel transcripts that are not expressed in the oocyte 
(Schultz, 2002).  The third function is likely responsible for driving the transformation 
of the differentiated oocyte into the totipotent blastomeres of the 2-cell embryo.   
ZGA has occurred by the 2-cell stage and there is some evidence demonstrating 
that the 1-cell embryo is, at least partly, transcriptionally active (Aoki et al., 1997; 
Wang et al., 2004).  For example, Aoki et al. found that BrUTP incorporation in the 1-  24 
cell embryo was approximately 20% that of the 2-cell embryo (Aoki et al., 1997). 
However, intriguingly, a microarray analysis found that the 1-cell embryo contained no 
α-amanitin-sensitive gene transcripts; which suggested that there was no de novo 
generation of mature mRNA transcripts (Zeng and Schultz, 2005).  Upon these 
findings, the authors suggested that the 1-cell embryo is transcriptionally active, but 
lacks the ability to produce polyadenylated, translatable mRNA (Zeng and Schultz, 
2005).  This theory is supported by other lines of evidence suggesting that 
transcription and translation may be uncoupled processes in the 1-cell embryo.  For 
example, when the plasmid-borne luciferase reporter gene was injected into 1-cell 
embryos, luciferase mRNA was detected whereas luciferase activity was not detected 
until after cleavage to the 2-cell stage (Nothias et al., 1996).  This group also showed 
that transcription and translation were temporally tightly coupled events if the 
luciferase gene was injected at the 2-cell stage (Nothias et al., 1996).  This finding 
thus demonstrated that transcription and translation are uncoupled processes in the 1-
cell embryo.   
In the 2-cell embryo soon after ZGA, a chromatin-based transcriptionally repressive 
state becomes apparent, where efficient gene transcription requires the presence of an 
enhancer (Schultz, 2002).  Inducing histone hyperacetylation relieves the repressive 
state and the requirement for an enhancer (Wiekowski et al., 1993).  Such a 
repressive state could be critical for the precise and controlled regulation of important 
sequential developmental events.  Interestingly, microarray analysis has shown that 
the types of genes expressed selectively in the 2-cell embryo are those involved with 
ribosome biogenesis and assembly, protein synthesis, RNA metabolism and 
transcription (Zeng and Schultz, 2005).  This analysis also implicated that the two 
genes, c-Myc and Hdac1 (Histone deacetylase 1), may be seminal components 
involved in the expression of crucial developmental genes and production of the 
transcriptionally repressive state, respectively (Zeng and Schultz, 2005).  Indeed, 
ablation of c-Myc function in 2-cell embryos post-ZGA resulted in the arrest of almost 
all embryos at the 8-cell-morula stage (Paria et al., 1992).   
1.1.3  Cell lineage specific transcription factors 
Lineage specification of the pluripotent ICM is regulated by restricted expression of key 
transcription factors, which include Oct4 (also called Pou5f1), Sox2 and Nanog.  Oct4 is 
expressed in the oocyte and all blastomeres of the cleavage stage embryo but by the 
blastocyst stage, expression is restricted to the ICM (Ovitt and Scholer, 1998).  Oct4-  25 
deficient embryos develop to the blastocyst stage but the ICM cells are not pluripotent 
and are restricted to differentiation along the trophoblast lineage (Nichols et al., 1998).  
Interestingly, Sox2 acts co-operatively with Oct4 to activate transcription of the gene 
encoding fibroblast growth factor 4 (FGF4, Fgf4) in the ICM and thus contributes to 
paracrine growth factor signalling in the blastocyst (Nichols et al., 1998).  Sox2 is also 
expressed in all cleavage stage blastomeres and becomes restricted to the ICM at the 
blastocyst stage (Avilion et al., 2003).  Interestingly, Sox2 expression is maintained in 
the TE and is required for the maintenance of proliferating TE cells, presumably in co-
operation with a factor other than Oct4 (Avilion et al., 2003).  Oct4 and Sox2 are not 
the only factors critical for maintaining pluripotency and repressing differentiation.  
Expression of Nanog is first seen in the inner cells of the late morula and is maintained 
in the ICM at the blastocyst stage (Mitsui et al., 2003).  It seems that Nanog function 
is required for ICM maintenance and repression of PE fate because Nanog-deficient 
ICM cells differentiate into the extraembryonic endoderm lineage (Mitsui et al., 2003).   
Differentiation of the PE and TE depends upon the expression of other sets of 
transcription factors.  Expression of the transcription factor GATA6 is essential for 
development of the PE from the ICM (Koutsourakis et al., 1999).  Interestingly, the 
Gata6 gene contains Nanog binding sites in its enhancer region and GATA6 is 
upregulated in Nanog-deficient cells (Mitsui et al., 2003).  Hamazaki et al. have shown 
that activation of the Grb2/Mek pathway, likely via FGFR signalling, relieves Nanog-
mediated repression of GATA6 expression and thus results in differentiation of PE 
(Hamazaki et al., 2006).  Cdx2 has been found to be essential for TE maintenance 
because Cdx2 null mice fail to implant, which is indicative of a major TE defect prior to 
implantation (Chawengsaksophak et al., 1997).  Blastocyst formation initiates in Cdx2-
null embryos, however Oct4 and Nanog do not become down-regulated in the TE and 
integrity of the TE is lost (Strumpf et al., 2005).  It is clear that lack of Cdx2 does not 
result in the complete inability to form TE cells in the blastocyst, thus suggesting that 
there are other factors upstream of Cdx2.  Recently the transcription factor TEAD4 
(TEA domain family transcription factor 4) has been shown to be required for TE 
formation upstream of Cdx2.  Tead4-null embryos died before implantation, did not 
form a blastocoel and failed to maintain Cdx2 expression (Nishioka et al., 2008).   
Overall, generation of the three cell lineages within the blastocyst seems to depend 
upon localized expression of both positive and negative factors.  Oct4 and Nanog 
promote pluripotent ICM formation, where Oct4 inhibits TE formation and Nanog   26 
inhibits PE formation.  TEAD4 and Cdx2 promote TE formation and inhibit pluripotent 
ICM formation, while GATA6 promotes PE formation and blocks pluripotent ICM 
formation.   
1.1.4  Epigenetic reprogramming 
Different cells and tissues within multicellular organisms acquire different patterns of 
gene expression during development and epigenetic modifications are thought to be 
highly important (Morgan et al., 2005).  These are covalent modifications of DNA (e.g. 
DNA methylation) and core histone proteins (e.g. histone acetylation) that regulate 
gene activity without altering the nucleotide sequence (Godfrey et al., 2007).  
Therefore, each cell within a multicellular organism has its own epigenetic signature 
which reflects genotype, developmental history and environmental influences, and 
ultimately, all of these aspects are reflected in the resulting phenotype (Morgan et al., 
2005).  DNA methylation is associated with transcriptional silencing (generally, 
methylated genes are silenced and hypomethylated gene are induced) and heritability 
of this phenomenon through cell divisions (Bird, 2002).  DNA modification takes place 
post-replication, primarily on cytosine residues (CpG dinucleotides) and often in 
promoter regions.  DNA methyltransferase (Dnmt) enzymes transfer methyl groups on 
to the C5 position of most of the cytosine residues in the genome (Reik et al., 2001).  
During normal development, it is a requirement that cells of the embryo undergo 
major epigenetic ‘reprogramming’, whereby the original epigenetic marks are removed 
and different ones are established (Morgan et al., 2005).  In, particular, this happens 
at fertilization when gamete markers are erased and replaced with embryonic markers 
that are important for early development and pluripotency.  The paternal genome that 
is delivered to the oocyte by the sperm is mostly packaged with protamines rather 
than histones, which is rapidly reversed upon fertilization.  Closely following this 
histone acquisition is the initiation of paternal genome wide loss of DNA methylation 
which is complete before DNA replication begins in the paternal pronucleus (Morgan et 
al., 2005).  Exactly, how and why paternal genome demethylation occurs is unknown.  
However, it is likely that the oocyte cytoplasm contains enzymatic demethylation 
factors that actively catalyse the process, and it seems that this is important for 
returning the specialized gamete genomes back to embryonic pluripotency (Fig. 1.2).     27 
 
Figure 1.2  Reprogramming of methylation in preimplantation embryos.  The paternal 
genome (green) is demethylated by an active mechanism and the maternal genome (pink) by a 
passive mechanism.  Both are remethylated at implantation to different extents in the embryonic 
(EM) and the extra-embryonic (EX) lineages (Reik et al., 2001).   
Global DNA methylation is lost progressively over the course of the first three 
cleavage division by a passive mechanism that is likely due to nuclear exclusion of the 
enzyme (Fig. 1.2), DNA methyltransferase-1 (Dnmt1) (Morgan et al., 2005).  At this 
stage, the only genes that do not become demethylated are the imprinted genes that 
retain their germ line imprints.  It has been postulated that unique histone 
modifications may guide DNA methylation maintenance of imprinted genes (Morgan et 
al., 2005).  By the blastocyst stage, combinations of active and passive demethylation 
result in very low levels of methylation on the genome of the TE cells (Fig. 1.2).  In 
contrast, the ICM shows clear signs of extensive de novo methylation, which may 
begin at the late morula stage (Morgan et al., 2005).  It is possible that this de novo 
methylation is catalysed by Dnmt3b, as this enzyme is synthesised in cells of the ICM 
but not the TE.  It appears that the epigenetic asymmetry established in the blastocyst 
is important developmentally, and it is conceivable that a higher degree of epigenetic 
control is needed in embryonic tissue (i.e. ICM) than in extra-embryonic tissue (i.e. 
TE).  This hypothesis stems from the fact that embryonic tissue derivatives have far 
greater longevity and undergo far more complex differentiation than extra-embryonic 
tissues that have limited differentiation potential and life expectancy (Morgan et al., 
2005).     28 
1.2  Developmental origins of health and disease 
The concept of  ‘developmental origins of health and disease’ (DOHaD) arose from 
human epidemiological studies relating size at birth to altered risk of adult 
cardiovascular disease (Barker and Osmond, 1986) and type 2 diabetes (Hales et al., 
1991).  Many studies have now linked prenatal adversity to the development of a 
range of adult diseases, which are collectively known as metabolic syndrome:  this 
includes coronary heart disease, stroke, insulin resistance, type 2 diabetes, 
hyperlipidaemia, hypertension and obesity (Gluckman and Hanson, 2004b).  This 
implies that the risk of developing some chronic noncommunicable diseases in 
adulthood is influenced not only by an individuals genes and life-style but also by 
environmental factors acting early in life (Gluckman and Hanson, 2004a).  Birth weight 
can act as an indicator of an adverse prenatal environment and is thus a convenient 
parameter to use for making associations with postnatal outcomes in the offspring 
(Gluckman et al., 2007).  However, birth weight is an incomprehensive marker 
because some alterations to the prenatal environment have been shown to result in 
long term phenotypic changes in the offspring without altering fetal growth; for 
example, the offspring of women subjected to under-nutrition in early pregnancy 
during the Netherlands famine did not have reduced birth weight but did have an 
increased risk of obesity (Painter et al., 2005).  It has been proposed that the DOHaD 
concept is a type of developmental plasticity whereby an organism has the ability to 
change its structure and function in response to environmental cues (Gluckman et al., 
2007).  Indeed, developmental plasticity permits the development of a range of 
phenotypes from a single genotype and is well know to occur in other organisms; for 
example, in the locust (Locusta migratoria), wing shape and metabolism are 
determined at the larval stage by pheromone signals indicating population density 
(Applebaum and Heifetz, 1999).   
There is now much evidence from experimental animal models to back up the 
human epidemiological evidence.  Such studies have shown that manipulation of the 
prenatal environment can lead to altered cardiovascular and/or metabolic function in 
later life (Fowden and Forhead, 2004; Gluckman and Hanson, 2004a).  Manipulating 
maternal nutrition by reducing total nutrient intake in a balanced manner, reducing the 
protein intake specifically or exposing the mother to a high fat diet all result in similar 
outcomes e.g. insulin resistance, alterations of the hypothalamic-pituitary-adrenal 
(HPA) axis, disturbances of endothelial function, hypertension and obesity.  For 
example, in rats, calorie restriction throughout pregnancy lead to hypertension in the   29 
adult offspring (Woodall et al., 1996).  Also in a rat model, maternal low protein diet 
throughout gestation lead to hypertension in offspring at weaning (Langley-Evans et 
al., 1994).  Offspring of rat dams fed a high-fat diet throughout pregnancy displayed 
hypertension and blunted endothelium-dependent vascular relaxation to acetylcholine 
(Khan et al., 2003).  Administration of glucocorticoids to the mother is also known to 
produce similar effects; for example, dexamethasone administered to rat dams in the 
last week of pregnancy resulted in adult offspring that displayed hyperglycaemia and 
hyperinsulinaemia (Nyirenda et al., 1998).   
Two conceptual models have been proposed to explain the DOHaD hypothesis.  The 
‘thrifty genotype’ model argued that ‘thrifty’ genes had been evolutionarily selected for 
by virtue of the fact that these genes enabled us to cope more successfully with the 
high energy expenditure and uncertain nutritional intake of our hunter-gather past 
(NEEL, 1962).  However, this explanation was deemed unsatisfactory as it failed too 
explain either the experimental animal data or patterns of disease seen in some 
populations (Gluckman and Hanson, 2004a).  As an alternative, the ‘thrifty phenotype’ 
model was proposed: it stated that the fetus becomes growth retarded in response to 
adverse conditions in utero, and the associated adaptations result in a phenotype 
better suited to a food deprived postnatal environment (Hales and Barker, 2001).  This 
model also had its limitations as it could readily explain the consequences in 
individuals born small, but could not explain how programming could continue to 
operate in individuals born in the upper birth size range, i.e. a well nourished fetus.   
The ‘predictive adaptive response’ (PAR) model has evolved from the ‘thrifty 
phenotype’ model in order to avoid the limitations associated with the latter.  The PAR 
model suggests that the adaptive responses made by the fetus need not necessarily be 
for immediate advantage but may be in expectation of the future post-natal 
environment (Gluckman and Hanson, 2004b).  An important suggestion that is implied 
by the PAR model is that disease risk is a consequence of the extent of match or 
mismatch between the environments that are experienced pre-and postnatally; greater 
risk of disease is associated with greater extent of mismatch (Fig. 1.3).   30 
 
Figure 1.3  The nature of the predictive adaptive response (PAR) is determined by the 
predicted and actual postnatal environment.  The fetus sets a range of homeostatic settings 
appropriate for postnatal life according to the information it receives in utero. If the actual 
postnatal environment matches the prenatal prediction, then the PARs are appropriate and 
disease risk is low; if they do not match, then the disease risk is increased (Gluckman and 
Hanson, 2004b). 
1.3  The effects of altered preimplantation embryo environment 
1.3.1  Embryo culture 
A number of studies show that pre-implantation embryos are sensitive to their 
environmental conditions, and that these conditions may influence their developmental 
programme, not only in the short term, but also in the long term.  Initially it was 
observed that in vitro cultured mouse embryos, after transfer into pseudo-pregnant 
mothers, resulted in reduced fetal growth when compared with their in vivo 
counterparts (Bowman and McLaren, 1970).  Further studies of this sort in mice have 
confirmed these initial findings and have identified culture systems that may act 
deleteriously on embryo development.  It seems that the addition of serum to the 
culture medium is detrimental to development.  Addition of serum to the culture 
medium resulted in fetuses at gestational day 14 that were 20% smaller than those 
derived from embryos cultured in the absence of serum or developing in vivo (Khosla 
et al., 2001).  Conversely, it has been found that the addition of insulin, albumin or 
specific amino acids to the culture medium leads to improved rates of implantation and 
development later in gestation (Kaye and Gardner, 1999; Lane and Gardner, 1997).     31 
Early embryos from cattle and sheep also display sensitivity to their environments.  
Ovine and bovine embryos that have been cultured in vitro, after transfer, often 
produce young that suffer from a condition known as large offspring syndrome (LOS).  
LOS is characterized by aberrant fetal and placental development, increased birth 
weight, myogenesis, dystocia (difficulty in giving birth), dysfunctional perinatal 
pulmonary activity, organomegally (particularly of the liver and heart) and increased 
mortality in early post-natal life (Young et al., 1998).  The animals that survive have 
been shown to retain the features of abnormal organ size during later life.  The 
occurrence of LOS is also particularly associated with the addition of sera to the culture 
medium (Sinclair et al., 1999).  Furthermore, adult mice derived from in vitro cultured 
embryos were shown to exhibit behavioural alterations that relate to anxiety and 
locomotor activity (Ecker et al., 2004; Fernandez-Gonzalez et al., 2004).  Watkins et 
al. recently showed in the mouse that in vito culture resulted in increased systolic 
blood pressure, serum angiotensin-converting enzyme (ACE; catalyses the conversion 
of Angiotensin I to Angiotensin II; Ang. II is a potent vasoconstrictor and thus acts to 
increase blood pressure) and hepatic phosphoenolpyruvate carboxykinase (PEPCK; rate 
limiting enzyme in gluconeogenesis; an increase of which could thus potentially lead to 
increased blood glucose levels) in adult offspring (Watkins et al., 2007).   
1.3.2  Maternal diet 
The environmental sensitivity of the embryo can also be demonstrated in vivo.  The 
effect of maternal diet is a particularly well studied aspect of in vivo model systems 
and has been shown to impact on pre-implantation phenotype and long term 
development.  In a rat model, maternal low protein diet fed exclusively during the pre-
implantation period (control diet was fed for the remainder of gestation and 
postnatally) resulted in offspring with low birth weight, over-compensatory adolescent 
growth, onset of adult hypertension and alterations of relative organ size in a gender 
specific manner.  In addition, in the blastocyst, this relatively modest reduction of 
protein in the maternal diet lead to a reduction of ICM cells in the early blastocyst and 
a reduction in both TE and ICM cell numbers in the late blastocyst (Kwong et al., 
2000).  Furthermore, the same maternal treatment was shown to cause an increase in 
the expression of 11β-hydroxysteroid dehydrodgenase type 1 (Hsd11b1; activates 
glucocorticoids in fetal liver) and PEPCK in fetal liver (Kwong et al., 2007).  Taken 
together, all of these lines of evidence show that the preimplantation embryo is highly 
sensitive to its environment and that behavioural, cardiovascular and metabolic 
aspects of postnatal physiology are vulnerable.     32 
1.4  Maternal immune response and its effects on the offspring 
Relatively few studies have investigated the effects of maternal infection and 
inflammation during gestation on the offspring postnatally.  There are even fewer 
studies that have investigated offspring phenotype following maternal immune 
activation during early gestation.  Our knowledge of the effects of maternal infection 
and inflammation has come from epidemiological studies of human populations and 
experimental animal models.  Furthermore, such studies have tended to focus on 
individual aspects of offspring physiology or phenotype; e.g. only behaviour or only 
certain aspects of the immune system.  Intriguingly, maternal infection and 
inflammation during gestation has been shown to lead to alterations in various aspects 
of postnatal offspring phenotype, including; behaviour (Limosin et al., 2003; Shi et al., 
2003), immunity (Reiterova et al., 2006; Yamaguchi et al., 1983), metabolic status 
(Nilsson et al., 2001) and hypothalamic-pituitary-adrenocortical (HPA) axis functioning 
(Reul et al., 1994).  Thus, it appears that a wide variety of body systems in the 
offspring are affected by maternal immune activation during gestation.   
Key evidence linking maternal infection during gestation to behavioural 
abnormalities in the offspring has come from human epidemiological research.  Such 
studies found an association between maternal influenza infection during mid-gestation 
and the development of schizophrenia in genetically susceptible offspring (Brown, 
2006; Limosin et al., 2003).  Epidemiological evidence also suggests that maternal 
infection with other pathogens, such as rubella, Toxoplasma gondii and Herpes simplex 
virus type 2, increases the risk of schizophrenia in the offspring (Brown, 2006).  This 
indicated that the maternal immune response, rather than the nature of the pathogen 
per se that was the important risk factor.  As such, this raised the possibility that an 
experimental animal model could be developed.  To model maternal infection during 
mid-late gestation, LPS or the viral mimic PolyI:C (polyriboinosinic-polyribocytidilic 
acid, a synthetic double-stranded RNA analogue) has been administered to pregnant 
rodents during mid-late gestation.  Indeed, in these animal models, activation of the 
maternal immune system lead to behavioural, morphological and pharmacological 
alterations in the offspring relevant to schizophrenia (Fortier et al., 2007; Zuckerman 
et al., 2003).  Furthermore, Smith et al. showed that a single maternal injection of IL-
6 on GD 12.5 lead to the same offspring behaviour abnormalities as administration of 
PolyI:C (Smith et al., 2007).  From these animal models it would thus appear that 
cytokine exposure, resulting from either infection or administration of individual   33 
cytokines, can precipitate schizophrenic-type behavioural abnormalities in the 
offspring.   
Interestingly, it seems that the precise timing of maternal immune activation can 
result in subtle differences in the behavioural phenotype that is induced in the 
offspring.  Meyer et al. administered PolyI:C to pregnant mice on GD 9 and GD 17 
(corresponding to mid- and late-gestation, respectively) and found that some 
behavioural abnormalities were present in offspring from both treatment times but that 
other behavioural abnormalities were present in GD 9 offspring but not in GD 17 
offspring and vice versa (Meyer et al., 2008; Meyer et al., 2006).  No experimental 
models have investigated schizophrenic behaviour in offspring following very early 
gestational maternal immune challenge; however, some human epidemiological 
evidence has shown that this stage may also be at risk.  One birth cohort study 
reported that maternal genital and reproductive infections during periconception 
increased the risk of schizophrenia in the offspring (Babulas et al., 2006).  Another 
human birth cohort study indicated that the risk of schizophrenia in offspring was 
increased 7-fold after serologically documented influenza exposure during the first 
trimester of pregnancy (Brown et al., 2004).   
Schizophrenia is most well known for its neuropsychiatric aspect; however, this 
disease is also associated with an abnormally high prevalence of metabolic syndrome 
and immune dysfunction (Schorr et al., 2009; Strous and Shoenfeld, 2006).  For 
example, drug-naïve patients with schizophrenia have been shown to have increased 
intra-abdominal adiposity, impaired glucose tolerance and altered levels of IL-2, IL-6, 
IL-10 and TNF-α (Spelman et al., 2007; Strous and Shoenfeld, 2006; Thakore et al., 
2002).  To my knowledge none of the maternal immune activation animal models of 
schizophrenia have investigated the presence of metabolic or immune abnormalities in 
the offspring.  However, in another study (that did not investigate behavioural 
parameters) metabolic-type abnormalities were found in rat offspring following 
maternal LPS administration during mid-gestation.  Nilsson et al. challenged rats with 
3 repeated doses of LPS (790 μg/kg) during mid-gestation and examined aspects of 
metabolic functioning in the offspring (Nilsson et al., 2001).  Adult male offspring 
displayed obesity and features of the metabolic syndrome, specifically; increased body 
weight, increased abdominal fat-pad weights, elevated food intake, increased 
circulating leptin, insulin resistance and increased serum levels of 17β-estradiol and 
progesterone.  In contrast, adult female offspring in the same study appeared to be   34 
less affected, exhibiting elevated serum testosterone levels, increased basal 
corticosterone levels and increased weight of the heart and adrenal glands.  
Furthermore, in another study, pregnant rats were injected with IL-6, TNF-α or 
dexamethasone (synthetic glucocorticoid) during mid-gestation and the offspring were 
examined postnatally for a range of physiological and endocrine parameters (Dahlgren 
et al., 2001).  The authors reported an overlapping but non-identical phenotype in the 
offspring following the different maternal treatments, including; increased body weight 
in all offspring that was due to increased adiposity, corticosterone response to stress 
was increased in the IL-6 group, insulin resistance was seen in IL-6 group males, 
males from the TNF-α group showed decreased locomotor activity whereas the IL-6 
females showed increased locomotor activity and plasma testosterone levels were 
increased in females from the IL-6 and TNF-α groups (Dahlgren et al., 2001).  This 
study indicates that aspects of offspring metabolic and behaviour can be altered by 
administering individual components of a typical immune response.  In another study, 
pregnant rats received a single challenge with either LPS (at a much lower dose than 
the Nilsson study; 30 μg/kg) or human red blood cells (HRBC; T cell-dependent foreign 
antigen) during mid-gestation, and postnatal HPA axis functioning was examined only 
in the male offspring (Reul et al., 1994).  This study reported that adult male offspring 
from both LPS and HRBC groups displayed increased basal plasma corticosterone 
levels, whereas after novelty-induced stress, only offspring from the HRBC group 
showed increased ACTH and corticosterone levels.  In addition, decreased levels of 
mineralocorticoid and glucocorticoid receptors were detected in the hippocampus.  
These studies thus show that offspring metabolic status can be altered by maternal 
immune challenge during mid-gestation.  To my knowledge no studies have been 
conducted to investigate the effect of maternal immune activation during early 
gestation on offspring metabolic status and body composition.   
Studies investigating the effect of maternal immune challenge on offspring immune 
status have tended to focus on the humoral immune system and have reported 
contradictory results.  Immunisation of female mice with sheep red blood cells (SRBCs; 
T cell-dependent foreign antigen) at any time point from 2 days before fertilisation to 
GD 16 induced suppression of anti-SRBC (IgM and IgG) plaque-forming cell (PFC) 
responses in their offspring, which suggested reduced ability to produce antigen-
specific antibody (Yamaguchi et al., 1983).  However, it should be noted, that this 
suppressive effect on anti-SRBC PFC response persisted only until ~15 weeks after 
birth.  Interestingly, this group went on to show by adoptive transfer of immune cells,   35 
that it was specifically the maternal CD4
+ T cells of SRBC-immunised mice that induced 
suppression in their offspring (Fujii and Yamaguchi, 1992).  Further study by the same 
group showed that the suppression in the offspring was restricted to the MHC type that 
was activated during pregnancy and that the suppression in the offspring was a result 
of the generation of CD4
+ suppressor T cells by the offspring (Fujii et al., 1993).  
Overall, the findings from this set of experiments is much alike the recent findings of 
Mold et al. (Mold et al., 2008).  This study reports that large numbers of maternal cells 
cross the placenta to reside in fetal lymph nodes (rich in TGF-β which can induce Treg 
differentiation), inducing the development of CD4
+CD25
highFOXP3
+ Tregs that suppress 
antimaternal fetal immunity and that persist into early adulthood (Mold et al., 2008).  
A similar process could thus be the cause of the (transient) anti-SRBC suppression 
seen in the mouse model above.   
In contrast, infection of female mice with the parasite Toxocara canis during mid-
late gestation (GD 12-18) seemed to be protective for the offspring if they were 
infected postnatally (Reiterova et al., 2006).  When offspring were postnatally infected 
(6 weeks of age) with the same parasite that their mothers had received (T. canis), 
offspring displayed reduced production of IFN-γ and IL-5, suppressed eosinophilia, 
increased levels of IgM and IgG1 and reduced larval recovery from the brain and 
muscles (Reiterova et al., 2006).  This finding implied that, in response to postnatal 
infection, increased levels of protective antibodies were produced in offspring from 
infected dams, which thus reduced the extent of infection without the requirement of a 
vigorous immune response, i.e. IFN-γ and IL-5 production and eosinophilia.  One 
important difference between this study and the study that found anti-SRBC 
suppression in the offspring (discussed above), is that offspring would have received 
maternally produced anti-T. canis IgG antibodies via the placenta and milk.  Increased 
levels of maternally derived antibodies would have been transferred to the offspring of 
infected dams and thus provided passive protection to the offspring upon reinfection.  
However, the offspring in this study also displayed increased production of antibody 
upon reinfection, thus showing that offspring from infected dams had secondary-type 
antibody response to a primary challenge.  This type of response has been found 
before: Enhanced production of DNA-specific antibodies was found in offspring from 
dams that had received anti-DNA antibodies two weeks prior to mating (Sasaki et al., 
1977).  It is thought that during the neonatal period, maternal antibodies induce T-cell 
dependent idiotypic responses that prime the offspring immune system (Lemke et al., 
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1.5  Lipopolysaccharide and Toll-like receptor signalling pathways 
Pathogen-associated molecular patterns (PAMPs) are essential components of most 
micro-organisms; of which lipopolysaccharide (LPS; also known as endotoxin) is an 
example (Akira et al., 2006).  LPS is an abundant and integral constituent of the outer 
membrane of Gram-negative bacteria (Fig. 1.4a).  It is released from the membrane 
when bacteria divide, die and lyse, and is therefore liberated into host tissues during a 
Gram-negative bacterial infection (Rietschel et al., 1994).  It is widely acknowledged 
that LPS is of prime importance in host recognition of infection and that it is a highly 
potent activator of the immune response, even in the absence of other bacterial 
components (Akira et al., 2006; Van Amersfoort et al., 2003).  Intravenous (i.v.) or 
intraperitoneal (i.p.) injection of LPS triggers an acute systemic inflammatory response 
that fully mimics the initial phase of a genuine systemic Gram-negative bacterial 
infection (Beutler, 2004; Dantzer, 2004).  Indeed, LPS has been used for decades to 
model systemic inflammation and sepsis (Beutler, 2004).   
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Figure 1.4  (a)  Schematic representation of a Gram-negative bacterial cell wall showing the 
position of LPS in the outer membrane; (b)  general structure of an LPS molecule (Akira et al., 
2006). 
LPS molecules from all Gram-negative bacteria have the same general structure; 
that is a polysaccharide attached to a lipid component called lipid A (Fig. 1.4b).  The 
polysaccharide component is made up of a core and a polymer of oligosaccharide 
molecules (O-antigen).  This polysaccharide component is highly variable and specific 
to each bacterial strain and is bound to lipid A through a core sugar moiety called 2-
keto-3-deoxyoctulosonic acid (KDO).  Lipid A consists of a phosphorylated glucosamine 
disaccharide to which long fatty acids are attached (Rietschel et al., 1994).  
Furthermore, Lipid A is thought to be the component of LPS that is responsible for 
inducing cytokine expression (Rietschel et al., 1994).  Several experiments have 
demonstrated much variance in the ability of various LPS species to induce the   37 
synthesis of cytokines.  For example, LPS molecules from E.coli and Salmonella 
typhimurium differentially activate cytokine production in mice deficient in TNF-α and 
lymphotoxin-α.  In these mice, E.coli induces the expression of very little IL-1α, IL-1β 
and IFN-γ, whereas S. typhimurium LPS induces the release of high concentrations of 
these cytokines (Netea et al., 2001).  Variation in the three-dimensional structure of 
lipid A is also observed between different bacterial strains and has been linked to its 
potency.  Lipid A species that have a conical shape (e.g. E.coli) have high levels of 
activity whereas those with a cylindrical shape (Rhodobacter capsulatum) are weaker 
(Schromm et al., 2000).   
The innate immune system is able to discriminate between self and invading micro-
organisms by expressing receptors for a number of different PAMPs, e.g. LPS, double 
stranded RNA, peptidoglycans (Vivier and Malissen, 2005).  The PAMP-recognising 
receptors of the innate immune system are known as Toll-like receptors (TLRs); LPS is 
recognised by TLR4.  TLRs are expressed on various immune cells, including antigen 
presenting cells (APCs; i.e. macrophages and dendritic cells, DCs), neutrophils, B cells, 
some types of T cells, as well as on non-immune cells such as fibroblasts and epithelial 
cells (Akira et al., 2006; Poltorak et al., 1998).  Recognition of LPS by TLR 4 alone is 
insufficient for signalling:  LPS binding protein (LBP; an acute phase protein present in 
the blood stream that is produced by the liver), CD14 (a proteinacious co-receptor that 
is either soluble, or glycosylphosphatidylinositol (GPI)-linked at the cell surface) and 
myeloid differentiation protein-2 (MD-2; a small protein associated with the 
extracellular part of TLR4 that is important for LPS recognition and cellular distribution 
of TLR4) are the three accessory proteins that are also required, which, together with 
TLR 4, comprise the LPS receptor complex (Fujihara et al., 2003).  To begin with LPS 
must associate with LBP, this complexed LPS then binds to soluble or GPI linked CD14.  
Next, CD14 facilitates the transfer of LPS to the extracellular portion of the TLR 4/MD-2 
receptor complex (Fig. 1.5), which in turn leads to TLR dimerisation and activation of 
intracellular signalling pathways (Fujihara et al., 2003; Lu et al., 2008b).     38 
 
Figure 1.5  Overview of LPS/TLR4 receptor complex and intra cellular signalling pathways 
(Lu et al., 2008b). 
Upon dimerisation, the intracellular TIR (Toll-interleukin-1 receptor) domain of TLR4 
recruits downstream signal transduction adaptor proteins to the complex; these are, 
MyD88 (myeloid differentiation primary response gene 88), TIRAP (TIR domain-
containing adaptor protein), TRIF (TIR domain-containing adaptor inducing IFN-β) and 
TRAM (TRIF-related adaptor molecule) (Lu et al., 2008b).  TLR4 signalling has been 
broadly divided into two pathways; MyD88-dependent and MyD88-independent (Fig. 
1.5).  Proinflammatory cytokines (e.g. IL-1, TNF-α, IL-6) are produced via the MyD88-
dependent pathway, where TIRAP facilitates the association between MyD88 and TLR4, 
then MyD88 activates IRAK (IL-1 receptor associated kinase) 4 and 1 which ultimately 
results in activation of the transcription factors NF-κB (nuclear factor κB) and AP-1 
(activator protein 1), via the IKK (IkB kinase) and MAPK (mitogen-activated protein 
kinase) pathways, respectively.  Type I interferons (e.g. IFN-α and IFN-β) are 
produced via the MyD88-independent pathway, where TRIF activates IKK and MAPK 
pathways via RIP1 (receptor-interacting protein 1) (Lu et al., 2008b).   
1.6  The acute phase response 
1.6.1  General aspects and initiation of an acute phase response 
The purpose of the acute phase response (APR) is to counteract the immunological 
stress and restore homeostasis as quickly as possible.  This is accomplished in two 
fundamental ways; firstly, by destruction and removal of the causative organisms   39 
and/or harmful molecules; and secondly, by activating host repair processes (Ceciliani 
et al., 2002).  The APR involves a myriad of changes both local to and distant from the 
affected site, including; immune, neuroendocrine, CNS, metabolic, hepatic and 
hematopoietic alterations (Table 1.1).   
Affected System  Nature of Change 
Immune system  •  Activation of peripheral innate immune system (e.g. 
tissue macrophage). 
•  Release of pro-inflammatory molecules (e.g. IL-1, 
TNF-α, IL-6, IL-8, PGs, histamine). 
•  Recruitment and activation of leukocytes from the 
blood (e.g. neutrophils). 
•  Increased dilation and permeability of capillary beds, 
leading to extravasion of fluid and plasma proteins 
into the tissue (oedema). 
Neuroendocrine/HPA 
system 
•  Increased CRH release from the hypothalamus. 
•  Increased ACTH release from the anterior pituitary. 
•  Increased glucocorticoid (e.g. cortisol) release from 
the adrenals. 
CNS  •  Induction of fever. 
•  Sickness behaviours; e.g. anorexia, adipsia, lethargy, 
somnolence, anhedonia and decreased social 
interaction. 
•  Hyperalgesia and allodynia. 
Metabolic  •  Increased protein catabolism (e.g. breakdown of 
muscle tissue). 
•  Increased gluconeogenesis (i.e. glucose production 
from certain amino acids or lactic acid). 
•  Increased adipose tissue lipolysis. 
•  Decreased levels of plasma zinc and iron. 
Hepatic  •  Increased synthesis of hepatic proteins (the acute 
phase proteins). 
•  Increased hepatic lipogenesis. 
Hematopoietic system  •  Increased leukocytosis (white blood cell count). 
•  Increased thrombocytosis (platelet count). 
•  Increased secretion of colony-stimulating factors. 
Table 1.1  Summary of the major changes that happen during an acute phase reaction 
(Ceciliani et al., 2002; Gruys et al., 2005; Konsman et al., 2002). 
Activation of the peripheral innate immune system is the first step in the APR. 
Antigen presenting cells (APCs; i.e. blood macrophages and dendritic cells, DCs) are 
particularly important because they release a wide range of inflammatory mediators 
that induce most features of the APR; these include: TNF-α, IL-1β, IL-6, IL-10, IL-12, 
MIP-1 α/β, MCP-1, RANTES, G-CSF, GM-CSF, platelet activating factor (PAF), 
prostaglandins, reactive oxygen species (ROS), nitric oxide (NO) and proteases   40 
(Fujihara et al., 2003).  Pro-inflammatory cytokines (e.g. TNF-α, IL-1β) act to recruit 
and activate additional immune help from the circulation.  For example, IL-1 and TNF-α 
act on vascular endothelial cells to induce expression of adhesion molecules that slow 
down circulating leukocytes and make them adhere to the vascular wall, and 
chemokines (e.g. IL-8 and MCP-1) chemoattract leukocytes into the affected area 
(Ceciliani et al., 2002).  Once in the affected tissue, leukocytes (e.g. neutrophils) 
phagocytose micro-organisms and debris, and release toxic free radical metabolites 
and proteolytic enzymes.  Vasoactive molecules such as prostaglandins (PGs), 
histamine and bradykinin are also released at the site of inflammation.  These 
molecules act in local capillary beds to increase vessel permeability and dilation which 
results in increased blood flow and, in turn, extravasion of fluid and plasma proteins 
into the tissue.  In addition to their effects on the local vasculature, PGs, histamine and 
bradykinin also mediate inflammatory pain.  In addition, IL-6 is the major mediator for 
stimulating hepatic secretion of the acute phase proteins (APPs) and TNF-α is 
important in the catabolism of muscle protein and adipose tissue (Ceciliani et al., 
2002; Gruys et al., 2005).   
1.6.2  Fever and sickness behaviour 
The CNS-related components of the APR, i.e. fever and sickness behaviour, are 
easily recognised indicators of illness that highlight the abundant cross-talk that must 
occur between the CNS and peripheral immune system.  It is believed that 
communication between the CNS and peripheral immune system is mediated in two 
ways:  (1) a neural route via afferent neurones that innervate the body site where the 
infection takes place; and (2) a humoral pathway that involves cytokines and PGs 
(Konsman et al., 2002).  Fever and sickness behaviour are frequently observed after a 
very short latency following immune stimulation; i.e. more quickly than cytokines 
could be transcribed, translated and secreted, and furthermore these symptoms 
frequently abate before the disappearance of blood-borne cytokines (Blatteis et al., 
2005; Campisi et al., 2003).  For instance, the first cytokines do not appear in the 
blood following intravenous (i.v.) LPS until at least 30 minutes after its injection, 
whereas fever is apparent within 10-12 minutes (Blatteis et al., 2005).  It seems very 
likely that the maintenance/latter phases of fever and sickness behaviour are mediated 
by PGs and cytokines that have been formed in the mean time.  Receptors for the pro-
inflammatory cytokines are expressed in many regions of the brain: intra-
cerebroventricular (icv) administration of IL-1 and IL-6 can induce typical sickness   41 
responses and furthermore, these cytokines are found in the brain after peripheral 
administration of IL-1 or LPS (Blatteis et al., 2005; Hopkins, 2007; Konsman et al., 
2002).  Direct transfer of peripherally produced cytokines to the CNS is highly 
implausible however, because cytokines are relatively large lipophobic molecules that 
cannot passively cross the blood-brain barrier (Blatteis et al., 2005; Campisi et al., 
2003).  It is becoming increasingly apparent that induction of other signalling 
molecules, PGE2 in particular, is key to the CNS effects (Konsman et al., 2002).  It has 
long been known that administration of cyclo-oxygenase (COX) inhibitors attenuates 
the febrile and behavioural aspects of sickness (Blatteis et al., 2005).  Importantly, 
Teeling et al. have recently shown that blockade of PG production with the COX 
inhibitor indomethacin, completely reversed LPS-induced changes in mouse burrowing 
behaviour without affecting peripheral or CNS cytokine levels (Teeling et al., 2007).   
In 1988 Hart put forward the view that sickness behaviour and fever represent a 
highly organised strategy to fight infection (Hart, 1988).  Fever is a transient 
physiological adjustment to a new homeostatic equilibrium that is characterised by a 
raised set-point of body temperature (Dantzer, 2004).  As such, an individual 
experiencing fever will feel cold even in thermoneutral environments.  Fever is an 
important aspect of the immune response because the increased body temperature 
that is achieved acts to stimulate immune cell proliferation and is unfavourable for the 
growth of many bacterial and viral pathogens.  Indeed, hosts that are unable to mount 
an appropriate fever response have a lower survival rate than those hosts which 
develop a normal fever (Dantzer, 2004).  Metabolic rate is increased quite substantially 
during fever; therefore, the energy cost of the febrile response is quite high.  
Increased catabolism of muscle protein and adipose tissue, and gluconeogenesis act to 
increase glucose availability for these costly energetic processes.  Since the metabolic 
cost of fever is so high, the host must conserve heat and energy.  Any unnecessary 
activity is reduced or stopped completely, hence the lethargy, somnolence, curled-up 
posture and reduced social interaction that is characteristic of sickness behaviour.  The 
hyperalgesia (extreme sensitivity to pain) and allodynia (exaggerated response to non-
painful stimuli, i.e. non-painful stimuli feel painful) that is associated with sickness not 
only directs recuperative behaviours (e.g. protection of the painful bodily site) to the 
affected part of the body, but additionally it encourages immobility, and in this way 
also serves to save energy (Dantzer, 2004).  The anorexic component of sickness 
behaviour seems counter productive in light of the increased energy requirements 
highlighted above.  However, all things considered, finding food and digesting it   42 
require energy expenditure, and doing so would increase the risk of exposure to 
predation and possible ingestion of further pathogenic organisms.  Communication at 
this level allows reorganisation of host perception and actions, in such a way that is 
most advantageous to fight infection and recover in optimal time (Dantzer, 2004).   
1.6.3  Hypothalamus-piuitay-adrendal (HPA) axis activation 
In response to a variety of stressors the hypothalamus releases corticotrophin 
releasing hormone (CRH) into the hypophyseal portal system, which causes the 
anterior pituitary gland to secrete adrenocorticotrophic hormone (ACTH) into the 
general circulation.  ACTH then stimulates the adrenal gland to secrete the 
glucocorticoids (GCs), cortisol, corticosterone and cortisone (mice and rats secrete 
corticosterone almost exclusively).  The HPA axis can be activated by neural afferent 
stimulation as well as humoral mediators.  Neural afferent signals from both the 
periphery (e.g. pain via peripheral nociceptive pathways) and from higher centres in 
the CNS (e.g. emotion via the limbic system) can rapidly activate the HPA axis 
(Hopkins, 2007).  Many studies have highlighted hypothalamic IL-1, IL-6 and PGE2 as 
potent activators of the HPA axis and much data indicates that humoral IL-6 is an 
important circulating mediator (Hopkins, 2007; Lenczowski et al., 1997; Sapolsky et 
al., 2000).  The GCs have a range of actions, but are particularly important for altering 
metabolic and immune functioning.  They increase the rate of protein and adipose 
tissue catabolism, and cause increased plasma glucose concentrations, partly by 
stimulating hepatic gluconeogenesis.  The effects of GCs on the immune system are 
overwhelmingly immunosuppressive and anti-inflammatory; however, they do have 
some important permissive actions.  Generally, GCs act to inhibit synthesis, release 
and/or efficacy of a variety of inflammatory mediators.  Such inflammatory mediators 
include; cytokines, chemokines, histamine, PGs, nitric oxide and protease enzymes 
(Sapolsky et al., 2000).  Furthermore, GCs reduce the number of leukocytes at 
inflammatory foci and in the circulation, and in addition have anti-proliferative and 
apoptotic actions in these cells.  GCs have permissive actions by enhancing the effect 
of other molecules; for example, they enhance liver APP production by increasing 
hepatic sensitivity to inflammatory mediators such as IL-6; and they up-regulate the 
tissue expression of receptors for hormones, cytokines and growth factors (Sapolsky et 
al., 2000).     43 
1.6.4  Other aspects of the acute phase response 
IL-6 is thought to be the major mediator for stimulating hepatic secretion of the 
acute phase proteins (APPs).  The pattern of protein synthesis by the liver is much 
altered within 4-8 hours of challenge; some proteins are up regulated (positive APP) 
and some proteins are down regulated (negative APP) (Ceciliani et al., 2002; Gruys et 
al., 2005).  The so called negative APPs tend to be the physiologically expressed 
proteins that are usually present in the blood (e.g. albumin), whereas the positive 
APPs have a number of roles that range from initiation and regulation, to resolution of 
the inflammation.  Positive APPs include those from the complement, coagulation and 
fibrinolytic systems, as well as scavenger proteins, inflammatory response participants 
and protease inhibitors (Ceciliani et al., 2002).  Complement pathways are involved in 
chemotaxis and opsonisation of pathogenic material; coagulation and fibrinolytic 
systems help to restore tissue integrity following damage; the scavenger molecule LPS 
binding protein (LBP) interacts with LPS and transfers it to its cell surface receptors, 
CD14/TLR-4; protease inhibitors help to prevent excessive tissue damage from 
pathogen and immune system derived proteases (Ceciliani et al., 2002).   
1.7  Rationale 
There is now ample evidence, from both in vitro and in vivo studies, showing that 
the preimplantation embryo is sensitive to its immediate environment (Fernandez-
Gonzalez et al., 2004; Watkins et al., 2008b).  Perturbations during preimplantation 
development have been shown to alter not only the immediate events of blastocyst 
formation, but also cardiovascular, metabolic and behavioural aspects of offspring 
phenotype (Fernandez-Gonzalez et al., 2004; Kwong et al., 2000; Watkins et al., 
2007; Watkins et al., 2008b).  A limited amount of evidence suggests that behaviour 
and immune function may be altered in offspring from mothers that experienced 
infection or immune challenge during early gestation.  Human epidemiological evidence 
has indicated that maternal infection during the first trimester increased the risk of 
offspring developing schizophrenia (Babulas et al., 2006; Brown et al., 2004).  In 
addition, immunisation of female mice with sheep red blood cells (a T cell-dependent 
antigen) during periconception and early gestation has been shown to reduce the 
ability of offspring to produce antibody until approximately 15 weeks of age postnatally 
(Yamaguchi et al., 1983).  However, detailed experimental models investigating how 
maternal inflammation activation during preimplantation gestation affects various 
aspects of prenatal and postnatal offspring phenotype are severely lacking.  Thus, the   44 
aim of my PhD is to investigate the effects of an inflammatory environment during 
preimplantation development on the phenotype of the blastocyst, fetus and offspring 
postnatally, with a major focus on an in vivo mouse model of maternal systemic 
infection.   
The hypothesis of this thesis is that, in the mouse, maternal systemic inflammation 
during preimplantation gestation will alter the immediate events of blastocyst 
formation and will perturb diverse aspects of postnatal offspring phenotype, including; 
growth, behaviour, systolic blood pressure, body structure and immune status.  Thus, 
the aims of this study are to develop an in vivo model of maternal systemic 
inflammation during preimplantation gestation in the mouse, and examine the 
resultant phenotype in the blastocyst, fetus and offspring postnatally.  First, the 
maternal immune response to administration of lipopolysaccharide will be confirmed by 
assessing maternal sickness behaviour, weight loss and serum cytokine profile.  Next 
the immediate effects of maternal LPS-injection will be assessed in the gestational day 
3.5 blastocyst by counting the number of cells in the trohectoderm and inner cell mass.  
The effects on the gestational day 17 fetus will be examined by dissection of the 
conceptus and its constituent parts.  The final part of the study will concentrate on the 
offspring postnatally.  Offspring will be assessed for growth by weekly weight until 
adulthood.  In addition, offspring will undergo a battery of behavioural tests and 
systolic blood pressure measurements.  Prior to cull, a subset of offspring will receive 
their own direct immune challenge (in the form of an LPS injection) or saline injection.  
In order to assess immune status of the injected offspring, serum cytokine profiles will 
be measured using multiplex technology and spleen lymphocyte populations will be 
examined by flow cytometry.  All offspring, regardless of postnatal treatment, will be 
fully dissected to investigate body structure and the mass of all major organs and fat-
pads will be recorded.  All postnatal data will be analysed using a multilevel random 
effects regression model that takes into consideration the hierarchical nature of the 
dataset (Kwong et al., 2004; Watkins et al., 2008b). 
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2  Materials and Methods 
2.1  Superovulation and in vitro procedures 
2.1.1  Mice 
The MF1 strain mice used throughout this study were bred and housed in the 
Biomedical Research Facility at the University of Southampton.  Prior to 
experimentation female mice were housed in groups and male studs were housed 
individually.  All animals were maintained under controlled 12 hour light/dark cycles 
(lights on 0700 hours, lights off 1900 hours), at a temperature of 18-22ºC and were 
allowed ad libitum access to standard rodent chow and tap water.   
2.1.2  Superovulation and mating 
5-6 week old virgin female MF1 mice were superovulated by intraperitoneal (i.p.) 
injection of 5 IU pregnant mare serum gonadotropin (PMSG; Intervet; Appendix I) at 
1400 hours, then 46-48 hours later with 5 IU human chorionic gonadotropin (hCG; 
Intervet; Appendix I) and caged individually overnight with MF1 stud males (6 weeks 
to 6 months of age).  The presence of a vaginal plug the following morning was taken 
as a sign of mating and this was then regarded as gestational day 0.5 (GD 0.5).  Plug-
positive females were removed from the stud cages and housed in groups until 
required.  
2.1.3  Embryo collection 
At GD 1.5 (48 hours post-hCG, two-cell embryo stage) female mice were killed by 
cervical dislocation (in accordance with Schedule 1 of the 1986 Animal Procedures 
Act), then their oviducts were dissected out and placed into normal saline solution 
(0.85% NaCl), pre-warmed to 37ºC.  Each oviduct was flushed by inserting a blunt-
ended needle (Coppers Needle Work, Birmingham, UK; hypodermic stainless steel 
needle, 30-gauge, 10mm) a short distance through the aperture of the infundibulum 
and flushing through pre-warmed (37ºC) H6 medium supplemented with 4 mg/ml 
bovine serum albumin (H6-BSA; Appendix I).  2-cell embryos with good morphology 
were selected and washed three times in 20 µl drops of equilibrated (37ºC, 5% CO2 in 
air for at least one hour) KSOM medium (Appendix I) covered in mineral oil (Sigma, 
M8410, embryo culture tested), in culture dishes.  The washed embryos were pooled 
and maintained in equilibrated KSOM at 37ºC, 5% CO2 in air until required.   46 
2.1.4  Embryo culture with IFN-γ 
Lyophilised recombinant mouse IFN-γ (8.43x10
3 IU/μg; R&D Systems, 485MI) was 
reconstituted with PBS (supplemented with 0.1% BSA) to obtain a stock solution of 
100 µg/ml.  Aliquots of the IFN-γ stock solution were stored at -20ºC until required.  
For each experiment, IFN-γ stock solution was defrosted and diluted 1:100 with PBS 
(supplemented with 0.1% BSA), to obtain a 1 µg/ml solution.  This solution was then 
diluted 1:100 with KSOM to obtain a 10 ng/ml solution.  Then, serial dilutions of 1:10 
(in KSOM) were performed in order to obtain the four experimental IFN-γ 
concentrations:  1000, 100, 10 and 1 pg/ml.  KSOM alone was used as the control.  
Six to ten, 20 µl drops of control or IFN-γ-containing medium were pipetted onto 
culture dishes, covered with mineral oil and allowed to equilibrate at 37ºC, 5% CO2 in 
air for at least one hour.  Pooled embryos were randomly assigned to each of the five 
groups (control, 1, 10, 100 or 1000 pg/ml IFN-γ) and, in order to minimise dilution of 
the IFN-γ in the final culture drops, were briefly placed into a ‘transfer drop’ that was 
at the same concentration of IFN-γ.  For example, embryos that were to be cultured in 
1000 pg/ml IFN-γ were placed into a ‘transfer drop’ at 1000 pg/ml IFN-γ.  Embryos 
were cultured at a density of 10 embryos per 20 µl drop for each IFN-γ concentration, 
for up to 146.5 hours post-hCG without any change of medium.  Embryo development 
was scored twice daily at 0830 and 1630 hours.  Embryos that had developed to the 
blastocyst stage (Fig. 2.1a) by approximately 117 hours post-hCG were removed from 
culture.  These embryos underwent differential nuclear staining to determine cell 
number in the trophectoderm (TE) and inner cell mass (ICM) cell lineages. 
2.1.5  Differential nuclear staining 
The method used was based on that described by Handyside and Hunter (Handyside 
and Hunter, 1984).  The zona pellucidae surrounding the blastocysts were removed by 
a brief period of incubation (20-30 seconds) in acidic Tyrode’s solution (Sigma, T1788, 
mouse embryo tested; pH 2.3), pre-warmed to 37ºC.  Next, blastocysts were 
transferred to a cavity block containing pre-warmed (37ºC) H6-BSA and allowed to 
recover for at least 20 minutes.  Then, blastocysts were incubated at room 
temperature in trinitrobenzene sulphonic acid (TNBS; Sigma, P2297; Appendix I) for 
10 minutes, followed by three washes in pre-warmed (37ºC) H6-BSA.  The embryos 
were then incubated for a further 10 minutes at room temperature in a 25 µl drop 
comprised of 10.4 µl goat anti-dinitrophenyl-BSA antibody solution (anti-DNP-BSA; 
Sigma, D9781 or D9656) and 14.6 µl H6-BSA, followed by three washes in pre-  47 
warmed (37ºC) H6-BSA.  Lysis and nuclear staining of the outer TE cells was achieved 
next by incubating the blastocysts at 37ºC, for 10 minutes, in a 25 µl drop comprised 
of 23 µl guinea pig complement (Cedarlane, CL4051; Appendix I) and 2 µl propidium 
iodide (PI; Sigma, P4864; Appendix I).  Again, the blastocysts were washed three 
times in pre-warmed H6-BSA.  The blastocysts were fixed in 990 µl of absolute ethanol 
to which 10 µl of bisBenzimide H 33258 DNA stain (Hoechst 33258, Sigma, B2883; 
Appendix I) was added.  The blastocysts were kept in the ethanol and Hoechst, at 4ºC 
and in the dark, for a minimum of 90 minutes and a maximum of 1 week.  After 
fixation, the blastocysts were placed into absolute ethanol for 5-8 minutes and then 
into a small drop of ultra pure glycerol (Amersham).  Next, a small volume of glycerol 
containing the blastocysts was carefully pipetted onto an ethanol-cleaned glass slide, 
and a cover slip was placed over the drop and pressed down gently.   
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Figure 2.1  Brightfield (a) and fluorescent (b) blastocyst images.  The blastocyst in 
photograph (b) was differentially stained:  blue, Hoechst-stained ICM nuclei and red, PI-stained 
TE nuclei.  On both images, * indicates the ICM, arrow indicates the TE and ‘C’ indicates the 
blastocoel cavity. 
The nuclei of the TE were stained red (PI) and the nuclei of the ICM were stained 
blue (Hoechst), which meant that the number of cells in each lineage could be 
differentiated and counted (Fig. 2.1b).  The blastocysts were viewed and imaged using 
a fluorescence microscope (Zeiss Axiovert 200) and MetaMorph software (Universal 
Imaging Corp., Version 6.2r6).  DAPI (blue, Hoechst-stain) and TRITC-CY3 (red, PI-
stain) filters were selected and then a Z-series (3-5 µm separations, X20 and X40 
magnification) was captured for each blastocyst.  A combined blue and red image (Fig. 
2.1b) was used for analysis and every Z-section from all blastocyst was examined 
separately.  The manual count application was used to differentially count and record 
the number of TE and ICM cells in each blastocyst. 
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2.2  Generation and assessment of maternal inflammation in vivo 
2.2.1  Natural mating 
Details of the mice are as in section 2.1.1.  7-8.5 week old virgin female MF1 mice, 
weighing between 27 and 33 grams, were naturally mated by housing them 
individually overnight with MF1 stud males (6 weeks to 6 months of age).  Female 
mice remained with a stud for up to four consecutive nights.  Each morning, the 
females were checked for the presence of a vaginal plug, which was taken as a sign of 
mating.  Plug-negative females remained with the stud male, and plug-positive 
females were removed from the stud cages, weighed and housed alone.   
2.2.2  LPS administration 
Naturally mated plug-positive females received a dose of either normal saline 
(0.85% NaCl; control) or one of three lipopolysaccharide (LPS; Salmonella enterica 
enteritidis, Sigma, L4774) dosages between 1400 and 1600 hours on the day of plug 
(GD 0.5) when embryos would be at the zygote stage, 13-15 hours post-fertilisation.  
Dosages of 10, 50 and 150 µg/kg body weight LPS were freshly prepared (lyophilised 
LPS reconstituted with 0.85% saline; 1 mg/ml) on each occasion and were 
administered by i.p. injection of 100 µl volumes.  The mice were put back into their 
cages directly following treatment and were housed alone until required. 
2.2.3  Assessment of the maternal response to LPS 
A group of females (treated as in section 2.2.2) was subjected to a variety of 
assessments in order to characterise maternal response to the injection of saline 
(control) or LPS dosages.  A subset of these females was assessed for sickness-related 
behaviours and body weight change.  The other subset of these females was sacrificed 
for collection of blood for analysis of serum cytokine concentrations using a multiplex 
cytokine assay kit (see section 2.2.3.3).   
2.2.3.1 Sickness behaviour and body weight 
At 1 hour post-injection, mice underwent an open field test to assess the extent to 
which locomotor and exploratory-related behaviour had been affected (see section 
2.4.2.1).  Maternal body weight, and food and water consumption was assessed in 
addition to the open field test.  Mice were weighed at the time of injection and at 24, 
48, 72, 96 and 120 hours post-injection (GD 0.5-5.5).  Furthermore, mice were   49 
weighed in late gestation, at GD 15.5.  The chow and tap water bottle of each mouse 
were also weighed at the time of injection and at 24, 48, 72, 96 and 120 hours post-
injection (GD 0.5-5.5).  Mice had access to ad libitum chow and tap water throughout 
all assessments, apart from the 3 minute duration of the open field test.   
2.2.3.2 Collection of blood 
Female mice from control and LPS treated groups were sacrificed by cervical 
dislocation at 3, 24, 48 and 72 hours post-injection.  Maternal blood samples were 
taken by cardiac puncture using a needle (BD Microlance 3, 23-gauge) and syringe (BD 
Plastipak, 1 ml).  Briefly, blood was drawn out slowly from the right ventricle by 
carefully puncturing the right ventricular wall.  Care was taken not to damage the atria 
(which would cause haemorrhage and reduced the volume of blood available for 
collection) or to suck air into the syringe (which would cause hemolysis) during this 
process.  The blood was immediately transferred to a 1.5 ml tube and placed on ice.  
The clotted blood samples were then centrifuged at 4ºC, at 9,300 g for 10 minutes and 
the resulting serum was aliquoted and stored at -80ºC until analysis.   
2.2.3.3 Multiplex cytokine assay 
The Bio-Plex Mouse Cytokine 23-Plex Panel kit (Bio-Rad) was used to detect and 
quantify the following cytokines, simultaneously, in each serum sample:  IL-1α, IL-1β, 
IL-2, IL-3, IL-4, IL-5, IL-6, IL-9, IL-10, IL-12 p40 (antagonist), IL-12 p70 (agonist), 
IL-13, IL-17, eotaxin (CCL11), granulocyte colony-stimulating factor (G-CSF), 
granulocyte-macrophage colony-stimulating factor (GM-CSF), IFN-γ, keratinocyte-
derived chemokine (KC; CXCL1), monocyte chemoattractant protein-1 (MCP-1; CCL2), 
macrophage inflammatory protein-1 α (MIP-1α; CCL3), MIP-1β (CCL4), RANTES 
(regulated upon activation, normal T-cell expressed and secreted; CCL5) and TNF-α.  
All buffers, diluents and cytokine standards required to perform the assay were 
provided in the kit.  All samples, standards and blanks were run in duplicate on every 
plate.  The assay was carried out in accordance with the manufacturer’s instructions.   
In brief, thawed serum samples were diluted 1:4 with mouse sample diluent (12.5 
µl serum + 37.5 µl diluent/well).  The lyophilized recombinant cytokine standard was 
reconstituted with standard diluent and a nine-point serial dilution was prepared, 
where each standard was a 4-fold dilution of the previous tube.  All samples and 
standards were kept on ice until ready for use.  Diluted standards and samples (50 
µl/well) were added to antibody-conjugated fluorescently-dyed beads in the wells of a   50 
96-well filter plate.  The samples and standards were incubated with the beads at room 
temperature, in the dark, on a microplate shaker (300 rpm), for 1 hour.  At the end of 
the incubation period, the plate was washed three times with wash buffer (100 
µl/well/wash).  Liquid was sucked out through the filter-bottom of each well by placing 
the 96-well plate on a vacuum manifold.  Next, freshly diluted detection antibody was 
added to the wells and incubated at room temperature, in the dark, on a microplate 
shaker (300 rpm) for 30 minutes.  The plate was washed a further three times (as 
above).  Freshly diluted streptavidin-phycoerythrin (PE) was then added to the wells 
and incubated at room temperature, in the dark, on a microplate shaker (300 rpm) for 
10 minutes.  The plate was washed again (as above).  Finally, the beads were 
resuspended in assay buffer (125 µl/well) and placed on the microplate shaker (300 
rpm), in the dark, at room temperature for approximately 10 minutes.  The plate was 
then run on a Luminex 100 (Luminex Corporation) multiplex array instrument.   
StarStation (version 2.0; Applied Cytometry Systems, Sheffield, UK) software was 
used to acquire and analyse all data from the Luminex 100 instrument.  The 
instrument was set to acquire 1000 total events/well.  All values were reported minus 
background, i.e. any background fluorescence detected in the blank sample was 
subtracted from the value obtained for each of the standards and samples.  Outliers 
were defined as follows:  points with negative mean fluorescence intensity (MFI); 
points with very extreme MFI and concentration.  The outliers were removed from the 
analysis and, where possible, the most appropriate standard curve for each cytokine 
was established by considering each point in duplicate.  The StarStation software then 
calculated the sample cytokine concentrations (pg/ml) based on these standard curves 
(Table 2.1), and reported the individual result for each well (as opposed to reporting 
the mean of the duplicate for each sample). 
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Cytokine 
Expected 
Concentration 
Range (pg/ml) 
Cytokine 
Expected 
Concentration Range 
(pg/ml) 
IL-1α  0.46 - 30,081  IL-17  0.77 – 50,600 
IL-1β  0.26 - 17,208 
Eotaxin 
(CCL11) 
0.65 – 42,582 
IL-2  0.90 - 58,666  G-CSF  0.60 – 39,312 
IL-3  0.64 - 41,713  GM-CSF  0.52 – 33,995 
IL-4  0.73 - 47,598  IFN-γ  0.67 – 44,043 
IL-5  0.43 - 28,327 
KC     
(CXCL1) 
0.45 – 29,709 
IL-6  0.35 – 23,116 
MCP-1 
(CCL2) 
0.42 – 27,783 
IL-9  0.30 – 19,936 
MIP-1α 
(CCL3) 
0.56 – 36,645 
IL-10  0.50 – 32,741 
MIP-1β 
(CCL4) 
0.54 – 35,161 
IL-12 p40  0.27 – 17,713 
RANTES 
(CCL5) 
0.44 – 28,968 
IL-12 p70  0.22 – 14,330  TNF-α  0.85 – 55,937 
IL-13  0.69 – 45,348 
Table 2.1  Expected concentration range (standard 1-9) of each cytokine within the 
recombinant standard provided in the multiplex kit.  The ranges were used to establish standard 
curves for each of the cytokines. 
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2.3  Assessment of embryonic and fetal development 
2.3.1  Blastocyst collection and analysis of cell number 
Uteri were dissected out and placed into normal saline solution that had been pre-
warmed to 37ºC.  Embryos were then flushed from each uterus by inserting a flushing 
needle (described in section 2.1.3) a short distance into the cut, anterior end of each 
uterine horn, and flushing through pre-warmed (37ºC) H6-BSA.  The blastocysts were 
washed three times (as in section 2.1.3) before undergoing differential nuclear staining 
to determine cell number in the TE and ICM cell lineages (see section 2.1.5). 
2.3.2  GD 17 fetal dissection 
At GD 17, female mice from each treatment group (as in section 2.2.1 and 2.2.2) 
were sacrificed by cervical dislocation.  The uterus containing the fetuses was dissected 
out (taking care to remember its orientation), placed into a petri dish containing cold 
PBS and immediately put onto ice.  Next, the wall of each uterine horn was carefully 
cut open.  Each conceptus (i.e. placenta, yolk sac, fetus and amniotic fluid) was 
‘plucked’ from its attachment site, placed on its own in a petri dish containing cold PBS 
and put onto ice.  Each conceptus was blotted to remove excess moisture and was 
weighed.  Each conceptus was then separated into its constituent parts, i.e. placenta, 
yolk sac and fetus, and each part was weighed individually.  After that, using a 
dissecting microscope (Zeiss Stemi SV6) and fine surgical instruments, each fetus was 
dissected and fetal brain, liver, left and right kidneys were removed and weighed.   
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2.4  Assessment of postnatal growth, behaviour, physiology and 
immune status 
A battery of postnatal assessments (Table 2.2) was conducted on the offspring of 
female mice that had been saline or LPS treated (as in section 2.2.2).  Details of each 
assessment are described in the following sections. 
Maternal 
Treatment 
Saline, 10, 50 and 150 µg/kg LPS 
Litter size  Yes Yes Yes 
Birth weight  Yes Yes Yes 
Growth  Yes Yes Yes 
Behaviour  Yes Yes Yes 
Systolic Blood 
Pressure 
Yes Yes Yes 
Organ Weight  Yes Yes Yes 
Offspring 
Treatment 
No treatment  Saline  50 µg/kg LPS 
Flow Cytometry of 
Splenocytes 
No  Yes Yes 
Multiplex cytokine 
assay of serum 
No  Yes Yes 
Table 2.2  Summary table of postnatal offspring treatment groups and assessments; those 
conducted before and after offspring treatment are highlighted.   
2.4.1  Birth weight and growth 
Female mice from each treatment group were allowed to give birth naturally.  Birth 
took place on GD 19; therefore mothers were checked for birth early in the morning on 
this day.  For each litter, the numbers of live and dead pups were recorded and any 
dead pups were removed from the cage.  The gender of each pup was assessed by 
examining the external, peri-anal anatomy, and the numbers of males and females 
were recorded.  Each pup was weighed on a digital balance and birth weights were   54 
recorded.  The litters were then culled back to six pups per litter.  Where possible, 
three pups of each gender were kept; the ones kept were those that had the median 
weights for their gender.  The pups were then returned to the cage with their mother, 
and had ad libitum access to standard rodent chow and tap water at all times.  At 3 
weeks of age the pups were weaned; littermates of the same gender were housed 
together and the mother was culled.  The offspring were weighed weekly until 30 
weeks of age. 
2.4.2  Behaviour 
Behaviour was assessed at 4, 5, 6, 8, 11, 14, 17, 20 and 23 weeks of age.  At each 
of these ages mice were tested as follows:   
•  Day 1 – open field test (afternoon) followed by nesting overnight.   
•  Day 2 – burrowing (1400-1600 hours) followed by overnight burrowing 
and consumption of glucose solution.   
Mice were housed in their home cages with their littermates when not involved in 
behavioural tests but underwent all behavioural tests individually.  Food and water 
were available ad libitum, except during the glucose solution test when glucose 
solution was substituted for tap water.   
2.4.2.1 Open field 
Open field tests (Fig. 2.2c,d) were conducted in the afternoon, in a normally lit room 
and prior to doing the test, mice were habitualised to the behaviour room for 30 
minutes.  The open field arena consisted of a white acrylic base enclosed on four sides 
with transparent, 0.7 cm thick acrylic (dimensions of 27.5 x 27.5 x 20 cm, model ENV-
520, Med Associates Inc., Georgia, Vermont).  Laser beams crossing the open field 
arena allowed animal movement to be detected and recorded automatically.  Each 
open field arena was surrounded by an aluminium shield that prevented the mouse 
under investigation from seeing other rodents.  Data was acquired by Activity Monitor 
software (Version 4.0, Med Associates Inc., Georgia, Vermont) for a 3 minute (180 
seconds) period which started as soon as a mouse was detected in the arena 
(Cunningham et al., 2007).  Each mouse was individually placed in the centre of the 
open field arena and the distance travelled, time spent resting, number of jumps and 
number of rears was recorded by the computer.  After each three minute recording   55 
period, the mouse was returned to its home cage and the open field arena was cleared 
of any droppings and wiped out with disinfectant solution and paper towels. 
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Figure 2.2  Representative images of behavioural and blood pressure assessments.  (a) 
Burrowing, (b) nesting, (c) and (d) open field.  Blood pressure apparatus, uncovered (e) and 
covered (f). 
2.4.2.2 Nesting and tap water consumption 
Normal tap water consumption was assessed overnight, concurrent with the nesting 
(see below).  Pre-weighed bottles of normal tap water were given at approximately 
1600 hours.  The bottles were reweighed at 1000 hours the following morning and the 
amount consumed (for an overnight period of approximately 18 hours) was calculated.  
At approximately 1600 hours mice were placed individually into cages that contained 
only sawdust bedding and a pressed cotton square (‘Nestlet’, Datesand Ltd, 
Manchester, UK; Fig. 2.2b).  The nests were rated the following morning by assigning 
a 1-5 score based on the following (Deacon, 2006a):   56 
1.  Nestlet not noticeably touched (>90% intact). 
2.  Nestlet partially torn up (50-90% remaining intact). 
3.  Nestlet mostly shredded, but no identifiable nest site; >50% of the Nestlet 
is torn up, but <90% of the Nestlet is within a quarter of the cage floor 
area, i.e. material is not gathered into a nest, but spread around the cage. 
4.  An identifiable, but flat nest:>90% of the Nestlet is torn up, the material is 
gathered into a nest within a quarter of the cage floor area, but the nest is 
flat, with walls less than the mouse body height (when curled up on its 
side) on >50% of its circumference. 
5.  A (near) perfect nest: >90% of the Nestlet is torn up, the nest is a crater, 
with walls larger than the mouse body height (when curled up on its side) 
on >50% of its circumference. 
2.4.2.3 Burrowing 
Plastic cylinders (blind ended, 20 cm long, 6.8 cm in diameter, open end supported 
by a block 3 cm in height) were filled with 190±2 g of standard rodent chow pellets 
and placed in individual mouse cages (Fig. 2.2a).  Mice were placed individually in the 
burrowing cages at approximately 1400 hours and were left undisturbed until 
approximately 1600 hours.  The chow remaining in the cylinders after two hours was 
weighed and the amount displaced (‘burrowed’) was calculated (Deacon, 2006b).  For 
the overnight burrowing, cylinders were returned to the cages immediately (without 
being topped up with additional chow) after weighing them at 1600 hours.  The chow 
remaining in the cylinders at approximately 1000 hours the following morning was 
weighed and the amount displaced (‘burrowed’ during an overnight period of 
approximately 18 hours) was calculated. 
2.4.2.4 Consumption of glucose solution 
Glucose solution consumption was assessed overnight, concurrent with the 
overnight burrowing (section 2.4.2.3 above).  A 5% glucose solution (D-(+)-glucose 
powder ≥99.5%; Sigma, G8270; dissolved 5% w/v in distilled water) in pre-weighed 
bottles was substituted for the normal tap water at 1600 hours.  The bottles were 
weighed again at approximately 1000 hours the following morning, and the amount 
consumed (during an overnight period of approximately 18 hours) was calculated.   57 
2.4.3  Systolic blood pressure 
Systolic blood pressure (SBP) was measured at 16, 22 and 28 weeks of age by tail 
cuff plethysmography using an ITC model 229 blood pressure monitor (Linton 
Instruments, Norfolk, UK).  Blood pressure measurements were taken at a room 
temperature of 27-30ºC which the mice were allowed to acclimatise to for at least 60 
minutes prior to readings being taken.  In order to take the SBP measurements, mice 
were restrained in an acrylic tube and their tails were threaded through the tail cuff 
(Fig. 2.2e,f).  The acrylic tube was then covered with a paper towel to provide the 
mouse with a ‘safer’ feeling environment (Fig. 2.2f).  Each mouse was allowed to 
acclimatise to the apparatus for approximately 5 minutes prior to readings being 
taken.  Five SBP readings were taken for each mouse at each of the ages studied and 
the mean value of the three median readings was taken as the SBP of that mouse at 
that age.   
2.4.4  Organ weight and immune status 
2.4.4.1 Postnatal treatment groups 
Mice were sacrificed between 37 and 42 weeks of age.  All animals were weighed 
the day of cull and, where possible, the mice in each litter were assigned to a postnatal 
treatment group according to this weight.  Two mice (one male and one female) from 
each litter were assigned to one of three postnatal groups; no treatment (the heaviest 
male and female), i.p. injection of normal saline (the lightest male and female) or i.p. 
injection of 50 µg/ml LPS (the median weight male and female; LPS, Salmonella 
enterica enteritidis).   
2.4.4.2 Organ collection and multiplex cytokine assay of serum 
On the day of cull, littermates from one litter were separated and each mouse was 
caged individually with ad libitum access to tap water but without chow.  Injected mice 
(saline and LPS) were culled 3.5 hours post-injection.  All mice were killed by cervical 
dislocation, blood samples were taken by cardiac puncture and serum was stored (as 
in section 2.2.3.2).  The Bio-Plex Mouse Cytokine 23-Plex Panel kit (Bio-Rad) was used 
to detect and quantify cytokine concentrations in each serum sample (see section 
2.2.3.3).  The following organs and fat pads were dissected out, weighed, snap frozen 
in liquid nitrogen and stored at -80ºC; heart, lungs, liver, left and right kidneys, brain, 
interscapular fat, retroperitoneal fat, gonadal fat, inguinal fat and mesenteric fat.  In 
addition, the spleen of every mouse was harvested and weighed.  Spleens from the   58 
injected mice (saline and LPS) were placed immediately into cold PBS and were kept 
on wet ice until splenocyte isolation was commenced (no longer than 3 hours).   
2.4.4.3 Isolation of splenocytes 
Splenocytes were isolated by preparation of single-cell suspensions from spleen and 
removal of red blood cell (RBC) contamination by hypotonic lysis.  A single-cell 
suspension was prepared by mashing a whole spleen (first cut into 4-5 pieces) through 
a cell strainer (BD Falcon Cell Strainer, 100 µm pore size, catalogue number 352360) 
into a 50 ml conical tube, using the plunger from a 1 ml syringe and rinsing regularly 
with plenty of cold PBS.  The resulting cell suspension was centrifuged at 4ºC, at 400 g 
for 7 minutes and the supernatant was discarded.  Next the cell pellet (dark red in 
colour due to the presence of RBCs) was re-suspended in 1-5 ml of RBC lysis buffer 
(ACK buffer; Appendix I) and incubated at room temperature for 10-15 minutes.  The 
tube was then filled with cold PBS, centrifuged at 4ºC, at 400 g for 7 minutes and the 
supernatant discarded.  The cell pellet (now white in colour indicating that RBCs had 
been eliminated) was re-suspended in 4 ml of cold PBS supplemented with 1% fetal 
calf serum (FCS) and 0.02% sodium azide.  These freshly isolated splenocytes were 
then immunostained (section 2.4.4.4) and fixed in preparation for analysis by flow 
cytometry (section 2.4.4.5). 
2.4.4.4 Immunostaining 
Freshly isolated splenocytes (section 2.4.4.3) were immunostained using 
combinations of fluorochrome-conjugated monoclonal antibodies (mAbs) against 
mouse leukocyte subpopulation markers (Table 2.3).   
Four spleens (i.e. the 2 LPS and 2 saline treated animals from one litter) were 
processed per staining session.  In all staining sessions, splenocytes from one mouse 
were stained with each mAb individually (single-colour tube), with no mAb (cells only, 
negative control tube) and with two mAbs together (2-colour tube).  As such, four 
tubes (BD Falcon 5 ml round bottom polystyrene test tube, 352032) were prepared (25 
µl of cell suspension/tube) for this mouse:  cells only (no mAb), CD4, CD8, CD19, and 
2-colours (CD4, CD8).  For each of the remaining three mice, i.e. three spleens, only 
two tubes were prepared (also 25 µl of cell suspension/tube):  CD19 and 2-colours 
(CD4, CD8,).     59 
Splenocytes were incubated with antibody in the dark, on ice for 30 minutes.  The 
tubes were then filled with cold PBS (supplemented with 1% FCS and 0.02% sodium 
azide), centrifuged at 4ºC, at 400 g for 7 minutes and the supernatant discarded.  
Next the cells were fixed by adding 1 ml of 4% formaldehyde to each tube and 
incubating in the dark, on ice for 20 minutes.  Finally, a further 3 ml of cold PBS were 
added to each tube.  The splenocytes were maintained in this 1% formaldehyde 
solution, well sealed, in the dark, at 4°C for up to 1 week before running on the flow 
cytometer.  Splenocytes were centrifuged at 4ºC, at 400 g for 7 minutes and re-
suspended in approximately 400 µl of PBS immediately before being run on the flow 
cytometer. 
Marker of 
Interest 
Fluorochrome 
Clone & 
Isotype 
Working Concentration 
(µg/10
6 cells/100 µl) 
CD4 
Fluorescein 
isothiocyanate (FITC) 
GK1.5, 
Rat IgG2b 
0.25 
CD8  PerCP-Cy5.5 
53-6.7, 
Rat IgG2a 
0.25 
CD19  Allophycocyanin (APC) 
MB19-1, 
Mouse 
IgA 
0.5 
Table 2.3  Summary of the fluorochrome-conjugated mAbs used to immunostain 
splenocytes for flow cytometry.  (All antibodies were purchased from eBioscience and were used 
at the concentrations recommended by the manufacturer). 
2.4.4.5 Flow cytometry 
Flow cytometry was performed using a FACSCanto instrument (BD Biosciences) and 
all data were analysed using FACSDiva software (Version 5.0.3, BD Biosciences).  In 
total, 10,000 or 20,000 events were collected for every tube.  Analysis of the collected 
data was conducted as follows.  To start with, singly stained tubes were used to set the 
appropriate compensation levels.  In brief, this was achieved by adjusting the median 
fluorescence of the positive population so that it was in alignment with the median 
fluorescence of the negative population.  Next, splenocyte populations were identified 
from a forward scatter (FSC; indicating cell size) vs. side scatter (SSC; indicating cell 
granularity) plot.  These splenocyte populations were gated and analysed further by 
creating dot plots to examine expression of the fluorescently-labelled cell markers.  For 
tubes labelled with CD19, a SSC vs. APC-CD19 plot was drawn.  For tubes labelled with   60 
two colours, a FITC-CD4 vs. PerCP-Cy5.5-CD8 dot plot was created.  The percentage of 
cells in each population and gate of interest was then quantified and displayed. 
2.5  Statistics 
Throughout the thesis significance was taken to be P≤0.05 and a trend was 
considered to exist if a P-value of between 0.051 and 0.1 was observed. 
All statistics were carried out using SPSS statistical software (SPSS, version 14).  All 
in vitro and in vivo blastocyst data (Chapters 3 and 5) and all maternal data (Chapter 
4) were analysed with a least significant difference (LSD) one-way analysis of variance 
(ANOVA) test.   
All GD 17 fetal dissection data (Chapter 5) and all postnatal data (Chapter 6) were 
analysed using a multilevel random effects regression model (Kwong et al., 2004; 
Watkins et al., 2008b).  This method of statistical analysis enabled the complex and 
hierarchical structure of the data set to be considered accurately.  The model not only 
takes into account between-litter and within-litter variation, but also makes possible 
the incorporation and evaluation of other measured parameters e.g. litter size.   
Pearsons correlation analysis was used were relevant to assess the degree of 
association between two parameters of interest.   
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3  Effect of interferon-γ on preimplantation mouse 
embryo development in vitro 
3.1  Introduction 
The essential role played by cytokines in reproductive and developmental processes 
is now as well recognised as their immune-modulating properties (Orsi, 2008).  
Interferon gamma (IFN-γ) is known to have important roles in both the immune and 
reproductive systems.  In the context of the immune system, IFN-γ is a pleiotropic 
cytokine that is produced predominantly by activated CD4
+ T H1 lymphocytes, cytotoxic 
CD8
+ T lymphocytes and natural killer (NK) cells.  Typically, IFN-γ is involved in 
antiproliferative and antiviral responses, tumour suppression, macrophage activation, 
antigen presentation and promoting the differentiation of naïve CD4
+ T lymphocytes 
into T H1 lymphocytes (Ramana et al., 2002).  The diverse biological actions of IFN-γ in 
the immune system are mediated mainly by regulation of gene expression within the 
target cell (Ramana et al., 2002).  Classically, IFN-γ signals intracellularly through the 
Janus kinase/signal transducer and activator of transcription-1 (JAK/STAT1) pathway 
(Ramana et al., 2002).  However, other intracellular signalling pathways, including 
MAP kinase, PI3-kinase and Src-kinases, are also known to play important roles in 
regulating the full repertoire of responses brought about by IFN-γ (Gough et al., 2008; 
Ramana et al., 2002).   
In the context of early pregnancy, IFN-γ is arguably most well recognized for its role 
at the feto-maternal interface during the peri-implantation period.  Uterine natural 
killer (uNK) cell-derived IFN-γ is imperative for normal decidual development and 
uterine artery remodelling during implantation (Ashkar et al., 2000).  In addition, there 
is some evidence to suggest that IFN-γ plays a functional role in trophoblast cells 
(TBCs); for example, in vitro culture with IFN-γ was found to induce the differentiation 
of ectoplacental cone cells into cytokeratin-positive TBCs (Athanassakis et al., 2000) 
and also to enhance TBC phagocytic activity (Albieri et al., 2005).  Interestingly, 
normal TBCs in vitro appear to be resistant to the characteristic IFN-γ-induced 
apoptosis and IFN-γ-induced expression of MHC class II molecules (Hoshida et al., 
2007; Murphy et al., 2004).   
In comparison, much less is known about the role of IFN-γ during preimplantation 
development.  The uterine fluid of naturally cycling mice has been found to contain   62 
IFN-γ at a concentration of approximately 100 pg/ml at oestrus (Orsi et al., 2007).  
Furthermore, in an elegant immunohistochemical study mapping the expression of 
IFN-γ in the normal mouse uterus, IFN-γ was detected in endometrial glands and 
luminal epithelium, and staining was strongest in estrus-phase uteri (Platt and Hunt, 
1998).  These experiments demonstrate that IFN-γ is present in the normal, healthy 
uterus and as such, suggests that the preimplantation embryo is exposed to IFN-γ 
physiologically.  Moreover, the preimplantation mouse embryo has been shown to 
express the complete IFN-γ receptor (IFNGR1 and IFNGR2 subunits) at all stages from 
one-cell to the blastocyst (Truchet et al., 2001).   
To my knowledge, there are very few studies investigating the effects of in vitro 
culture with IFN-γ on preimplantation development, and all of these studies used very 
high IFN-γ concentrations.  In addition, only one of these studies used recombinant 
mouse (rm) IFN-γ; limited conclusions can be drawn from the other studies since they 
cultured mouse embryos in IFN-γ from other species and IFN-γ is known to be highly 
species specific (Cameo et al., 1999; Hill et al., 1987; Warner et al., 1993).  Warner et 
al. (Warner et al., 1993) used rmIFN-γ in their study and reported a dose-dependent 
IFN-γ-stimulated increase in preimplantation cleavage rate that was associated with 
increased cell surface expression of Qa-2 protein.  The Qa-2 protein is a MHC class Ib 
(non-classical) protein that is coded for by the preimplantation embryo development 
(Ped) gene; the presence of which is known to confer an intrinsically fast rate of 
preimplantation cleavage, i.e. the Ped fast phenotype (Wu et al., 1998).  The 
aforementioned Warner study used an inbred, Ped fast strain of mice (C57BL/6J); it 
seems therefore, that exposure to IFN-γ can enhance preimplantation cleavage rate in 
embryos that are already genetically ‘fast’ and indeed, the Ped gene is known to 
contain an interferon responsive sequence (IRS) in its promoter (Cai et al., 1996).   
Overall, therefore, evidence seems to suggest that the effects of IFN-γ in early 
pregnancy are not as deleterious as might be expected from what is know of its 
characteristic actions in the immune system.  However, we know very little about how 
a physiological rmIFN-γ concentration range affects preimplantation mouse embryo 
development; and furthermore the effect of IFN-γ on embryos that are from an outbred 
stock of mice, the genetic diversity of which likely better reflects the situation in 
human populations (Byrne et al., 2007).  Furthermore, it is conceivable that altered 
levels of this cytokine could be found in the uterine fluid, if a female experiences 
systemic inflammation during the preimplantation period of gestation.  As such, the   63 
aim of this study was to examine the direct effect of a physiological rmIFN-γ 
concentration range on the development of outbred (MF1) preimplantation mouse 
embryos in vitro.  Groups of preimplantation embryos were cultured from the 2-cell to 
the blastocyst stage in 0 (medium only), 1, 10, 100 and 1000 pg/ml rmIFN-γ.  The 
effect of IFN-γ on development was assessed as follows:  i) by daily morphological 
scoring; and ii) by differential nuclear labelling of the two cell lineages (ICM and TE) 
within the blastocyst.   
3.2  Methods 
3.2.1  Superovulation and embryo collection 
Female MF1 mice were superovulated and mated with MF1 males (section 2.1.2).  
Embryos were flushed from oviducts at the 2-cell stage (GD 1.5, ~48 hours post-hCG) 
and temporarily maintained in equilibrated KSOM at 37ºC, 5% CO2 in air (section 
2.1.3). 
3.2.2  Embryo culture with IFN-γ 
Embryos were cultured from 2-cell to blastocyst stage (up to 146.5 hours post-hCG) 
in KSOM only (control) or increasing concentrations of IFN-γ (8.43 x 10
3 IU/μg); 1, 10, 
100 and 1000 pg/ml, without any changes of medium (section 2.1.4).  The 
developmental stage of each embryo was assessed twice daily at 0830 and 1630 
hours.  An embryo was described as compact when no individual cell outlines could be 
discerned clearly.  An embryo that had a visible cavity of any size was described as 
cavitated. 
3.2.3  Differential nuclear staining 
Embryos that had developed to the blastocyst stage by approximately 117 hours 
post-hCG were removed from culture and differentially stained (section 2.1.5).  After 
mounting, the embryos were viewed under a fluorescence microscope and the 
numbers of TE and ICM nuclei were counted. 
3.2.4  Statistics 
All statistics (section 2.5) were carried out using SPSS statistical software (SPSS, 
version 14).  Developmental stage data and blastocyst cell number data were analysed 
with a LSD one-way ANOVA test.  Pearsons correlation analysis was used to assess the 
degree of association between increasing IFN-γ concentrations and blastocyst cell   64 
number and the degree of association between percentage of embryos cavitated and 
percentage of embryos arrested.  Developmental stage data were additionally 
converted to Z-scores (using SPSS), which were analysed using a LSD one-way 
ANOVA.  The Z-score transformation used the entire developmental stage dataset to 
standardise the developmental stage to the same scale, with a mean of 0 and a 
standard deviation of 1.  This transformation allowed for analysis between treatment 
groups by comparing the developmental stage curve for each treatment as a whole, 
hence avoiding the use of multiple comparisons across time. 
3.3  Results 
3.3.1  Developmental rate of embryos cultured in vitro with increasing 
concentrations of IFN-γ 
This set of experiments shows that embryo culture with increasing concentrations of 
IFN-γ (1, 10, 100 and 1000 pg/ml) has no effect on development before cavitation.  
Fig. 3.1a-c illustrates the similarity between treatment groups at every time point, up 
to the 4-cell (Fig. 3.1a), 8-cell (Fig. 3.1b) and compact (Fig. 3.1c) stages of 
development.  However, embryo culture with increasing concentrations of IFN-γ did 
appear to have an effect on cavitation, as shown in Fig. 3.1d.  Of all treatment groups, 
control embryos (Fig. 3.1d, solid black line) have the slowest cavitation rate and the 
lowest percentage of cavitated embryos at 138.5 hours post-hCG (~60% maximum 
cavitated).  Embryos cultured in 1 and 100 pg/ml IFN-γ (Fig. 3.1d, black dashed and 
blue lines, respectively) are similar to one another, and have a higher percentage of 
embryos cavitated, with approximately 9% more cavitated embryos than control at 
138.5 hours post-hCG (not significant).  Embryos cultured in 10 and 1000 pg/ml IFN-γ 
(Fig. 3.1d, green and red lines, respectively) are also similar to one another, and have 
the highest percentage of embryos cavitated out of all treatment groups, with 
approximately 17% more cavitated embryos than control at 138.5 hours post-hCG (not 
significant).     65 
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Figure 3.1  Developmental stage data for preimplantation embryos cultured in vitro with 
KSOM and increasing concentrations of IFN-γ (1, 10, 100 and 1000 pg/ml).  IFN-γ had no effect 
at any concentration, at any time point on embryo development (a) to the 4-cell stage and 
beyond, (b) the 8-cell stage and beyond, (c) compaction and beyond, (d) on the percentage of 
embryos that cavitated or (e) on the percentage of arrested embryos.  Z-scores analysis showed 
that the overall percentage of cavitated embryos was increased (P≤0.05) in 10 and 1000 pg/ml 
IFN- γ treated groups when compared with control (f).  Data in (a) to (e) are mean±SEM; 
*denotes that the entire curve is significantly different (P≤0.05) from the control group.  n=918 
embryos in total; n=180-190 embryos per treatment group; experimental n=4.   
Assessment of overall embryo development using Z-score analysis supported the 
suggestion that embryo culture with increasing concentrations of IFN-γ (1, 10, 100 and   66 
1000 pg/ml) has no effect on developmental rate up to the 4-cell, 8-cell and compact 
stages of development (plots not shown).  Interestingly however, the Z-score analysis 
showed that embryos cultured in the presence of 10 and 1000 pg/ml IFN-γ, overall, 
have a significantly (P≤0.05) higher percentage of cavitated embryos than control (Fig. 
3.1f).   
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Table 3.1  Correlation analysis assessed the relationship between the percentage of 
cavitated embryos and the percentage of arrested embryos at each time point post-hCG (h) 
after cavitation had become evident (i.e. from 90.5 h post-hCG).  Correlation coefficients (r-
value) showed that as the % of cavitated embryos increased the % of arrested embryos 
decreased (P≤0.01) at every time point examined.   
There appeared to be an increased percentage of cavitated embryos in the 
treatment groups where there was a decreased percentage of arrested embryos.  This 
suggested that survival was improved in the treatment groups that exhibited a high 
percentage of cavitated embryos concomitantly with a low percentage of arrested 
embryos.  For example, at 122 hours post-hCG, the percentage of embryos cavitated 
was 73% (high) and 58% (low) for the 1000 pg/ml rmIFN-γ and control treated groups 
respectively, whereas a reciprocal pattern was seen for the percentage embryos 
arrested, which was 22% (low) and 31% (high) respectively, for the same groups.  
Indeed, correlation analysis revealed a strong and significant (P≤0.01) negative 
relationship between the percentage of cavitated embryos and the percentage of 
arrested embryos at each time point post-hCG (Table 3.1).  Therefore, the percentage 
of cavitated embryos increased as the percentage of arrested embryos decreased, 
which suggested improved survival.     67 
3.3.2  Blastocyst cell number and ICM:TE ratio of embryos cultured in vitro 
with increasing concentrations of IFN-γ 
Analysis of blastocyst cell number revealed a lineage-specific alteration in embryos 
that had been cultured in the presence of particular concentrations of IFN-γ (Fig. 3.2a).   
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Figure 3.2  Blastocyst cell number (a) and ICM:TE cell ratios (b) of embryos cultured in vitro 
with KSOM and increasing concentrations of IFN-γ (1, 10, 100 and 1000 pg/ml).  Embryo culture 
in the presence of 10 and 1000 pg/ml IFN-γ reduces ICM:TE cell ratio (b), which appears to be 
attributable to reduced cell number in the ICM lineage specifically (a).  Values are mean±SEM; 
*P≤0.05; † P≤0.1.  n=176 embryos in total; n=27-49 embryos per treatment group; 
experimental n=2.   
Across all treatment groups, the mean total blastocyst cell number ranged from 54 
to 62 cells (Fig. 3.2a).  Blastocysts from the 10 pg/ml IFN-γ treatment group had the 
lowest mean total cell number, while blastocysts from the 100 pg/ml IFN-γ treatment 
group had the highest mean total cell number.  However, no statistical differences in 
total cell number were found to exist.  In addition, no statistical differences in TE cell   68 
number were found to exist.  Across treatment groups the mean TE cell number 
ranged from 38 to 42 cells (Fig. 3.2a).  Blastocysts from the 1 pg/ml IFN-γ treatment 
group had the lowest mean TE cell number, while blastocysts from the 1000 pg/ml 
IFN-γ treatment group had the highest mean TE cell number.  Statistically significant 
differences were however found to exist specifically within the ICM cell lineage (Fig. 
3.2a).  Blastocysts from the 10 and 1000 pg/ml IFN-γ treatment groups contained 
fewer (P≤0.05) ICM cells (mean of 15 and 16 ICM cells, respectively) than control 
blastocysts (mean of 21 ICM cells).  Blastocysts from the 1 pg/ml IFN-γ treatment 
group also contained fewer (P≤0.1) ICM cells (mean of 18 ICM cells).  Essentially, 
there appeared to be a concentration dependent decrease in ICM cell number as IFN-γ 
concentration increased.  Indeed, a negative correlation (r = -0.165, P≤0.05; Table 
3.2) was found to exist between ICM cell number and increasing concentrations of IFN-
γ.  No such correlation was found to exist when total and TE cell number were analysed 
(Table 3.2).   
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Table 3.2  Correlation analysis assessed the relationship between increasing IFN-γ 
concentrations and blastocyst cell number.  Correlation coefficients (r-value) showed that ICM 
cell number and ICM:TE ratio decreased as concentration of IFN-γ increased.  No such 
correlation was found to exist when total and TE cell number were considered.  *P≤0.05. 
Unsurprisingly, the reduced ICM number had the effect of reducing ICM:TE cell ratio 
in blastocysts from the 10 and 1000 pg/ml IFN-γ treatment groups when compared 
with control.  Control blastocysts were found to have an ICM:TE ratio of 0.57, whereas 
blastocysts from the 10 and 1000 pg/ml IFN-γ treatment groups had a reduced 
(P≤0.05) ICM:TE ratio (ICM:TE ratio of 0.40 and 0.39, respectively).  Moreover, a 
negative correlation (r = -0.207, P≤0.05; Table 3.2) was also found to exist between 
ICM:TE ratio and increasing concentrations of IFN-γ.     69 
3.4  Discussion 
In this part of the study mouse preimplantation embryos were cultured from the 2-
cell to the blastocyst stage in medium only or increasing concentrations of rmIFN-γ 
within a physiological range; the effects of which were assessed by twice-daily scoring 
of developmental stage and by quantification of cell number in the ICM and TE of 
blastocysts.  To summarise, in this chapter I have shown that; i) select concentrations 
of rmIFN-γ (1000 pg/ml) result in an overall greater percentage of cavitated embryos; 
and ii) essentially, there is a dose dependent reduction in ICM cell number as rmIFN-γ 
concentrations increase.  The results obtained for the 100 pg/ml rmIFN-γ treatment 
group are curious because they are similar to the control group for every parameter 
examined, and therefore do not fit in with the dose-dependent pattern that was 
observed with the other treatment groups.   
Development of embryos from all treatment groups was similar until the compact 
stage and, in general, proceeded with the slight developmental delay that is well 
known to occur in in vitro cultured embryos when compared with embryo development 
in vivo (Sharkey, 1998; Watkins et al., 2007).  Cavitation was affected to the greatest 
extent since in vivo, cavitation would have occurred by 96 hours post-hCG in most 
embryos, whereas only 15-20% of embryos had cavitated by this time in this study.  
In addition, the final percentage of embryos cavitating in the control group is low, at 
only 60%.  Embryos could have been compromised for the following technical reasons:  
embryos were taken out of the incubator for a short time twice-daily for scoring 
purposes, during which time detrimental alterations in temperature or medium-pH 
could have occurred; also, embryos were cultured for the duration of the experiment 
(~4 days) in the same medium, without any changes or additions to the media, 
therefore there may have been a progressive lack of nutrients and/or build-up of toxic 
metabolites.  All treatment groups were exposed to the same routine, therefore it is 
interesting that rmIFN-γ seemed to improve the maximum percentage of cavitated 
embryos (discussed below).   
It is clear from this study that preimplantation mouse embryo development does 
not require an exogenous source of rmIFN-γ, since the control group were cultured in 
KSOM-medium free of IFN-γ.  Other lines of evidence confirm this:  it seems that IFN- γ 
is not absolutely essential for development, since IFN-γ and IFN-γ-receptor knockout 
mice are fertile and produce viable young (Dalton et al., 1993; Huang et al., 1993; Lu 
et al., 1998).  It should be noted however, that the rate of fetal resorbtion in IFN-γ   70 
knockout mice is very high and that surviving implantation sites are extremely 
abnormal (Ashkar and Croy, 1999; Ashkar et al., 2000).  This suggests therefore, that 
IFN-γ is not essential for preimplantation development but becomes so for healthy 
implantation.  Despite IFN-γ appearing not to be essential for preimplantation 
development, it is clear that the preimplantation embryo is exposed to IFN-γ.  Orsi et 
al. (Orsi et al., 2007) found IFN-γ to be at a concentration of approximately 100 pg/ml 
(~0.1 IU/ml; WHO standard units=1000 IU/μg IFN-γ) in mouse uterine fluid at estrus.  
In addition, Ashkar et al. (Ashkar and Croy, 1999) found a similar amount of IFN-γ, 
~0.1 IU/uterus (~100 pg/uterus), in homogenates of cycling mouse uterus, and up to 
10 IU/implantation site during mid-pregnancy.   
The Jak/STAT1 pathway mediates many of the classical immune functions of IFN-γ, 
of which most would be deleterious to the preimplantation embryo, e.g. its anti-
proliferative and pro-apoptotic actions.  Indeed, STAT1 knockout mice produce viable 
young, which suggests that Jak/STAT1 signalling is not essential for gestational 
development (Durbin et al., 1996).  Interestingly, Truchet et al. (Truchet et al., 2004) 
reported the presence of constitutively phosphorylated (activated) STAT1 in the 
nucleus throughout mouse preimplantation development; in spite of this however, very 
low or undetectable levels of mRNA were detected for the IFN-γ primary response 
gene, interferon regulatory factor 1 (IRF-1).  This finding suggested the presence of a 
transcriptional inhibition mechanism which, according to some recent evidence in mice, 
could involve histone deacetylase 1 (HDAC1).  In one study, RNAi-mediated reduction 
of HDAC1 in preimplantation mouse embryos resulted in histone hyperacetylation, 
elevated expression of a subset of genes and a developmental delay (Ma and Schultz, 
2008).  In another study, treatment of mouse trophoblast cells with a HDAC-inhibitor 
alleviated the repression of IFN-γ -inducible gene expression of genes, including; IRF1, 
class II transactivator (CIITA), low molecular protein (LMP), guanylate-binding protein 
(GBP) (Choi et al., 2009).  Taken together this evidence suggests that any response 
made by the preimplantation mouse embryo to IFN-γ must occur via a STAT1-
independent pathway.  As noted in the introduction, other intracellular signalling 
pathways, including MAP kinase, PI3-kinase and Src-kinases, are known to play 
important roles in regulating the full repertoire of IFN-γ-mediated responses (Gough et 
al., 2008; Ramana et al., 2002).  Several signal transduction pathways are known to 
be involved in preimplantation embryo development and include some of the STAT1-
independent pathways that are activated by IFN-γ, e.g. MAP kinase and PI3-kinase 
(Zhang et al., 2007).     71 
Interestingly, the PI3-kinase/Akt pathway is known to be important mediator of 
anti-apoptotic survival signals in the preimplantation embryo (Zhang et al., 2007).  In 
the present study, a strong negative correlation was found to exist between the 
percentage of embryos cavitated and the percentage of embryos arrested, which was 
suggestive of improved survival.  Therefore, it seemed that 10 and 1000 pg/ml rmIFN-
γ treated groups may have had improved survival, because a lower percentage of 
arrested embryos were seen in these treatment groups that had the greatest 
percentage of cavitated embryos and vice versa.  However, it was impossible to 
ascertain whether the embryos were cavitated or not upon arrest.   
Significantly reduced ICM cell numbers and ICM:TE ratios were seen in the 10 and 
1000 pg/ml rmIFN-γ treated groups that also displayed the highest percentage of 
embryos cavitated and the lowest percentage of embryos arrested.  Taken together 
these data suggest that select, higher physiological concentrations of rmIFN-γ (10 and 
1000 pg/ml) have a positive effect on the percentage of embryos cavitated, which is 
associated with improved survival and reduction in ICM and ICM:TE ratio.  Reduced 
ICM cell number could have occurred for the following reasons; reduced proliferation, 
increased differentiation or increased apoptosis.  Specific assays for each of these 
eventualities were not conducted therefore definitive conclusions could not be made.  
However, no change in total cell number was observed therefore increased ICM 
apoptosis is unlikely.  As such, the reduced ICM:TE ratio is more likely to be due to 
reduced proliferation of the ICM specifically, or increased differentiation towards the TE 
cell lineage.  A very interesting recent study conducted by Lu et al. (Lu et al., 2008a) 
found that activation of the Ras-MAPK/ERK1/2 pathway is highly important for Cdx2 
expression and TE differentiation from in vitro cultured embryonic stem cells, and that 
it is asymmetrically expressed at the apical membrane of the 8-cell embryo.  In 
addition activation of PKC isoforms in the preimplantation embryo has been shown to 
contribute to the regulation of cavitation (Eckert et al., 2004a; Eckert et al., 2004b).  
It is possible, therefore, that IFN-γ-mediated activation of the PKC and Ras-
MAPK/ERK1/2 pathways induced precocious and/or increased TE cell differentiation, 
which lead to reduced cell number in the ICM compartment. 
To conclude, in the present study select higher doses of rmIFN-γ (10 and 1000 
pg/ml) were found to increase the maximum percentage of cavitated embryos and to 
reduce the ICM:TE ratio in the blastocyst, which was specifically due to a reduction in 
ICM cell number.  It is possible that these effects were due to IFN-γ-mediated   72 
modulation of signalling pathways (e.g. Ras-MAPK/ERK1/2, PI3-K/Akt, PKC) that are 
important for preimplantation development.  An effect on survival potentially being 
mediated by PI3-K/Akt; and TE differentiation mediated by PKC and Ras-MAPK/ERK1/2 
is possible.  The results obtained for the 100 pg/ml rmIFN-γ treatment group are 
curious because they are similar to the control group for every parameter examined, 
and therefore do not fit in with the dose-dependent pattern that was observed with the 
other treatment groups.  It is interesting that this 100 pg/ml rmIFN-γ is the same as 
the IFN-γ concentration found in mouse uterine fluid at oestrus and in oestrus mouse 
uterus homogenate (Ashkar and Croy, 1999; Orsi et al., 2007).  Taken together, this 
leads me to suggest that there may be an ‘optimal’ IFN-γ concentration provided by 
the maternal reproductive tract.  Furthermore, it should be born in mind any IFN-γ 
signalling that occurs in the preimplantation embryo is subject to interaction and cross-
regulation by the many different factors present within the complex milieu of the 
uterine environment.   
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4  The maternal response to lipopolysaccharide 
administration 
4.1  Introduction 
Lipopolysaccharide (LPS) is an abundant and integral constituent of the outer 
membrane of Gram-negative bacteria.  It is released from the membrane when 
bacteria divide, die and lyse, and is therefore liberated into host tissues during a 
Gram-negative bacterial infection (Rietschel et al., 1994).  It is widely acknowledged 
that LPS is of prime importance in host recognition of infection and that it is a highly 
potent activator of the immune response, even in the absence of other bacterial 
components (Akira et al., 2006; Van Amersfoort et al., 2003).  Intravenous (i.v.) or 
intraperitoneal (i.p.) injection of LPS triggers an acute systemic inflammatory response 
that fully mimics the initial phase of a genuine systemic Gram-negative bacterial 
infection (Beutler, 2004; Dantzer, 2004).  Indeed, LPS has been used for decades to 
model systemic inflammation and sepsis (Beutler, 2004).   
Very minor inflammatory responses that occur within a particular tissue often 
remain localised and do not evoke a systemic response.  In contrast, more severe 
tissue inflammation and inflammation directly within the circulation (as with i.v. and 
i.p. injection of LPS), evoke an acute systemic inflammatory reaction known as the 
acute phase reaction (APR).  LPS is recognised by Toll-like receptor (TLR) 4, which is 
expressed predominantly by cells of the innate immune system (Fujihara et al., 2003; 
Poltorak et al., 1998).  Of these, antigen presenting cells (APCs; i.e. macrophages and 
dendritic cells, DCs) are particularly important because they release a wide range of 
inflammatory mediators that induce most features of the APR; these include: TNF-α, 
IL-1β, IL-6, IL-10, IL-12, MIP-1 α/β, MCP-1, RANTES, G-CSF, GM-CSF, platelet 
activating factor (PAF), prostaglandins, reactive oxygen species (ROS), nitric oxide 
(NO) and proteases (Fujihara et al., 2003).  The APR lasts 1-2 days and encompasses 
a wide range of responses that reflect the host’s concerted effort to neutralise the 
pathogenic stimulus and subsequently restore homeostasis (Dantzer, 2004).  Major 
features of the APR include; production of hepatic acute phase proteins (APPs), 
increased adrenocorticotropic hormone (ACTH) and glucocorticoid (GC) release, 
catabolism of muscle and adipose tissue, leukocytosis, fever, display of sickness   74 
behaviour (e.g. lethargy, somnolence, anhedonia, impaired cognitive function, 
anorexia and adipsia) and reduced body weight (Ceciliani et al., 2002; Dantzer, 2004).   
The features of an APR provide focus for the quantitative assessment of immune 
activation, and many are relatively straight forward to assess, e.g. weight loss.  Many 
studies involving the systemic administration of LPS have measured circulating 
cytokine concentrations, body weight, food and water consumption and 
locomotor/exploratory activity (frequently by open field test).  Teeling et al. (Teeling et 
al., 2007) conducted an open field test 2 hours after i.p. administration of 1, 10 and 
100 µg/kg LPS (Salmonella abortus equi) to mice and reported reduced levels of 
activity.  Also in this study, circulating concentrations of the major proinflammatory 
cytokines were found to be elevated compared with control three hours after i.p. 
injection of 100 µg/kg LPS.  In another study, Ogimoto et al. (Ogimoto et al., 2006) 
injected mice i.p. with 50 µg/kg LPS (Escherichia coli serotype 055:B5) and examined 
its effects on food and water consumption, and body weight.  When compared with 
vehicle injected controls at 20 hours post-injection, LPS injected mice exhibited 
reductions in all of the aforementioned parameters:  food consumption was 63% of 
control, water consumption was 58% of control and a loss of ~1.4 g of body weight 
was observed.   
Here in this part of the study I wanted to assess the extent of maternal immune 
activation following LPS administration on the first day of gestation (GD 0.5).  Thus, 
female mice were injected i.p with 0 (saline only), 10, 50 or 150 µg/kg LPS 
(Salmonella enterica enteritidis) on GD 0.5, and subsequently underwent the following 
assessments: open field test at 1 hour post-injection to examine locomotor and 
exploratory activity; measurement of food and water consumption every 24 hours for 
the first 5 days (GD 0.5-5.5) to assess the extent of anorexia and adipsia; 
measurement of body weight every 24 hours for the first 5 days (GD 0.5-5.5) and also 
once in late gestation (GD 15.5) to determine any longer lasting effects on maternal 
weight gain.  In addition, serum samples were collected every 24 hours for the first 3 
days (GD 0.5-3.5) to track maternal serum cytokine concentrations using multiplex 
technology.     75 
4.2  Methods 
4.2.1  Natural mating and LPS administration 
Female MF1 mice (controlled for age and weight) were naturally mated with MF1 
males (section 2.2.1).  Successfully mated females (vaginal-plug positive) received a 
dose of either normal saline (0.85% Sodium chloride, control) or one of three LPS 
(Salmonella enterica enteritidis, Sigma) doses between 1400 and 1600 hours on the 
day of plug (GD 0.5).  LPS doses of 10, 50 and 150 µg/kg body weight were 
administered by i.p. injection of 100 µl volumes (section 2.2.2). 
4.2.2  Assessment of the maternal response to LPS 
These females were subjected to a variety of assessments in order to characterise 
maternal response to the injection of saline (control) or LPS dosages.  One subset of 
females was assessed for sickness-related behaviours and body weight change.  The 
other subset of females was instead sacrificed to allow the collection of blood for 
analysis of serum cytokine concentrations using a multiplex cytokine assay kit (section 
2.2.3.3).   
4.2.2.1 Sickness behaviour and body weight 
At 1 hour post-injection mice underwent an open field test (section 2.2.3.1) as a 
quantitative measure of sickness behaviour.  Each mouse was individually placed in the 
centre of the open field arena and the distance travelled, time spent resting, number of 
jumps and number of rears was recorded.  Maternal body weight, and food and water 
consumption was also assessed.  Mice were weighed at the time of injection and at 24, 
48, 72, 96 and 120 hours post-injection (GD 0.5-5.5).  In addition, the mice were 
weighed in late gestation, at 360 hours post-injection (GD 15.5).  The chow and tap 
water bottle of each mouse were also weighed at the time of injection and at 24, 48, 
72, 96 and 120 hours post-injection (GD 0.5-5.5).  Mice had access ad libitum to chow 
and tap water throughout all assessments, apart from the 3 minute duration of the 
open field test.   
4.2.2.2 Collection of blood and multiplex cytokine assay 
Female mice from control and LPS treated groups were sacrificed by cervical 
dislocation at 3, 24, 48 and 72 hours post-injection.  Maternal blood samples were 
taken by cardiac puncture.  The clotted blood samples were centrifuged at 4ºC, at 
9,300 g for 10 minutes and the resulting serum was stored in aliquots at -80ºC until   76 
analysis (section 2.2.3.2).  The Bio-Plex Mouse Cytokine 23-Plex Panel kit (Bio-Rad) 
was used to detect and quantify 23 cytokines simultaneously, in each serum sample.  
The multiplex assay plates were read on a Luminex 100 instrument and results were 
analysed using StarStation software (section 2.2.3.3).   
4.2.3  Statistics 
All statistics (section 2.5) were carried out using SPSS statistical software (SPSS, 
version 14).  All data were analysed with a LSD one-way ANOVA.  Pearsons correlation 
analysis was used to assess the degree of association between increasing LPS dosages 
and relevant maternal parameters of interest.   
4.3  Results 
4.3.1  Sickness behaviour:  maternal open field 
A noticeable reduction in open field activity was evident in LPS treated mice at 1 
hour post-injection (Fig. 4.1).  Compared with saline-injected controls, LPS treated 
mice displayed a 28% (P≤0.1; 10 and 150 μg/kg) or 36% (P≤0.05; 50 μg/kg) 
reduction in distance travelled (Fig. 4.1a).  Control mice rested for 52% of the duration 
of the open field test, whereas 10 μg/kg LPS treated mice rested for 59% of the time 
and 50 and 150 μg/kg LPS treated mice for 63% and 61% of time respectively 
(P≤0.05; Fig. 4.1b).  Mice treated with 10 μg/kg LPS reared 31% less than control 
mice, while 50 and 150 μg/kg LPS treated mice reared 35% and 37.5% less 
respectively, than control mice (P≤0.1; Fig. 4.1c).  Of all parameters tested in the 
open field, LPS administration affected jumping activity to the greatest extent (Fig. 
4.1d).  LPS treated mice jumped 90-95% less (P≤0.05) than saline-injected control 
mice.     77 
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Figure 4.1  Assessment of maternal sickness behaviour:  A noticeable reduction in open field 
activity was evident in LPS treated mice at 1 hour post-injection.  Compared with saline-injected 
controls, LPS treated mice; travelled a shorter distance (a), spent more time resting (b), reared 
less (c) and jumped less (d).  Values are mean±SEM; *P≤0.05; † P≤0.1.  n=5-7 per treatment 
group.     78 
4.3.2  Sickness behaviour:  maternal food consumption 
In the first 24 hours post-injection (GD 0.5–1.5), LPS treated mice had significantly 
(P≤0.05) reduced food consumption when compared with saline-injected controls (Fig. 
4.2a).  Thus, between 0 and 24 hours post-injection, saline-injected control mice 
consumed 1.7-fold more food than 10 μg/kg LPS treated mice (P≤0.05) and, 2.5- and 
2.8-fold more than 50 and 150 μg/kg LPS treated mice, respectively (P≤0.05; Fig. 
4.2a).  Females entering the experiment were controlled for body weight (all females 
weighed between 27 g and 33 g) but nevertheless, in order to ensure that small 
variations in body weight were not influencing food consumption, the amount 
consumed in each 24 hour period post-injection was expressed in relation to pre-
injection maternal body weight (Fig. 4.2b).  Here, LPS treated mice had significantly 
(P≤0.05) reduced food consumption compared with saline-injected controls between 0 
and 24 hours post-injection (Fig. 4.2b).  Food consumption in all treatment groups 
(including saline-injected controls) increased between 24 and 48 hours post-injection 
(GD 1.5–2.5) compared with the previous 24 hours (Fig. 4.2a,b).  Between 24 and 48 
hours post-injection food consumed by control mice increased 1.2-fold, and food 
consumed by 10, 50 and 150 μg/kg LPS treated mice increased 3-fold, 3.5-fold and 4-
fold, respectively.  Food consumption between 24 and 48 hours was similar for all 
treatment groups (21-24% of pre-injection body weight).  Patterns of food 
consumption were also similar between treatment groups from 48 to 120 hours post-
injection (GD 2.5-5.5), except for a trend (P≤0.1) in 150 μg/kg LPS treated mice 
consuming more at 48-72 hours post-injection and 10 μg/kg LPS treated mice less at 
72-96 hours post-injection compared with controls (Fig. 4.2a,b).  Cumulative food 
consumption is shown in Fig. 4.2c.  Here, consumption by control mice was increased 
compared to all LPS treated groups equally at 24 and 48 hours post-injection.   79 
7.4 ± 0.92 8.3 ± 0.91 8.6 ± 0.81 6.6 ± 0.40 1.7 ± 0.29* 150 μg/kg 
LPS
7.7 ± 0.59 7.1 ± 0.44 7.1 ± 0.54 6.4 ± 0.59 1.9 ± 0.08* 50 μg/kg 
LPS
5.9 ± 0.38 5.8 ± 0.15† 5.6 ± 0.00 7.4 ± 1.57 2.7 ± 0.25* 10 μg/kg 
LPS
7.1 ± 0.79 8.1 ± 0.15 6.9 ± 0.77 6.2 ± 0.77 4.7 ± 0.38 Control
96 – 120 h 72 – 96 h 48 – 72 h 24 – 48 h 0 -24 h
Weight of food (g) consumed at the following times post-injection:
7.4 ± 0.92 8.3 ± 0.91 8.6 ± 0.81 6.6 ± 0.40 1.7 ± 0.29* 150 μg/kg 
LPS
7.7 ± 0.59 7.1 ± 0.44 7.1 ± 0.54 6.4 ± 0.59 1.9 ± 0.08* 50 μg/kg 
LPS
5.9 ± 0.38 5.8 ± 0.15† 5.6 ± 0.00 7.4 ± 1.57 2.7 ± 0.25* 10 μg/kg 
LPS
7.1 ± 0.79 8.1 ± 0.15 6.9 ± 0.77 6.2 ± 0.77 4.7 ± 0.38 Control
96 – 120 h 72 – 96 h 48 – 72 h 24 – 48 h 0 -24 h
Weight of food (g) consumed at the following times post-injection: a
0
5
10
15
20
25
30
35
0 - 24 24 - 48 48 - 72 72 - 96 96 - 120
Time post-injection (h)
W
e
i
g
h
t
 
o
f
 
f
o
o
d
 
c
o
n
s
u
m
e
d
 
(
g
)
/
m
a
t
e
r
n
a
l
 
b
o
d
y
 
w
e
i
g
h
t
 
(
g
)
 
(
%
)
 
 
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
*
†
† b
0
5
10
15
20
25
30
35
40
45
0 2 44 87 29 6 1 2 0
Time post-injection (h)
C
u
m
u
l
a
t
i
v
e
 
f
o
o
d
 
c
o
n
s
u
m
p
t
i
o
n
 
(
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
*
*
†
†
c
a
0
5
10
15
20
25
30
35
0 - 24 24 - 48 48 - 72 72 - 96 96 - 120
Time post-injection (h)
W
e
i
g
h
t
 
o
f
 
f
o
o
d
 
c
o
n
s
u
m
e
d
 
(
g
)
/
m
a
t
e
r
n
a
l
 
b
o
d
y
 
w
e
i
g
h
t
 
(
g
)
 
(
%
)
 
 
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
*
†
† b
0
5
10
15
20
25
30
35
40
45
0 2 44 87 29 6 1 2 0
Time post-injection (h)
C
u
m
u
l
a
t
i
v
e
 
f
o
o
d
 
c
o
n
s
u
m
p
t
i
o
n
 
(
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
*
*
†
†
c
0
5
10
15
20
25
30
35
0 - 24 24 - 48 48 - 72 72 - 96 96 - 120
Time post-injection (h)
W
e
i
g
h
t
 
o
f
 
f
o
o
d
 
c
o
n
s
u
m
e
d
 
(
g
)
/
m
a
t
e
r
n
a
l
 
b
o
d
y
 
w
e
i
g
h
t
 
(
g
)
 
(
%
)
 
 
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
*
†
† b
0
5
10
15
20
25
30
35
0 - 24 24 - 48 48 - 72 72 - 96 96 - 120
Time post-injection (h)
W
e
i
g
h
t
 
o
f
 
f
o
o
d
 
c
o
n
s
u
m
e
d
 
(
g
)
/
m
a
t
e
r
n
a
l
 
b
o
d
y
 
w
e
i
g
h
t
 
(
g
)
 
(
%
)
 
 
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
* *
† †
† † b
0
5
10
15
20
25
30
35
40
45
0 2 44 87 29 6 1 2 0
Time post-injection (h)
C
u
m
u
l
a
t
i
v
e
 
f
o
o
d
 
c
o
n
s
u
m
p
t
i
o
n
 
(
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
*
*
†
†
c
0
5
10
15
20
25
30
35
40
45
0 2 44 87 29 6 1 2 0
Time post-injection (h)
C
u
m
u
l
a
t
i
v
e
 
f
o
o
d
 
c
o
n
s
u
m
p
t
i
o
n
 
(
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
*
*
†
†
0
5
10
15
20
25
30
35
40
45
0 2 44 87 29 6 1 2 0
Time post-injection (h)
C
u
m
u
l
a
t
i
v
e
 
f
o
o
d
 
c
o
n
s
u
m
p
t
i
o
n
 
(
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
* *
* *
† †
† †
c
 
Figure 4.2  Maternal food consumption following i.p. injection of saline or LPS doses:  (a) 
raw weight of food consumed during each 24 hour period post-injection, (b) food consumption 
normalised to pre-injection body weight for each 24 hour period post-injection (%), (c) 
cumulative weight of food consumed at each 24 hour time point post-injection.  Values are 
mean±SEM; *P≤0.05; † P≤0.1.  n=5-7 per treatment group.     80 
4.3.3  Sickness behaviour:  maternal water consumption 
Maternal water consumption is shown in Fig. 4.3.  Raw volume of water consumed 
was significantly reduced (P≤0.05) in 50 and 150 μg/kg LPS treated mice versus 
controls at 24 hours post-injection (Fig. 4.3a).  Thereafter, raw water volume 
consumed was similar between groups.  Water consumption/maternal body weight (%) 
was similarly reduced in 50 and 150 μg/kg LPS treated mice versus controls at 24 
hours post-injection before stabilising across groups thereafter (Fig. 4.3b).  Cumulative 
water consumption was also reduced at 24 hours post-injection in the 50 and 150 
μg/kg LPS treated mice versus control (Fig. 4.3c).     81 
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Figure 4.3  Maternal water consumption following i.p. injection of saline or LPS doses:  (a) 
raw volume of water consumed during each 24 hour period post-injection, (b) water 
consumption normalised to pre-injection body weight for each 24 hour period post-injection (%), 
(c) cumulative volume of water consumed at each 24 hour time point post-injection.  Values are 
mean±SEM; *P≤0.05; † P≤0.1.  n=5-7 per treatment group.     82 
4.3.4  Maternal body weight 
Maternal body weight following treatment is shown in Fig. 4.4.  These were similar 
between groups up to 120 hours post-injection except for a significant reduction in 150 
µg/kg LPS treated mice at 24 and 48 hours post-injection (P≤0.05) and a trend 
reduction at 72, 96 and 120 hours post-injection (P≤0.1).  By late gestation (360 
hours post-treatment, GD 15.5), mice from 10 and 50 µg/kg LPS treatment were 
heavier than saline-injected control mice (P≤0.1; Fig. 4.4).   
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Figure 4.4  Maternal body weight following i.p. injection of saline or LPS doses.  Reduction in 
maternal body weight was evident in LPS treated mice at 24 hours post-injection (GD 1.5), 
significantly so (P<0.05) in 150 µg/kg LPS treated mice.  Regain of maternal body weight had 
begun by 48 hours post-injection (GD 2.5) and was slowest in 150 µg/kg LPS treated mice.  By 
late gestation (360 hours post-injection, GD 15.5), maternal body weight was increased (P<0.1) 
in 10 and 50 µg/kg LPS treated mice when compared with saline-injected controls.  Values are 
mean±SEM; *P≤0.05; † P<0.1.  n=5-7 per treatment group.   
Post-injection maternal body weight was normalised to pre-injection maternal body 
weight by expressing the former as a percentage of the latter (Fig. 4.5).  This showed 
that all groups initially lost weight over ~96 hours before regaining their post-injection 
body weight.  This weight loss was enhanced in all LPS treated groups.  Thus, at 24 
and 48 hours post-injection, control mice had a significantly greater body weight ratio 
compared to all LPS treated groups (P≤0.05).     83 
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Figure 4.5  Normalised maternal body weight following i.p. injection of saline or LPS doses 
(%).  Maternal body weight was reduced (P<0.05) in all LPS treated groups at 24 and 48 hours 
post- injection (GD 1.5 and 2.5) when compared with saline-injected controls.  Regain of body 
weight was evident from 48 hours (GD2.5) post-injection and mice from all treatment groups 
regained their pre-injection body weight by 96 hours (GD4.5) post-injection.  Dashed orange line 
indicates pre-injection body weight.  Values are mean±SEM; *P≤0.05.  n=5-7 per treatment 
group.   
4.3.5  Maternal serum cytokines 
I will first characterise the general features of the cytokine profiles observed before 
focusing on LPS-induced changes in the profiles.  The profile of each cytokine over the 
course of this experiment proved to be quite different between treatment groups (Fig. 
4.6).  Little change was seen in the serum profile of most cytokines from saline-
injected control mice during the course of the experiment, however some cytokines 
were seen to increase between GD 0.5 and GD 3.5 (3 and 72 hours post-injection; Fig. 
4.6).  In control mice the following cytokines were increased at GD 3.5 (72 hours post-
injection) compared with GD 0.5 (3 hours post-injection); IL-3 (2.2-fold; P=0.081), IL-
4 (2.2-fold; P=0.008), IL-12-p40 (2.4-fold; P=0.045), IL-12-p70 (2.4-fold; P=0.076), 
GM-CSF (1.5-fold; P=0.004), RANTES (2.4-fold; P=0.058), TNF-α (4-fold; P=0.076).  
A common pattern emerged for the LPS treated groups.  Firstly, at 3 and 24 hours 
post-injection, serum cytokine concentrations from the 10 and 50 µg/kg LPS treated 
groups were similar to each other, whereas the 150 µg/kg LPS treated group tended to 
be higher.  Secondly, by 48 hours post-injection, serum cytokine concentrations from   84 
all LPS treated groups tended to be similar to one another (Fig. 4.6).  In many cases 
this pattern appeared to be a consequence of 150 µg/kg LPS treatment inducing higher 
serum cytokine concentrations than 10 and 50 µg/kg LPS treatment initially, and 
subsequently cytokine concentrations falling more slowly in 150 µg/kg LPS treated 
mice than in 10 and 50 µg/kg LPS treated mice.  Thirdly, this resulted in all LPS 
treated groups only achieving equivalent serum cytokine concentrations to each other 
by 48 hours post-injection (Fig. 4.6).  Serum concentrations of many cytokines from 
LPS treated mice reached a peak at 3 hours post-injection, e.g. IL-2, IL-3 and RANTES.  
Serum concentrations of IL-1α and IL-9 from LPS treated mice reached a peak later, at 
24 hours post-injection.  It was the case with almost all of the cytokines, that 
treatment with 150 µg/kg LPS resulted in the highest serum cytokine concentrations at 
3 and 24 hours post-injection (Fig. 4.6).   
Analysis of the effect of LPS treatment on cytokine profile (versus controls) also 
showed diverse effects.  Thus, in many cases the cytokine concentration was between 
2- and 5-fold higher in serum from 150 µg/kg LPS than in serum from saline-injected 
control mice; for example, at 3 hours post-injection, IL-3 was increased 3-fold 
(P=0.002), IL-4 was increased 2-fold (P=0.002) and Eotaxin was increased 5-fold 
(P=0.02; Fig. 4.6).  Also at 3 hours post-injection, in serum from 150 µg/kg LPS 
treated mice, a rather more striking increase was seen compared with control in; IL-
12-p40 (48-fold; P=0.001), MCP-1 (58-fold; P=0.004), and RANTES (52-fold; 
P=0.044).  Interestingly, at 48 hours post-injection, serum concentrations of IL-12-
p70 and TNF- α from LPS treated mice were at their highest and LPS treated groups 
were similar to one another (Fig. 4.6).  As stated above, by 48 hours post-injection 
serum cytokine concentrations from all LPS treated groups tended to be similar to one 
another.  For some cytokines this meant that their concentrations were also similar to 
control (e.g. IL-4, GM-CSF), but for other cytokines their concentrations were several-
fold increased or decreased compared with control.  Concentrations of IL-2, IL-10, and 
IL-13 were all decreased compared with control at 48 hours post-injection.  Of these 
cytokines, IL-2 exhibited the most extreme reduction since 10, 50 and 150 µg/kg LPS 
treatment groups were less than control by 8-, 34- and 21-fold (all P≤0.001), 
respectively (Fig. 4.6).  In contrast, the concentrations of the following cytokines were 
increased 2-fold to 4-fold compared with control at 48 hours post-injection (P≤0.1 and 
P≤0.05); IL-6, IL-12-p70, RANTES and TNF-α (Fig. 4.6).     85 
NB:  The multiplex assay was able to detect and quantify the full concentration 
range of every cytokine at every time point examined, except for G-CSF, KC and IL-6 
at 3 hours post injection (discussed below; marked by ‘!’ in Fig. 4.6).  The data 
presented here for G-CSF, KC and IL-6 at 3 hours post injection are inaccurate and 
under-representative of actual concentrations, particularly for the LPS treated groups.  
In these cases, 40-100% of readings could not be converted to concentrations because 
the values obtained were above the upper limit of detection of the assay; for example, 
no G-CSF concentrations were calculated for the 10 µg/kg LPS treatment group at 3 
hours post-injection because all samples had readings above the upper limit of 
detection.   
 
 
 
 
 
 
 
 
Figure 4.6 (overleaf) Maternal serum cytokine concentrations (pg/ml) at 3, 24, 48 and 72 
hours post-injection (GD 0.5-3.5).  Graphs for each of the 23 cytokines are displayed in name 
order; first the interleukins in numerical order and then all others in alphabetical order.  Values 
mean ±SEM; n=5-7 per treatment group.   
* P≤0.05 compared with saline-injected control group 
♦ P≤0.05 compared with 10 μg/kg LPS group 
§ P≤0.05 compared with 50 μg/kg LPS group 
† P≤0.1 compared with saline-injected control group 
NB:  At certain time points, cytokine concentrations were very high; as such, values at these 
time points were divided by 10 or 30 to allow all bars to be displayed on the same graph, on the 
same scale.  A horizontal bracket with ‘X 10’ or ‘X 30’ indicates that the values for those bars 
should be multiplied by 10 or 30 to obtain the actual concentration.   
! - indicates technical problems with quantification of cytokine concentrations   86 
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Fig. 4.6 (Continued)   87 
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Fig. 4.6 (end) 
4.4  Discussion 
In this part of the study I examined the maternal response to i.p. LPS 
administration on the first day of gestation (GD 0.5).  This, to my knowledge, is the 
first time that the maternal response to LPS has been studied at such an early stage of 
gestation.  The response to systemic administration of LPS has been well studied in 
non-pregnant murine models and is known to result in an APR, of which characteristic 
features include; sickness behaviour, reduced body weight and increased circulating   92 
concentrations of proinflammatory cytokines.  My findings here indicate that the 
maternal APR during very early gestation is comparable to that typically observed in 
non-pregnant mice following i.p. injection of LPS within a similar dosage range.   
As expected, open field activity was found to be reduced at 1 hour post-injection in 
all LPS treated groups compared with control.  LPS treated mice travelled a shorter 
distance and spent more time resting.  Interestingly, jumping in the open field was 
reduced by 90-95% in the LPS treated mice and was the most severely affected open 
field parameter assessed in this study.  It is perhaps not surprising that jumping was 
more severely affected given the physically strenuous action involved.  All LPS doses 
reduced open field activity at 1 hour post-injection to a broadly similar level; for 
example, compared with control, mice treated with 10 µg/kg LPS reared ~31% less 
and mice treated with 50 and 150 µg/kg LPS reared only ~35% less.  Teeling et al. 
(Teeling et al., 2007) conducted an open field test 2 hours after i.p. administration of 
LPS (Salmonella abortus equi) to mice and reported ~36% less rears in mice treated 
with 10 µg/kg LPS and ~56% less rears in mice treated with 100 µg/kg LPS.  Teeling 
et al. clearly observed a more pronounced dose-dependent reduction in rearing than 
that seen in the present study.  Open field testing in the present study was conducted 
at 1 hour post-injection whereas the open field testing in the Teeling study was 
conducted at 2 hours post-injection, and likely contributes to the difference in results.   
The Teeling study also reported increased plasma concentrations of the major 
proinflammatory cytokines (IL-1β, IL-12-p70, IL-6, IFN-γ, KC, IL-10, TNF-α) three 
hours after i.p. injection of 100 µg/kg LPS (using a Mesoscale Discovery multiplex kit).  
In the present study, IL-1β, IL-10 and TNF-α were all found to be increased at 3 hours 
after injection with LPS, particularly so in the 150 µg/kg LPS group.  Although, IL-12-
p70 concentrations were increased in LPS treated mice at 3 hours, this was not 
statistically significant and interestingly, IFN-γ concentrations were not increased.  
Accurate comparisons cannot be made for circulating G-CSF, KC and IL-6 
concentrations due to aforementioned problems with quantification of the very high 
MFI values obtained.  Indeed, it has previously been reported in a study using 
multiplex cytokine technology (TNF-α, IL-6, MCP-1) that IL-6 concentrations could not 
be quantified in serum following i.p. LPS injection (1000 µg/kg, E.coli K-235), because 
the MFI measured was much greater than that ascribed to the highest standard (Ao et 
al., 2005).  However, it should be noted that the samples with unquantifiable MFI   93 
values could be rerun at a higher dilution in order to bring them into the range of the 
standard curve.   
Ogimoto et al. (Ogimoto et al., 2006) injected mice i.p. with 50 µg/kg LPS 
(Escherichia coli serotype 055:B5) and examined its effects on food and water 
consumption, and body weight.  When compared with vehicle injected controls at 20 
hours post-injection, LPS injected mice exhibited reductions in all of the 
aforementioned parameters:  food consumption was 63% of control, water 
consumption was 58% of control and a loss of ~1.4 g of body weight was observed 
(Ogimoto et al., 2006).  As expected, the present study showed that LPS 
administration resulted in reduced food and water consumption and also reduced body 
weight at 24 hours post-injection.  Furthermore, the reductions were quantitatively 
similar for the 50 µg/kg LPS treated group in the present study as they were for 50 
µg/kg LPS treated mice in the Ogimoto study: the corresponding results in the present 
study were as follows; food consumption was ~38% of control, water consumption was 
~61% of control and a loss of ~1.4 g of body weight was observed.   
There did not appear to be any clear pattern relating food/water consumption to 
serum cytokine concentrations.  This may at first appear surprising since the brain is 
known to express receptors for proinflammatory cytokines and furthermore, that both 
the administration of such cytokines peripherally, and directly into the brain, results in 
the same sickness behaviours as LPS administration, including anorexia and adipsia.  
However, in light of some recent studies, the disengagement seen here between 
food/water consumption and serum cytokine concentrations may not be so 
unexpected.  Pre-treatment of mice with the non-selective cyclooxygenase (COX) 
inhibitor indomethacin, has been shown to reverse LPS-induced reduction in burrowing 
activity and to attenuate LPS-induced anorexic actions, without altering the peripheral 
production of proinflammatory cytokines (Naoi et al., 2006; Teeling et al., 2007).  
Consequently, it seems that prostaglandins can affect behaviour independently of 
peripheral cytokines. However, PG levels were not assessed in the current study 
therefore this association could not be confirmed here.   
The concentration of many cytokines is known to change in the maternal circulation 
as pregnancy progresses, with many beginning to increase substantially at mid-
gestation and reaching high levels by late pregnancy (Orsi et al., 2006).  For example, 
Orsi et al. highlighted the following cytokines as increasing markedly in late   94 
pregnancy; TNF-α, IL-1β, IL-2, IL-6, IL-10, IL-12p40, IL-12p70 and IL-18 (Orsi et al., 
2006).  Interestingly, in the present study, several serum cytokines in control mice 
were found to increase through preimplantation gestation (i.e. GD 3.5 compared with 
GD 0.5), these included; IL-3 (2.2-fold; P=0.081), IL-4 (2.2-fold; P=0.008), IL-12-p40 
(2.4-fold; P=0.045), IL-12-p70 (2.4-fold; P=0.076), GM-CSF (1.5-fold; P=0.004), 
RANTES (2.4-fold; P=0.058), TNF-α (4-fold; P=0.076).  Thus, the present study 
echoes the findings in the Orsi study (mentioned above).   
In 1993 the Th1/Th2 paradigm of pregnancy was proposed, which essentially stated 
that successful pregnancy was a Th2 phenomena (Wegmann et al., 1993).  Since then 
however, it has been acknowledged that, despite being a helpful stepping stone in our 
understanding of the immunology of pregnancy, it is a gross over simplification, as 
discussed extensively in a review by Gérard Chaouat (Chaouat, 2007).  In the present 
study, the types of cytokines that were seen to increase physiologically during the 
preimplantation period included, chemokines (RANTES), hematopoietic growth factors 
(GM-CSF), proinflammatory (IL-12-p40, IL-12-p70, TNF-α) and T helper type 2 (T H2; 
IL-3, IL-4) cytokines.  Thus, the data presented in this chapter further support the idea 
that the T H1/T H2 paradigm is an over simplification of events.  Murine endometrial 
leukocyte infiltration and maternal hyporesponsiveness to paternal MHC antigens is 
mediated by seminal fluid and involves local alterations in a number of chemokines and 
cytokines including GM-CSF and RANTES (Johansson et al., 2004; Robertson et al., 
1997).  Thus, it is possible that the uterus is a source of the systemic GM-CSF and 
RANTES.  TNF-α is reported to be present in the preimplantation uterus and is 
suggested to have an important role to play in trophoblast invasion of the uterus due 
to it inducing trophoblastic expression of matrix metalloprotease 9 (MMP9) (Cohen et 
al., 2006).  It is thus possible that the systemic TNF-α could also be from a uterine 
source.  In addition, the uterus could be a source of the IL-12 found in the serum:  a 
moderate expression of IL-12 family members has been found to be necessary for 
normal uterine receptivity to implantation, whereby it is thought that IL-12 induces IFN 
production which in turn activates uNK cells to direct appropriate spiral artery 
remodelling (Ledee-Bataille et al., 2005).  Furthermore, it has been shown that during 
the third trimester of normal human pregnancy peripheral blood monocytes are primed 
to produce IL-12 (Sacks et al., 2003).  The increase in the T H2 type cytokines, IL-3 
and IL-4, could be mediated by progesterone-induced blocking factor (PIBF).  
Progesterone is essential for the maintenance of pregnancy and induces the release of   95 
PIBF from lymphocytes during pregnancy, where PIBF acts to skew the T H1/T H2 
balance in favour of T H2 cytokine production (Szekeres-Bartho and Wegmann, 1996).   
Patterns of maternal serum cytokine concentrations differed between treatment 
groups in the days following LPS injection.  Injection of LPS, particularly the highest 
dose (150 μg/kg), induced acute (3 and 24 hours post-injection) increases in maternal 
serum concentrations of a broad range of cytokines, including; chemokines (e.g. 
Eotaxin, MCP-1, MIP-1α, MIP-1β, RANTES), hematopoietic growth factors (e.g. G-CSF, 
GM-CSF), proinflammatory (e.g. IL-1β, TNF-α), T H1 (e.g. IL-2) and T H2 (e.g. IL-3, IL-
4, IL-5, IL-10) type cytokines.  Later, at 48 hours post-LPS, concentrations of IL-2, IL-
10 and IL-13 were all decreased compared with control, whereas IL-6, IL-12p70, 
RANTES and TNF-α were all increased compared with control.  Interestingly, those that 
were decreased at 48 hours are predominantly anti-inflammatory T H2 type (i.e. IL-10 
and IL-13) and those that were increased are predominantly proinflammatory (i.e. IL-
6, IL-12p70 and TNF-α).  This pattern of serum cytokines could be due in part to cross 
regulation of cytokine production.  For example, IL-10 is known to have potent 
immunosuppressive effects on macrophages, suppressing the production of 
proinflammatory mediators (e.g. IL-6, IL-12, TNF-α).  Since the IL-10 concentration 
was reduced at 48 hours, it is possible that there was reduced macrophage 
suppression which thus created a permissive environment for the release of 
proinflammatory cytokines from macrophages.  Exactly how fluctuations in maternal 
serum cytokines influence intrauterine cytokine composition is unclear.  Indeed, large 
discrepancies were found between the intrauterine and serum compartments for some 
cytokines in the mouse during estrus (Orsi et al., 2007).  It seems likely therefore, 
that the compartmentalisation of the uterine lumen ‘protects’ it from being directly 
influenced by fluctuations in serum cytokine concentrations.  However, it is quite 
possible that serum cytokine concentrations have an indirect effect on uterine luminal 
composition and could thus potentially alter preimplantation embryo development.  
The composition of the luminal fluid is impossible to ascertain in the present study 
because uterine fluid was not collected, but it should be noted that LPS treatment did 
affect blastocyst cell lineage allocation (as discussed in Chapter 5).   
In this chapter, I have demonstrated activation of the maternal immune response 
resulting from i.p. injection of 10, 50 and 150 µg/kg LPS.  Furthermore, this maternal 
immune response during very early gestation is comparable to that typically observed 
in non-pregnant mice following i.p. injection of LPS within a similar dosage range.     96 
5  Effect of maternally administered LPS during the 
preimplantation period on development of the 
blastocyst and fetus 
5.1  Introduction 
The preimplantation mammalian embryo is well known to be sensitive to alterations 
in its surrounding environment (Watkins et al., 2008a).  Evidence from both in vitro 
and in vivo studies indicate that altered preimplantation embryo environment can 
affect not only the immediate events of blastocyst formation, but can also give rise to 
long-term phenotypic consequences during fetal and/or postnatal life (Fleming et al., 
2004a; Watkins et al., 2008a).  Furthermore, certain lines of evidence suggest that 
blastocyst cell number is indicative of implantation potential (Richter et al., 2001), 
fetal development (Lane and Gardner, 1997) and postnatal phenotype (Kwong et al., 
2000; Watkins et al., 2007).  Implantation potential of human blastocysts following 
assisted reproductive technology (ART) was found to be improved if blastocysts had 
larger ICMs (presumably comprising more cells) (Richter et al., 2001).  Lane and 
Gardner (Lane and Gardner, 1997) found a significant positive correlation between 
fetal development and blastocyst and ICM cell number, whereas interestingly, there 
was no relationship with TE cell number.  Kwong et al. (Kwong et al., 2000) showed, in 
a rat model, that maternal low protein diet during preimplantation development led to 
reduced ICM and TE cell number in the mid-late blastocyst and also to altered 
postnatal phenotype, including; reduced birth weight, increased growth, increased 
systolic blood pressure and altered organ/body weight ratios for the liver and kidneys.  
In another study, in vitro culture of mouse embryos was found to reduce TE and ICM 
cell number in the blastocyst and subsequent to embryo transfer, resulted in increased 
offspring systolic blood pressure postnatally (Watkins et al., 2007).   
Maternal infection and inflammation specifically during early gestation has been 
associated with increased rates of abortion in human and animal studies.  A human 
birth cohort study found that bacterial vaginosis was associated with increased risk of 
miscarriage in the first trimester but did not affect conception rates in women 
undergoing in vitro fertilisation (Ralph et al., 1999).  Furthermore, in an animal study, 
female mice had a 54% abortion rate following maternal infection with the parasite 
Toxocara canis on the first day of gestation (Reiterova et al., 2003).  In support of this   97 
finding, Deb et al. (Deb et al., 2004) administered a range of LPS (Salmonella 
Minnesota Re-595) doses i.p. to pregnant female mice on the first day of gestation and 
found that 250 μg/kg LPS caused total embryonic loss and that 50, 100 and 200 μg/kg 
LPS resulted in 52%, 56% and 86% embryonic loss, respectively.  Very little else is 
known about the effects of maternal immune activation during very early gestation on 
pre-and post-implantation embryo development.  Thus, in this part of the study I 
sought to characterise the phenotype of blastocysts and fetuses from mothers that 
received an immune challenge during preimplantation development.  Pregnant female 
mice were injected i.p with 0 (saline only), 10, 50 or 150 µg/kg LPS (Salmonella 
enterica enteritidis) on GD 0.5.  To assess blastocyst phenotype, uteri of females from 
each treatment group were flushed at GD3.5, whereupon blastocysts were 
differentially labelled to allow quantification of cell number in the TE and ICM lineages.  
Post-implantation fetal development was assessed in each treatment group by GD17 
fetal dissection where placenta, yolk sac, fetus and a selection of fetal organs were 
weighed. 
5.2  Methods 
5.2.1  Natural mating and LPS administration 
Female MF1 mice (controlled for age and weight) were naturally mated with MF1 
males (section 2.2.1).  Successfully mated females (vaginal-plug positive) received a 
dose of either normal saline (0.85% Sodium chloride, control) or one of three LPS 
(Salmonella enterica enteritidis, Sigma) doses between 1400 and 1600 hours on the 
day of plug (GD 0.5).  LPS doses of 10, 50 and 150 µg/kg body weight were 
administered by i.p. injection of 100 µl volumes (section 2.2.2). 
5.2.2  Embryo collection and differential nuclear staining 
Female mice from each treatment group were sacrificed at GD 3.5 whereupon 
embryos were flushed from uteri and temporarily maintained in equilibrated KSOM.  
Blastocysts were washed three times before undergoing differential nuclear staining.  
After mounting, differentially stained blastocysts were viewed under a fluorescence 
microscope and the numbers of TE and ICM nuclei were counted (section 2.3.1). 
5.2.3  GD 17 fetal dissection 
At GD 17, female mice from each treatment group were sacrificed.  The uterus 
containing GD 17 fetuses was dissected out and placed in cold PBS on ice.  Each   98 
conceptus was weighed and separated into its constituent parts, i.e. placenta, yolk sac, 
fetus, whereupon each part was weighed.  A selection of organs (brain, liver, left and 
right kidneys) from each fetus was then rapidly dissected out and weighed (section 
2.3.2). 
5.2.4  Statistics 
All statistics (section 2.5) were carried out using SPSS statistical software (SPSS, 
version 14).  All blastocyst data were analysed with a LSD one-way ANOVA test.  All 
GD 17 fetal dissection data were analysed using a multilevel random effects regression 
model (Kwong et al., 2004; Watkins et al., 2008b).   
5.3  Results 
5.3.1  Embryo number 
The total number of embryos recovered from GD 3.5 uteri did not differ between 
treatment groups (Table 5.1).  Furthermore, the proportion of embryos that were 
blastocysts did not differ between treatment groups, either in terms of raw number of 
blastocysts recovered or when normalised as a percentage of the total number of 
embryos flushed (Table 5.1, bottom row).   
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Table 5.1  Embryos flushed from control and LPS-injected mothers at GD 3.5.  There were 
no differences between treatment groups in total number of embryos flushed, number of 
embryos that were blastocysts or the percentage of embryos that were blastocysts (number of 
blastocysts as % of total flushed).  n=4-8 mothers per treatment group.   
5.3.2  Cell number and ICM:TE ratio of blastocysts from control and LPS 
treated mothers 
Blastocysts from the 10 μg/kg LPS treatment group had 10.2% more cells in total 
than control blastocysts (P=0.003; Fig. 5.1a).  In contrast, blastocysts from the 50 and   99 
150 μg/kg LPS treatment groups had fewer cells in total than control, reduced by 
11.4% (P=0.025) and 19.5% (P=0.001), respectively (Fig. 5.1a).  The increased total 
cell number in the 10 μg/kg LPS treatment group appeared to be due to an increase in 
TE cell number specifically, as blastocysts from the 10 μg/kg LPS treatment group had 
21.2% more TE cells than control (P<0.001; Fig. 5.1a).  TE cell number in blastocysts 
from the 50 and 150 μg/kg LPS treatment groups was not different from control (Fig. 
5.1a).  Strikingly, ICM mass cell number was reduced in all LPS treatment groups 
compared with control; the 10 μg/kg LPS group was reduced by 14.3% (P=0.002) and 
the 50 and 150 μg/kg LPS groups were both reduced by 33.3% (P<0.001; Fig. 5.1a).   
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Figure 5.1  (a) Cell number and (b) ICM:TE cell ratio of blastocysts from control and LPS 
treated mothers.  Values are mean±SEM; *P≤0.05.  n= 33-50 blastocysts per treatment group; 
n=4-8 mothers per treatment group. 
The alterations in cell number resulted in reduced ICM:TE cell ratios in all LPS 
treatment groups compared with control; the 10 μg/kg LPS treatment group ratio was 
reduced by 37.8%, the 50 μg/kg LPS treatment group ratio was reduced by 41.7% and 
the 150 μg/kg LPS treatment group ratio was reduced by 24.4% (all groups P<0.001; 
Fig. 5.1b).  The reduced ICM:TE cell ratio in the 50 and 150 μg/kg LPS treatment   100 
groups seemed to be caused by a reduction in ICM cell number specifically.  However, 
in the 10 μg/kg LPS treatment group, the magnitude of the increase in TE cell number 
was greater than the reduction in ICM cell number, thus the increase in TE cell number 
is likely to have contributed most to the reduced ICM:TE ratio in this group (Fig. 5.1b).   
5.3.3  GD 17 fetal dissection 
No differences in mean total fetus number, or mean fetus number in the left or right 
uterine horn (Table 5.2) were observed between treatment groups.   
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Table 5.2  GD 17 litter size; mean total number of fetuses and mean number of fetuses in 
each uterine horn.  No differences in total fetus number, or fetus number in the left or right 
uterine horn were observed between treatment groups.  n=2-3 mothers per treatment group. 
 
Raw weight of the placenta, yolk sac (both Fig. 5.2a), conceptus and fetus (both 
Fig. 5.2b) did not differ between treatment groups.  In addition, no differences 
between treatments were found for fetal liver, brain, left and right kidneys, either 
when analysed as raw organ weight (data not shown) or when normalised to fetal body 
weight (Fig. 5.2c,d).     101 
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Figure 5.2  (a) Weight of GD 17 placenta and yolk sac; (b) conceptus and fetus weight at 
GD 17.  Normalised GD 17 fetal organ weight (%), (c) fetal liver and fetal brain; (d) left and 
right fetal kidneys.  Values are mean±SEM; n= 12-17 fetuses per treatment group; n=2-3 
mothers per treatment group.   102 
5.4  Discussion 
In this chapter I have shown that administration of 10, 50 and 150 μg/kg LPS to 
pregnant mice on GD 0.5 resulted in significantly reduced ICM:TE cell ratio in the GD 
3.5 blastocyst, but did not affect the number of embryos generated, the GD 17 litter 
size or GD 17 fetal phenotype, in terms of litter size, weight of conceptus, fetus, 
placenta, yolk sac, fetal liver, fetal brain or fetal kidneys.   
Maternal infection and inflammation specifically during early gestation has been 
associated with increased rates of abortion in human and animal studies (Deb et al., 
2004; Ralph et al., 1999; Reiterova et al., 2003).  The study conducted by Deb et al. 
(Deb et al., 2004) was relevant to the present study because this group administered a 
similar range of LPS doses i.p. to pregnant female mice on the first day of gestation.  
They found that 250 μg/kg LPS caused total embryonic loss and that 50, 100 and 200 
μg/kg LPS resulted in 52%, 56% and 86% embryonic loss, respectively.  In contrast, I 
found no effect of maternal LPS administered on GD 0.5 on embryonic loss, since 
numbers of embryos at GD 3.5 were similar to fetal litter size at GD 17.  This disparity 
is in spite of both studies using equivalent LPS doses, administered i.p. at the same 
time point of gestation and in a mouse model.  Additionally, in this study I have 
confirmed that an inflammatory response is induced in mothers following LPS 
administration (Chapter 4), therefore the lack of an effect on embryonic loss cannot be 
attributed to a weak/absent maternal immune response.  The major differences 
between the studies are in the type of LPS and the strain of mouse used: the Deb 
study used Park strain mice and Salmonella Minnesota Re-595 LPS, whereas MF1 mice 
and Salmonella enterica enteritidis LPS were used in the present study.   
In the present study, reduced ICM:TE ratio in the 50 and 150 μg/kg LPS treatment 
groups was due to a reduced ICM cell number specifically, whereas in the 10 μg/kg LPS 
treatment group the reduced ICM:TE ratio seemed to be a consequence of both 
increased TE cell numbers and reduced ICM cell numbers.  The magnitude of the 
increase in TE cell number was greater than the reduction in ICM cell number, thus the 
increase in TE cell number is likely to have contributed most to the reduced ICM:TE 
ratio in the 10 μg/kg LPS group.  This result suggests that proliferation of TE cells was 
enhanced specifically in the 10 μg/kg LPS treatment group, since TE cell number was 
unaffected in the 50 and 150 μg/kg LPS treatment groups.  Although not statistically 
significant, the percentage of embryos at the blastocyst stage of development was 
higher in the 10 μg/kg LPS treatment group (87%) than in the other treatment groups   103 
(62.5-65%).  Therefore, I suspect that the TE cells in embryos from the 10 μg/kg LPS 
treatment group had a greater propensity for proliferation, differentiation and 
maturation, which lead to increased TE cell number and promoted cavitation, i.e. 
blastocyst formation.   
In contrast to the effects on TE cell number, the present study revealed that ICM 
cell number was reduced in all LPS treatment groups (vs. control).  Similarly, a study 
in the rat reported a 15% reduction in ICM cell number in early blastocysts from 
females fed a low protein diet during the preimplantation stage of gestation (Kwong et 
al., 2000).  Furthermore, blastocysts from streptozotocin-induced diabetic rats were 
found to have reduced cell number which was specifically due to reduced ICM cell 
number (Pampfer et al., 1997).  It is important to note however, that the mechanisms 
resulting in reduced blastocyst cell number were different in the two studies 
highlighted above.  Blastocyst cell number in the low protein maternal diet model was 
reportedly reduced due to slowed cellular proliferation rather than apoptosis (Kwong et 
al., 2000).  In contrast, the reduced blastocyst cell number in the maternal diabetes 
model was due to high levels of cell death within the ICM (Pampfer et al., 1997).  In 
the present study assays for cell death and/or cell proliferation were not conducted, 
therefore it is not possible to conclude whether the reduced ICM cell number seen in 
blastocysts from LPS treated mothers was due to increased cell death, reduced 
proliferation or a combination of the two.   
The placenta develops from the TE cell lineage and the entire fetus is derived from 
the ICM cell lineage, therefore reductions in blastocyst cell number deplete the pool of 
cells available for subsequent stages of development.  In this study administration of 
10, 50 and 150 μg/kg LPS to pregnant female mice on GD 0.5 did not alter GD 17 fetal 
litter size, weight of conceptus, fetus, placenta, yolk sac, fetal liver, fetal brain or fetal 
kidneys, despite significant decreases in ICM cell number in blastocysts from all LPS 
groups and increased TE cell number in the 10 μg/kg LPS group.  It is interesting to 
note that the rat low protein maternal diet model also showed no reduction in litter 
size and no changes in the size of GD 10 deciduum or visceral yolk sac despite reduced 
blastocyst cell number (Kwong et al., 2000).  Experimental reduction of 
preimplantation embryo cell number resulted in decreased post-implantation viability 
and caused a delay in the timing of gastrulation and morphogenesis (Hishinuma et al., 
1996; Power and Tam, 1993; Tam, 1988).  However, interestingly, these studies 
revealed a remarkable restorative capacity of the fetus, whereby increased   104 
proliferation compensated for earlier losses in blastocyst cell number so that fetal size 
was comparable to control by approximately GD 10-12 (Hishinuma et al., 1996; Power 
and Tam, 1993; Tam, 1988).  Thus, in the present study, a possible explanation for 
altered blastocyst cell number without alterations in fetal phenotype could due to a 
compensatory fetal growth phase prior to GD 17 when the dissections took place.  
Examination of an earlier post-implantation time point potentially could reveal an effect 
of maternal LPS treatment.   
Overall, the effects of 10-150 μg/kg LPS administered to mothers i.p. on GD 0.5 
were subtle; embryo number and implantation capacity were not affected and the 
altered blastocyst cell number appeared to have been restored by late gestation, since 
GD 17 fetal phenotype was found to be normal.  Other studies have indicated that 
treatments which result in altered blastocyst cell number can also result in altered 
postnatal physiology (Kwong et al., 2000; Watkins et al., 2007), thus the altered 
blastocyst cell number found in the present study may herald alterations in postnatal 
offspring phenotype.  The postnatal consequences of maternal immune activation 
during very early preimplantation gestation are the subject of the next chapter.   
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6  Effect of maternally administered LPS during 
preimplantation development on postnatal growth, 
behaviour and physiology 
6.1  Introduction 
Maternal infection and inflammation during gestation can lead to alterations in 
various aspects of postnatal offspring phenotype, including; behaviour (Limosin et al., 
2003; Shi et al., 2003), immunity (Reiterova et al., 2006; Yamaguchi et al., 1983), 
metabolic status (Nilsson et al., 2001) and hypothalamic-pituitary-adrenocortical (HPA) 
axis functioning (Reul et al., 1994).   
Key evidence linking maternal infection during gestation to behavioural 
abnormalities in the offspring has come from human epidemiological research carried 
out over the last 20 years.  These studies have indicated that maternal influenza 
infection during mid-gestation is a significant risk factor for development of 
schizophrenia in genetically susceptible offspring (Brown, 2006; Limosin et al., 2003).  
To model maternal infection during mid-late gestation, LPS or the viral mimic PolyI:C 
(polyriboinosinic-polyribocytidilic acid, a synthetic double-stranded RNA analogue) has 
been administered to pregnant rodents.  In these animal models, activation of the 
maternal immune system during mid-late gestation lead to behavioural, morphological 
and pharmacological alterations in the offspring relevant to schizophrenia (Fortier et 
al., 2007; Zuckerman et al., 2003).  These data thus imply that the maternal immune 
response, rather than a particular pathogen, is the important link between prenatal 
maternal infection and postnatal behavioural abnormalities.   
Studies investigating the effect of maternal immune challenge on offspring immune 
status have tended to focus on the humoral immune system and have reported 
contradictory results.  Immunisation of female mice with sheep red blood cells (SRBCs; 
T cell-dependent foreign antigen) at any time point from 2 days before fertilisation to 
GD 16 induced suppression of anti-SRBC (IgM and IgG) plaque-forming cell (PFC) 
responses in their offspring, which suggested reduced ability to produce antigen-
specific antibody (Yamaguchi et al., 1983).  However, it should be noted, that this 
suppressive effect on anti-SRBC PFC response persisted only until ~15 weeks after 
birth.  In contrast, infection of female mice with the parasite Toxocara canis during 
mid-late gestation (GD 12-18) seemed to be protective for the offspring if they were   106 
infected postnatally (Reiterova et al., 2006).  When offspring were postnatally infected 
(6 weeks of age) with the same parasite that their mothers had received (T. canis), 
offspring displayed reduced production of IFN-γ and IL-5, suppressed eosinophilia, 
increased levels of IgM and IgG1 and reduced larval recovery from the brain and 
muscles (Reiterova et al., 2006).  The latter study implied that, in response to 
postnatal infection, increased levels of protective antibodies were produced in offspring 
from infected dams, which thus reduced the extent of infection without the 
requirement of a vigorous immune response, i.e. IFN-γ and IL-5 production and 
eosinophilia.  Hodyl et al. (Hodyl et al., 2007) administered 3 repeated doses of LPS 
(200 μg/kg) to rat dams during mid-late gestation (GD 16, 18 and 20) and reported 
severely blunted plasma cytokine (IL-1β and TNF-α) production in 19 day old offspring 
upon offspring challenge with LPS.  In contrast, the cytokine response of adult 
offspring in the Hodyl study was no different to control, but adult female offspring from 
LPS treated mothers had fewer leukocytes, which the authors attributed to an 
accelerated rate of immunosenescence.   
Alterations in offspring metabolic status and HPA axis functioning have been 
reported following maternal immune activation during gestation.  Nilsson et al. (Nilsson 
et al., 2001) challenged rats with 3 repeated doses of LPS (790 μg/kg) during mid-
gestation and examined aspects of metabolic functioning in the offspring.  Adult male 
offspring displayed obesity and features of the metabolic syndrome, specifically; 
increased body weight, increased abdominal fat-pad weights, elevated food intake, 
increased circulating leptin, insulin resistance and increased serum levels of 17β-
estradiol and progesterone.  In contrast, adult female offspring in the same study 
appeared to be less affected, exhibiting elevated serum testosterone levels, increased 
basal corticosterone levels and increased weight of the heart and adrenal glands.  In 
another study, pregnant rats received a single challenge with either LPS (30 μg/kg) or 
human red blood cells (HRBC) during mid-gestation, and postnatal HPA axis 
functioning was examined only in the male offspring (Reul et al., 1994).  This study 
reported that adult male offspring from both LPS and HRBC groups displayed increased 
basal plasma corticosterone levels, whereas after novelty-induced stress, only offspring 
from the HRBC group showed increased ACTH and corticosterone levels.  In addition, 
decreased levels of mineralocorticoid and glucocorticoid receptors were detected in the 
hippocampus.     107 
In the majority of the studies discussed above, maternal immune challenge 
occurred at a post-implantation time point, most frequently during mid- late gestation.  
Very limited knowledge is available about offspring phenotype following maternal 
immune challenge during early gestation.  In humans, one birth cohort study reported 
that maternal genital and reproductive infections during periconception increased the 
risk of schizophrenia in the offspring (Babulas et al., 2006).  Another human birth 
cohort study indicated that the risk of schizophrenia in offspring was increased 7-fold 
after serologically documented influenza exposure during the first trimester of 
pregnancy (Brown et al., 2004).  In relation to offspring immune status, as mentioned 
above, immunisation of female mice with SRBC at any time point from 2 days before 
fertilisation to GD 16 induced suppression of anti-SRBC (IgM and IgG) PFC responses 
in their offspring (Yamaguchi et al., 1983).   
The postnatal consequences of other types of challenge sustained during 
preimplantation development have been studied, and have established preimplantation 
development as being a sensitive stage during which a number of postnatal 
phenotypes may be induced from one genotype.  The postnatal consequences of in 
vitro culture have been found to include; altered locomotor and anxiety-related 
behaviour (Ecker et al., 2004; Fernandez-Gonzalez et al., 2004), altered organ/body 
weight ratios (Fernandez-Gonzalez et al., 2004) and increased systolic blood pressure 
(Watkins et al., 2007).  In vivo, feeding of a low protein maternal diet exclusively 
during preimplantation development lead to altered birth weight and growth, increased 
blood pressure and altered locomotor and anxiety-related behaviour in the offspring 
postnatally (Kwong et al., 2000; Watkins et al., 2008b).  Such findings show that 
preimplantation embryo environment can affect the structure and function of many 
different body systems.   
Here, in this part of the study, I sought to characterise the postnatal phenotype of 
offspring from mothers that received an immune challenge during preimplantation 
development.  Pregnant female mice were injected i.p with 0 (saline only), 10, 50 or 
150 µg/kg LPS (Salmonella enterica enteritidis) on GD 0.5 and were allowed to give 
birth naturally.  Offspring were assessed for growth, behaviour and systolic blood 
pressure at several time points throughout life, and were fully dissected at the time of 
cull in order to assess organ/body weight ratios.  In addition, a subset of offspring was 
injected with saline or 50 µg/kg LPS prior to sacrifice in order to assess immune status 
in terms of serum cytokine concentrations and spleen lymphocyte populations.   108 
6.2  Methods 
6.2.1  Natural mating and LPS administration 
Female MF1 mice (controlled for age and weight) were naturally mated with MF1 
males (section 2.2.1).  Successfully mated females (vaginal-plug positive) received a 
dose of either normal saline (0.85% Sodium chloride, control) or one of three LPS 
(Salmonella enterica enteritidis, Sigma) doses between 1400 and 1600 hours on the 
day of plug (GD 0.5).  LPS doses of 10, 50 and 150 µg/kg body weight were 
administered by i.p. injection of 100 µl volumes (section 2.2.2). 
6.2.2  Birth weight and growth 
Female mice from each treatment group were allowed to give birth naturally, which 
took place on GD 19.  Litter size, gender and birth weight was recorded.  Litters were 
culled back to six pups per litter; the three median-weight pups of each gender were 
kept.  Offspring were weaned at three weeks of age and were housed with littermates 
of the same gender thereafter.  Offspring were weighed weekly until 30 weeks of age.  
Mice had ad libitum access to chow and tap water throughout (section 2.4.1).   
6.2.3  Behaviour 
Behaviour (section 2.4.2) was assessed at 4, 5, 6, 8, 11, 14, 17, 20 and 23 weeks 
of age.  At each of these ages mice were tested as follows:   
•  Day 1 – open field test (afternoon) followed by nesting overnight 
(sections 2.4.2.1 and 2.4.2.2).   
•  Day 2 – burrowing (1400-1600 hours) followed by overnight burrowing 
and consumption of 5% glucose solution (sections 2.4.2.3 and 2.4.2.4).   
6.2.4  Systolic blood pressure 
Systolic blood pressure (SBP) was measured at 16, 22 and 28 weeks of age by tail 
cuff plethysmography.  Each mouse was allowed to acclimatise to the apparatus for 
approximately 5 minutes prior to readings being taken.  Five SBP readings were taken 
for each mouse at each of the ages studied and the mean value of the three median 
readings was taken as the SBP of that mouse at that age (section 2.4.3).     109 
6.2.5  Organ weight and immune status 
Mice were sacrificed between 37 and 42 weeks of age.  Prior to sacrifice, mice from 
each litter received either; no treatment, i.p. injection of normal saline (0.85%) or i.p. 
injection of 50 µg/ml LPS.  Two mice (one male and one female) from each litter were 
assigned to each of these three postnatal treatment groups (section 2.4.4.1).  Injected 
mice (saline and LPS) were culled 3.5 hours post-injection.  All mice were killed by 
cervical dislocation, blood was taken by cardiac puncture and serum was stored at -
80ºC.  The Bio-Plex Mouse Cytokine 23-Plex Panel kit (Bio-Rad) was used to detect 
and quantify cytokine concentrations in each serum sample (section 2.2.3.3).  Organs 
and fat pads were dissected out, weighed, snap frozen in liquid nitrogen and stored at 
-80ºC (section 2.4.4.2).  Splenocytes were isolated from the spleens of the injected 
mice (saline and LPS) by preparation of single-cell suspensions (section 2.4.4.3). 
Freshly isolated splenocytes were immunostained using combinations of fluorochrome-
conjugated monoclonal antibodies (mAbs) against mouse leukocyte subpopulation 
markers (section 2.4.4.4).  Flow cytometry was performed using a FACSCanto 
instrument and all data were analysed using FACSDiva software (section 2.4.4.5).   
6.2.6  Statistics and calculations 
All statistics (section 2.5) were carried out using SPSS statistical software (SPSS, 
version 14).  Pre-treatment maternal body weight data was analysed with a LSD one-
way ANOVA test.  All postnatal data were analysed using a multilevel random effects 
regression model which takes into account the hierarchical nature of the data set with 
between-litter and within-litter variation (Kwong et al., 2004; Watkins et al., 2008b).  
Thus, differences identified between treatment groups are independent of maternal 
origin of litter and gestational litter size (i.e. all pups, before standardisation of litter 
size), unless otherwise stated.  Body mass index (BMI) was calculated as follows:  
[Body weight in grams/(body length in centimetres)
2] x 100.   
6.3  Results 
All results in this section were based on replicates of 6 mothers (i.e. 6 litters) per 
treatment group.  Results for litter size, offspring gender ratio and birth weight 
(section 6.3.1) were based on non-standardised offspring numbers (i.e. all pups born).  
Results for all offspring experiments i.e. offspring growth, behaviour, systolic blood 
pressure and tissue weights (sections 6.3.2-6.3.5) were based on standardised   110 
offspring numbers.  Results for offspring immune status were based on selected 
offspring from standardised litters (section 6.3.6).   
6.3.1  Gestational parameters, litter size and birth weight 
Female mice were controlled for age and weight, and were randomly allocated to 
treatment groups however, females in the 10 and 50 μg/kg LPS groups were heavier 
than control (P=0.029 and P=0.026, respectively; Table 6.1).  There was no difference 
in the length of gestation.  Compared with control, litter size was 1.3-fold larger in the 
10 μg/kg LPS group (P=0.008) and there was a trend towards larger litter size (1.2-
fold, P=0.070) in the 50 μg/kg LPS group (Table 6.1).  In addition, the number of male 
offspring born was 1.4-fold larger in 10 μg/kg LPS group (vs. control; P=0.028; Table 
6.1).  Offspring gender ratio (male:female) and birth weight was not significantly 
different between treatment groups, except for a trend towards reduced birth weight in 
male offspring (vs. control; P=0.093; Table 6.1).   
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Table 6.1  Maternal pre-treatment body weight and effect of early gestational maternal 
inflammation on gestation length, litter size, male:female ratio and birth weight.  Values are 
mean(±SEM); *P≤0.05; † P≤0.1 (vs. control).  n=6 mothers per treatment group; n=65-82 
offspring per treatment group (32-39 females and 33-46 males).     111 
6.3.2  Offspring growth 
No differences in mean weekly body weight were evident between treatment groups 
for either female or male offspring up to 30 weeks of age (Fig. 6.1a,b).   
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Figure 6.1  Growth of female (a) and male (b) offspring from birth to 30 weeks of age.  
Growth is not different between treatments at any time point.  Values are mean±SEM.  n=6 
mothers per treatment group; n= 18 females and 18 males per treatment group.   
6.3.3  Behaviour 
For each individual mouse, behavioural tests were repeated 9 times between 4 and 
23 weeks of age.  In general, open field activity (section 6.3.3.1) and nesting activity 
(section 6.3.3.2) declined upon repeated exposure, whereas burrowing activity   112 
(section 6.3.3.3) seemed to improve with repetition.  Consumption of 5% glucose 
solution (section 6.3.3.4) appeared to decrease in male offspring with repetition, but 
did not vary much between time points for female offspring.   
6.3.3.1 Open field 
When examined on a weekly basis, minimal differences were found between 
treatment groups in open field activity, for either female (Fig. 6.2) or male (Fig. 6.3) 
offspring.  However, differences were detected at select time points and are detailed as 
follows.  Compared with control, 150 μg/kg LPS females reared less at week 8 
(reduced by 61.7%, P=0.001; Fig. 6.2d) and 150 μg/kg LPS males reared less at 
weeks 4 (reduced by 20.6%, P=0.029), 6 (reduced by 53.2%, P=0.045), 11 (reduced 
by 51.7%, P=0.013), 14 (reduced by 41.2%, P=0.033) and 20 (reduced by 58.2%, 
P=0.011; Fig. 6.3d).  In addition, 150 μg/kg LPS males jumped less than control at 
weeks 6 (80.3% less, P=0.031) and 17 (91.2% less. P=0.034; Fig. 6.3c), and rested 
for longer at week 6 (12.9% longer, P=0.040; Fig. 6.3b).   
No significant differences between treatments were found for female offspring in 
distance travelled or number of jumps (Fig. 6.2a,c).  However, a trend was detected 
for 50 μg/kg LPS females to spend longer resting at week 6 (vs. control, 9% longer, 
P=0.097; Fig. 6.2b).  Additionally, compared with control, trends towards reduced 
rearing activity were detected in 10 μg/kg LPS females at week 8 (reduced by 44.4%, 
P=0.065) and in 150 μg/kg LPS females at week 11 (reduced by 49.4%, P=0.072; Fig. 
6.2d).  Compared with control, a trend towards reduced distance travelled was seen in 
150 μg/kg LPS males at week 8 (47.4% reduction, P=0.072) and in 50 and 150 μg/kg 
LPS males at week 11 (reduced by 24.6%, P=0.091 and 30.8%, P=0.069, 
respectively; Fig. 6.3a).  A trend was also detected for 150 μg/kg LPS males to rest 
longer than control at weeks 8 and 11 (10.5% and 8.3% longer, respectively, P≤0.1; 
Fig. 6.3b).  Trends towards reduced jumping were seen in 150 μg/kg LPS males (vs. 
control) at weeks 8 (75.5% less. P=0.086), 11 (70.7% less. P=0.051), and 20 (70.8% 
less. P=0.064; Fig. 6.3c).  In addition, there was a trend towards 10 μg/kg LPS males 
jumping less than control at week 20 (64.6% less, P=0.065; Fig. 6.3c).  A trend was 
also detected for 150 μg/kg LPS males to rear less at week 8 (vs. control, reduced by 
48%, P=0.064).  All differences and trends were independent of maternal origin and 
gestational litter size.     113 
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Figure 6.2  Open field assessment of locomotor and exploratory behaviour in female 
offspring:  (a) distance travelled, (b) time resting, (c) number or jumps and (d) number of 
rears.  Values are mean±SEM; *P≤0.05; † P≤0.1; independent of maternal origin and litter size.  
n=6 mothers per treatment group; n= 18 females per treatment group.     114 
0
100
200
300
400
500
600
700
800
900
1000
4 5 6 8 1 11 41 72 02 3
Age (weeks)
D
i
s
t
a
n
c
e
 
t
r
a
v
e
l
l
e
d
 
(
c
m
 
/
3
 
m
i
n
s
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
a
† † †
0
20
40
60
80
100
120
140
160
4 5 6 8 11 14 17 20 23
Age (weeks)
T
i
m
e
 
r
e
s
t
i
n
g
 
(
s
 
/
3
 
m
i
n
s
)
b * † †
0
1
2
3
4
5
6
7
8
9
4 5 6 8 11 14 17 20 23
Age (weeks)
N
u
m
b
e
r
 
o
f
 
j
u
m
p
s
 
(
p
e
r
 
3
 
m
i
n
s
) c
*
†
†
*
†
†
0
10
20
30
40
50
60
4 5 6 8 1 11 41 72 02 3
Age (weeks)
N
u
m
b
e
r
 
o
f
 
r
e
a
r
s
 
(
p
e
r
 
3
 
m
i
n
s
) d
*
*
† *
*
*
0
100
200
300
400
500
600
700
800
900
1000
4 5 6 8 11 14 17 20 23
Age (weeks)
D
i
s
t
a
n
c
e
 
t
r
a
v
e
l
l
e
d
 
(
c
m
 
/
3
 
m
i
n
s
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
a
† † †
0
100
200
300
400
500
600
700
800
900
1000
4 5 6 8 11 14 17 20 23
Age (weeks)
D
i
s
t
a
n
c
e
 
t
r
a
v
e
l
l
e
d
 
(
c
m
 
/
3
 
m
i
n
s
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
a
† † †
0
20
40
60
80
100
120
140
160
4 5 6 8 11 14 17 20 23
Age (weeks)
T
i
m
e
 
r
e
s
t
i
n
g
 
(
s
 
/
3
 
m
i
n
s
)
b * † †
0
20
40
60
80
100
120
140
160
4 5 6 8 11 14 17 20 23
Age (weeks)
T
i
m
e
 
r
e
s
t
i
n
g
 
(
s
 
/
3
 
m
i
n
s
)
b * † †
0
1
2
3
4
5
6
7
8
9
4 5 6 8 11 14 17 20 23
Age (weeks)
N
u
m
b
e
r
 
o
f
 
j
u
m
p
s
 
(
p
e
r
 
3
 
m
i
n
s
) c
*
†
†
*
†
†
0
1
2
3
4
5
6
7
8
9
4 5 6 8 11 14 17 20 23
Age (weeks)
N
u
m
b
e
r
 
o
f
 
j
u
m
p
s
 
(
p
e
r
 
3
 
m
i
n
s
) c
*
†
†
*
†
†
0
10
20
30
40
50
60
4 5 6 8 1 11 41 72 02 3
Age (weeks)
N
u
m
b
e
r
 
o
f
 
r
e
a
r
s
 
(
p
e
r
 
3
 
m
i
n
s
) d
*
*
† *
*
*
0
10
20
30
40
50
60
4 5 6 8 1 11 41 72 02 3
Age (weeks)
N
u
m
b
e
r
 
o
f
 
r
e
a
r
s
 
(
p
e
r
 
3
 
m
i
n
s
) d
*
*
† *
*
*
 
Figure 6.3  Open field assessment of locomotor and exploratory behaviour in male offspring:  
(a) distance travelled, (b) time resting, (c) number or jumps and (d) number of rears.  
Reduction in open field activity was evident in male offspring from the 150 μg/kg LPS group.  
Values are mean±SEM; *P≤0.05; † P≤0.1; independent of maternal origin and litter size.  n=6 
mothers per treatment group; n= 18 males per treatment group.     115 
Life-time open field activity of female and male offspring was integrated by 
averaging all weekly data for each open field parameter (Fig. 6.4).  Male 150 μg/kg 
LPS offspring displayed reduced life-mean number of jumps and rears (reduced by 
67.4%, P=0.027 and 40.1%, P=0.015, respectively; Fig. 6.4c,d) and a trend towards 
increased life-mean time resting (increased by 7.5%, P=0.059), but no differences in 
life-mean distance travelled (Fig. 6.4a).  Female 150 μg/kg LPS offspring displayed a 
trend towards reduced life-mean number of rears (reduced by 32.1%, P=0.064; Fig. 
6.4d).  No differences existed between treatment groups for females when life-mean 
distance travelled, time resting or number of jumps were examined (Fig. 6.4a,b,c).  All 
differences and trends in life-time mean data were independent of maternal origin and 
gestational litter size.     116 
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Figure 6.4  Life-time open field activity of individual female and male offspring was 
integrated by averaging all weekly data for each open field parameter:  (a) distance travelled, 
(b) time resting, (c) number or jumps and (d) number of rears.  Male offspring from the 150 
μg/kg LPS group displayed reduced life-time open field activity.  Values are mean±SEM; 
*P≤0.05; † P≤0.1; independent of maternal origin and litter size.  n=6 mothers per treatment 
group; n= 18 females and 18 males per treatment group.     117 
6.3.3.2 Nesting 
At week 14, 50 and 150 μg/kg LPS males had significantly increased nest building 
activity (increased by 9.1% and 11.1%, respectively, P≤0.01, versus control; Fig. 
6.5b).  A trend towards increased nest building activity was seen in 150 μg/kg LPS 
males at week 6 (increased by 6.1%, P=0.087, versus control; Fig. 6.5b) and by 10 
μg/kg LPS males at week 14 (increased by 4.8%, P=0.059, versus control; Fig. 6.5b).  
In contrast, at week 23, 10 μg/kg LPS males exhibited a trend towards reduced nest 
building activity (reduced 12.8%, P=0.089, versus control; Fig. 6.5b).  No differences 
in female nesting behaviour were seen between treatments at any time point.  
However, at week 8, 150 μg/kg LPS females exhibited a trend towards reduced nest 
building activity (reduced 15.9%, P=0.092, versus control; Fig. 6.5a).  No differences 
were observed between treatment groups for life-time mean nesting, for either 
females or males (Fig. 6.5c).  All data were independent of maternal origin and 
gestational litter size.     118 
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Figure 6.5  Nesting scores of (a) female and (b) male offspring across time; and (c) life-
time nesting scores.  Overall, little difference in nesting was seen between groups.  Values are 
mean±SEM; *P≤0.05; † P≤0.1; independent of maternal origin.  n=6 mothers per treatment 
group; n= 18 females and 18 males per treatment group.     119 
6.3.3.3 Burrowing 
No differences were seen between treatment groups for burrowing between 1400 
and 1600 hours for either male or female offspring (Fig. 6.6a,b), although a trend was 
detected at week 23 for 50 μg/kg LPS females to burrow less than control (reduced by 
7.7%, P=0.087; Fig. 6.6a).  In addition, there were no significant differences between 
treatments for life-time mean burrowing between 1400 and 1600 hours for female or 
male offspring (Fig. 6.6c).  These data were independent of maternal origin and 
gestational litter size.  The only difference seen between treatment groups for 
burrowing overnight was at week 23, where 50 μg/kg LPS females burrowed less than 
control (reduced by 6.5%, P=0.046; Fig. 6.7a).  These data were independent of 
maternal origin, whereas gestational litter size was found to have a positive influence 
(+4.6 g per value increase in litter size, P=0.032).  There were no differences between 
treatment groups for life-time mean burrowing overnight, for either female or male 
offspring (Fig. 6.7a,b,c).     120 
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Figure 6.6  Amount burrowed from 1400-1600h for (a) female and (b) male offspring across 
time; and (c) life-time amount burrowed from 1400-1600h.  Little difference was seen between 
groups.  Values are mean±SEM; † P≤0.1; independent of maternal origin.  n=6 mothers per 
treatment group; n= 18 females and 18 males per treatment group.     121 
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Figure 6.7  Amount burrowed overnight for (a) female and (b) male offspring across time; 
and (c) life-time amount burrowed overnight.  Little difference was seen between groups.  
Values are mean±SEM; *P≤0.05; independent of maternal origin.  n=6 mothers per treatment 
group; n= 18 females and 18 males per treatment group.     122 
6.3.3.4 Consumption of glucose solution and tap water 
When examined on an individual weekly basis, 150 μg/kg LPS females consumed 
more 5% glucose solution than control at week 5 (increased by 36.4%, P=0.038).  At 
weeks 6 and 8, a trend was detected for 150 μg/kg LPS females to consume more 5% 
glucose solution than control (increased by 41.2%, P≤0.1; Fig. 6.8a).  Furthermore, 
when compared with control, there was a trend towards 150 μg/kg LPS females having 
increased life-time mean consumption of 5% glucose solution (increased by 36%, 
P=0.094; Fig. 6.8c).  Male offspring displayed no differences between treatments at 
any time point, or when life-time mean consumption of 5% glucose solution was 
analysed (Fig. 6.8b).  Tap water consumption was not different between treatments for 
females or males, at any time point (data not shown).     123 
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Figure 6.8  Consumption of 5% glucose solution for (a) female and (b) male offspring across 
time; and (c) life-time consumption of 5% glucose solution.  Female offspring from the 150 
μg/kg LPS group tended to consume more glucose solution compared with control.  Values are 
mean±SEM; *P≤0.05; † P≤0.1; independent of maternal origin and litter size.  n=6 mothers per 
treatment group; n= 18 females and 18 males per treatment group.     124 
6.3.4  Systolic blood pressure 
When compared with control, 10 μg/kg LPS males displayed increased systolic blood 
pressure (SBP) at weeks 16 and 28 (increased by 4.5%, P=0.035 and 7%, P=0.040, 
respectively; Fig. 6.9b).  Furthermore, life-time mean SBP was significantly increased 
in 10 μg/kg LPS males (increased by 3.9%, P=0.029; versus control; Fig. 6.9c).  There 
were no differences in SBP or life-time mean SBP between treatments for female 
offspring (Fig. 6.9a).  All data were independent of maternal origin and gestational 
litter size.     125 
70
75
80
85
90
95
100
105
16 22 28
Age (weeks)
S
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
Females a
70
75
80
85
90
95
100
105
110
115
16 22 28
Age (weeks)
S
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
Males b
* *
70
75
80
85
90
95
100
105
110
Females Males
L
i
f
e
 
s
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
c
*
70
75
80
85
90
95
100
105
16 22 28
Age (weeks)
S
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
Females a
70
75
80
85
90
95
100
105
16 22 28
Age (weeks)
S
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
Control
10 µg/kg LPS
50 µg/kg LPS
150 µg/kg LPS
Females a
70
75
80
85
90
95
100
105
110
115
16 22 28
Age (weeks)
S
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
Males b
* *
70
75
80
85
90
95
100
105
110
115
16 22 28
Age (weeks)
S
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
Males b
* *
70
75
80
85
90
95
100
105
110
Females Males
L
i
f
e
 
s
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
c
*
70
75
80
85
90
95
100
105
110
Females Males
L
i
f
e
 
s
y
s
t
o
l
i
c
 
b
l
o
o
d
 
p
r
e
s
s
u
r
e
 
(
m
m
H
g
)
c
*
 
Figure 6.9  Systolic blood pressure (SBP) of (a) female and (b) male offspring across time; 
and (c) life-time SBP.  Overall, male offspring from the 10 μg/kg LPS group had higher SBP than 
control.  Values are mean±SEM; *P≤0.05; independent of maternal origin and litter size.  n=6 
mothers per treatment group; n= 18 females and 18 males per treatment group.     126 
6.3.5  Organ and fat-pad weights 
All organ and fat-pad weights were normalised by expression as a percentage of 
body weight.  Organ/body weight ratios in male offspring appeared to have been 
affected to a greater extent than in female offspring.  Compared with control, 150 
μg/kg LPS males had increased retro-peritoneal fat/body weight ratio (increased by 
28.5%, P=0.013) and inguinal fat pad/body weight ratios (increased by 27.8%, 
P=0.031; Fig. 6.12c,d), and displayed a trend towards increased inter-scapular 
fat/body weight ratios (increased by 21.1%, P=0.089; Fig. 6.12c).  BMI was 
significantly increased in 150 μg/kg LPS males compared with control (increased by 
6.9%, P=0.033; Fig. 6.13c), although total fat/body weight ratio and carcass/body 
weight ratio (Fig. 6.13a,b) did not differ between treatments.  In addition, when 
compared with control, 150 μg/kg LPS males tended to have decreased lung/body 
weight ratios (decreased by 9.8%, P=0.098; Fig. 6.12a), and 50 μg/kg LPS males 
tended to have reduced liver/body weight ratios (reduced by 9.5%, P=0.052; Fig. 
6.12b).  In female offspring no differences between treatments were seen for any 
organ or fat pad, except liver (Fig. 6.10).  Females from 50 μg/kg LPS treatment had 
significantly reduced liver/body weight ratio compared with control (reduced by 11.6%, 
P=0.033; Fig. 6.10b), whereas 10 and 150 μg/kg LPS females displayed a trend level 
reduction (both of the latter treatments reduced by 9.3%, P=0.057; Fig. 6.10b).  All 
data were independent of maternal origin and gestational litter size.     127 
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Figure 6.10  Normalised organ and fat-pad weights of female offspring (%): (a) major 
organs; (b) liver; (c) and (d) fat-pads.  Female offspring from LPS treated groups had 
proportionally reduced liver mass compared with control.  Values are mean±SEM; *P≤0.05; † 
P≤0.1; independent of maternal origin and litter size.  n=6 mothers per treatment group; n= 18 
females per treatment group.     128 
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Figure 6.11  (a) Normalised total fat mass (%), (b) normalised carcass weight (%) and (c) 
BMI for female offspring.  Values are mean±SEM.  n=6 mothers per treatment group; n= 18 
females per treatment group.     129 
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Figure 6.12  Normalised organ and fat-pad weights of male offspring (%): (a) major organs; 
(b) liver; (c) and (d) fat-pads.  Compared with control, male offspring from the 150 μg/kg LPS 
group tended to have proportionally reduced organ mass and increased fat-pad mass.  Values 
are mean±SEM; *P≤0.05; † P≤0.1; independent of maternal origin and litter size.  n=6 mothers 
per treatment group; n= 18 males per treatment group.     130 
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Figure 6.13  (a) Normalised total fat mass (%), (b) normalised carcass weight (%) and (c) 
BMI for male offspring.  Male offspring from the 150 μg/kg LPS group had increased BMI 
compared with control (P≤0.05).  Values are mean±SEM;*P≤0.05; independent of maternal 
origin and litter size.  n=6 mothers per treatment group; n= 18 males per treatment group.     131 
6.3.6  Immune status 
In this part of the study, serum cytokine concentrations and splenocyte populations 
were quantified in LPS-injected (immune challenged) and saline-injected (non-immune 
challenged control) adult offspring from mothers that received saline, 10, 50 or 150 
μg/kg LPS on GD 0.5.  After postnatal challenge (i.e. saline or 50 μg/kg LPS), offspring 
fell into eight different treatment groups, saline-injected offspring from saline, 10, 50 
or 150 μg/kg LPS mothers and LPS-injected offspring from saline, 10, 50 or 150 μg/kg 
LPS mothers, and were designated as follows:  Sal:Sal, 10 LPS:Sal, 50 LPS:Sal, 150 
LPS:Sal, Sal:LPS, 10 LPS:LPS, 50 LPS:LPS, 150 LPS:LPS (Table 6.2).   
150 LPS:LPS LPS 150 LPS
50 LPS:LPS LPS 50 LPS
10 LPS:LPS LPS 10 LPS
Sal:LPS LPS Sal
150 LPS:Sal Sal 150 LPS
50 LPS:Sal Sal 50 LPS
10 LPS:Sal Sal 10 LPS
Sal:Sal Sal Sal
Combined treatment 
group
Offspring treatment 
group
Maternal treatment 
group
150 LPS:LPS LPS 150 LPS
50 LPS:LPS LPS 50 LPS
10 LPS:LPS LPS 10 LPS
Sal:LPS LPS Sal
150 LPS:Sal Sal 150 LPS
50 LPS:Sal Sal 50 LPS
10 LPS:Sal Sal 10 LPS
Sal:Sal Sal Sal
Combined treatment 
group
Offspring treatment 
group
Maternal treatment 
group
 
Table 6.2  Summary of treatment groups following postnatal offspring challenge. 
A number of comparisons were made when analysing the data.   
1.  The effect of maternal treatment on saline-injected offspring was examined 
by comparing the saline-injected offspring from different maternal treatment 
groups (Sal:Sal, 10 LPS:Sal, 50 LPS:Sal, 150 LPS:Sal).   
2.  The effect of maternal treatment on LPS-injected offspring was examined by 
comparing the LPS-injected offspring from different maternal treatment 
groups (Sal:LPS, 10 LPS:LPS, 50 LPS:LPS, 150 LPS:LPS).     132 
3.  The effect of LPS-injection within a maternal treatment group was examined 
by comparing saline-injected and LPS-injected offspring from the same 
maternal treatment group (e.g. Sal:Sal vs. Sal:LPS, 10 LPS:Sal vs. 10 
LPS:LPS, 50 LPS:Sal vs. 50 LPS:LPS, 150 LPS:Sal vs. 150 LPS:LPS).   
6.3.6.1 Offspring serum cytokines 
Figures 6.14 and 6.15 show the serum cytokine concentrations obtained for female 
and male offspring, respectively.   
 
 
 
 
 
 
 
 
 
 
Figure 6.14 (overleaf)  Serum cytokine concentrations (pg/ml) of female offspring 3.5 
hours post-injection of saline (open bars; offspring = Sal) or 50 μg/kg LPS (dark bars; offspring 
= LPS).  Maternal treatments; Sal = saline, 10 LPS = 10 μg/kg LPS, 50 LPS = 50 μg/kg LPS, 150 
LPS = 150 μg/kg LPS.   
Graphs for each of the 23 cytokines are displayed in name order; first the interleukins in 
numerical order and then all remaining cytokines in alphabetical order.   
Values mean±SEM; * P≤0.05; † P≤0.1 when comparing the effect of maternal treatments on 
offspring.  Bars have an open star m or open diamond ◊ (P≤0.05), or an open triangle h 
(P≤0.1), when comparing the effect of offspring treatment within the same maternal treatment.  
Differences are independent of maternal origin and litter size unless otherwise stated; n=6 
mothers per maternal treatment group; n=4-6 females per combined treatment group.   
NB:  The data presented here for IL-6, G-CSF and KC are inaccurate and should be interpreted 
with caution.  Some readings could not be converted to concentrations because the values 
obtained were above the upper limit of detection of the assay.   133 
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Figure 6.15 (overleaf)  Serum cytokine concentrations (pg/ml) of male offspring 3.5 
hours post-injection of saline (open bars; offspring = Sal) or 50 μg/kg LPS (dark bars; offspring 
= LPS).  Maternal treatments; Sal = saline, 10 LPS = 10 μg/kg LPS, 50 LPS = 50 μg/kg LPS, 150 
LPS = 150 μg/kg LPS.   
Graphs for each of the 23 cytokines are displayed in name order; first the interleukins in 
numerical order and then all remaining cytokines in alphabetical order.   
Values mean±SEM; * P≤0.05; † P≤0.1 when comparing the effect of maternal treatments on 
offspring.  Bars have an open star m or open diamond ◊ (P≤0.05), or an open triangle h 
(P≤0.1), when comparing the effect of offspring treatment within the same maternal treatment.  
Differences are independent of maternal origin and litter size unless otherwise stated; n=6 
mothers per maternal treatment group; n=5-6 males per combined treatment group.   
NB:  The data presented here for IL-6, G-CSF and KC are inaccurate and should be interpreted 
with caution.  Some readings could not be converted to concentrations because the values 
obtained were above the upper limit of detection of the assay.   142 
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Fig. 6.15 males (end) 
NB:  The multiplex assay was able to detect and quantify the full concentration 
range of every cytokine at every time point examined, except for IL-6, G-CSF and KC.  
Thus the data presented here for IL-6, G-CSF and KC should be interpreted with 
caution.  Many readings could not be converted to concentrations because the values 
obtained were above the upper limit of detection of the assay.   
 
Next, I describe the cytokine data (Figs. 6.14 and 6.15, presented above), in a way 
that reflects the various comparisons made during analysis (see section 6.3.6).     150 
Comparison 1:  The effect of maternal treatment on saline-injected offspring. 
Basal (saline-injected) serum concentrations of many cytokines were lower in 
offspring from maternal LPS treatment groups (i.e. 10 LPS:Sal, 50 LPS:Sal and 150 
LPS:Sal) when compared with control (Sal:Sal).  Interestingly, this pattern was more 
prominent in females than in males.  A summary of the significant and trend level 
results for comparison 1 are shown below in Table 6.3.   
Table 6.3  Summary table of the significant and trend level results for comparison 1.  The 
effect of maternal treatment on saline-injected offspring.   
0.086 74.6 IL-12p40 50 LPS:Sal
0.079 92.1 MCP-1
0.072 53.6 IL-12p70 150 LPS:Sal
0.008 50.4 IL-17
0.033 55.3 IL-1β
0.015 75.3 IL-2
0.019 83.1 IL-12p40
0.064 25.4 GM-CSF
0.038 85.4 MCP-1
0.062 27.6 MIP-1α
0.021 34.5 MIP-1α
0.041 52.6 Eotaxin
0.079 25.3 GM-CSF
FEMALES
0.098 38.4 IL-1α 10 LPS:Sal
0.003 83.7 IL-1β
0.089 32.8 IL-5
0.022 94.5 IL-12p40
0.061 95.9 MCP-1
0.048 93.9 MIP-1β
0.008 50.4 IL-17
0.072 53.6 IL-12p70 150 LPS:Sal
0.058 49.6 IL-17 10 LPS:Sal
MALES
P-value
Change
(% decrease vs. Sal:Sal)
Cytokine
Treatment Group
(vs. Sal:Sal)
0.086 74.6 IL-12p40 50 LPS:Sal
0.079 92.1 MCP-1
0.072 53.6 IL-12p70 150 LPS:Sal
0.008 50.4 IL-17
0.033 55.3 IL-1β
0.015 75.3 IL-2
0.019 83.1 IL-12p40
0.064 25.4 GM-CSF
0.038 85.4 MCP-1
0.062 27.6 MIP-1α
0.021 34.5 MIP-1α
0.041 52.6 Eotaxin
0.079 25.3 GM-CSF
FEMALES
0.098 38.4 IL-1α 10 LPS:Sal
0.003 83.7 IL-1β
0.089 32.8 IL-5
0.022 94.5 IL-12p40
0.061 95.9 MCP-1
0.048 93.9 MIP-1β
0.008 50.4 IL-17
0.072 53.6 IL-12p70 150 LPS:Sal
0.058 49.6 IL-17 10 LPS:Sal
MALES
P-value
Change
(% decrease vs. Sal:Sal)
Cytokine
Treatment Group
(vs. Sal:Sal)
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Comparison 2:  The effect of maternal treatment on LPS-injected offspring. 
After challenge with 50 µg/ml LPS, offspring from LPS-treated mothers (i.e. 10 
LPS:LPS, 50 LPS:LPS and 150 LPS:LPS) generally had lower serum cytokine 
concentrations than offspring from control mothers (Sal:LPS).  Essentially, serum 
cytokine concentrations were lowest in offspring from mothers that received the 
highest doses of LPS (i.e. Sal:LPS vs 50 LPS:LPS and Sal:LPS vs 150 LPS:LPS).  This 
pattern was evident in both male and female offspring.  Table 6.4 (below) summarises 
the significant and trend level results for comparison 2.   
Table 6.4  Summary table of the significant and trend level results for comparison 2.  The 
effect of maternal treatment on LPS-injected offspring (table continued on next page).   
0.016 66.2 MCP-1
0.090 31.3 MIP-1α
0.047 75.4 MIP-1β
0.013 76.3 RANTES
0.003 59.6 IL-1α 150 LPS:LPS
0.043 50.8 IL-1β
0.064 35.0 IL-3
0.007 43.8 IL-9
0.022 31.3 IL-10
0.063 64.9 IL-12p70
0.078 25.4 IL-13
0.071 38.9 IFN-γ
0.026 67.2 RANTES
0.032 80.5 MIP-1β
0.023 97.4 G-CSF
0.003 90.9 MCP-1
0.057 71.5 MIP-1β
0.085 51.2 RANTES
0.048 28.7 IL-1α 50 LPS:LPS
0.033 29.0 IL-9
0.038 26.2 IL-10
0.053 26.6 MIP-1α
0.091 49.7 MCP-1
0.042 99.3 G-CSF
0.030 30.9 IL-1α 10 LPS:LPS
MALES
P-value
Change
(% decrease vs. Sal:LPS)
Cytokine
Treatment Group
(vs. Sal:LPS)
0.016 66.2 MCP-1
0.090 31.3 MIP-1α
0.047 75.4 MIP-1β
0.013 76.3 RANTES
0.003 59.6 IL-1α 150 LPS:LPS
0.043 50.8 IL-1β
0.064 35.0 IL-3
0.007 43.8 IL-9
0.022 31.3 IL-10
0.063 64.9 IL-12p70
0.078 25.4 IL-13
0.071 38.9 IFN-γ
0.026 67.2 RANTES
0.032 80.5 MIP-1β
0.023 97.4 G-CSF
0.003 90.9 MCP-1
0.057 71.5 MIP-1β
0.085 51.2 RANTES
0.048 28.7 IL-1α 50 LPS:LPS
0.033 29.0 IL-9
0.038 26.2 IL-10
0.053 26.6 MIP-1α
0.091 49.7 MCP-1
0.042 99.3 G-CSF
0.030 30.9 IL-1α 10 LPS:LPS
MALES
P-value
Change
(% decrease vs. Sal:LPS)
Cytokine
Treatment Group
(vs. Sal:LPS)
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0.061 28.2 IL-10
0.004 87.6 KC
0.043 51.2 IL-2
0.005 77.4 IL-12p40
0.010 76.1 MCP-1
<0.001 99.5 G-CSF
0.027 52.0 IL-1α 150 LPS:LPS
0.004 55.0 IL-1β
0.067 32.9 IL-9
0.003 39.6 MIP-1α
0.054 56.0 MIP-1β
0.052 42.0 IL-2
0.001 96.1 KC
0.005 84.9 IL-12p40
<0.001 99.4 G-CSF
0.004 95.6 MCP-1
0.002 42.1 MIP-1α
0.006 93.8 MIP-1β
0.001 65.0 IL-1β 50 LPS:LPS
0.001 89.6 RANTES
FEMALES
0.018 59.1 RANTES
0.003 70.0 TNF-α
0.027 51.0 TNF-α
P-value
Change
(% decrease vs. Sal:LPS)
Cytokine
Treatment Group
(vs. Sal:LPS)
0.061 28.2 IL-10
0.004 87.6 KC
0.043 51.2 IL-2
0.005 77.4 IL-12p40
0.010 76.1 MCP-1
<0.001 99.5 G-CSF
0.027 52.0 IL-1α 150 LPS:LPS
0.004 55.0 IL-1β
0.067 32.9 IL-9
0.003 39.6 MIP-1α
0.054 56.0 MIP-1β
0.052 42.0 IL-2
0.001 96.1 KC
0.005 84.9 IL-12p40
<0.001 99.4 G-CSF
0.004 95.6 MCP-1
0.002 42.1 MIP-1α
0.006 93.8 MIP-1β
0.001 65.0 IL-1β 50 LPS:LPS
0.001 89.6 RANTES
FEMALES
0.018 59.1 RANTES
0.003 70.0 TNF-α
0.027 51.0 TNF-α
P-value
Change
(% decrease vs. Sal:LPS)
Cytokine
Treatment Group
(vs. Sal:LPS)
 
Comparison 3:  The effect of offspring LPS challenge within a maternal 
treatment group. 
In offspring from control mothers, the serum concentration of many cytokines 
increased following LPS-injection i.e. Sal:Sal vs. Sal:LPS.  In addition, the serum 
concentration of many cytokines increased following LPS-injection in offspring from 
mothers treated with 10 μg/kg LPS (i.e. 10 LPS:Sal vs. 10 LPS:LPS).  However, the 
serum concentration of very few cytokines increased following LPS-injection in 
offspring from mothers treated with 50 and 150 μg/kg LPS.  Table 6.5 (below) 
summarises the significant and trend level results for comparison 3.     153 
Table 6.5  Summary table of significant and trend level results for comparison 3.  The effect 
of offspring LPS challenge within a maternal treatment group. 
0.066 29.5 IL-9
0.007 95.2
IL-
12p40
0.029 53.1 Eotaxin
0.001 99.4 G-CSF
0.007 96.7 MCP-1
<0.001 88.4 IL-1β
0.030 37.5 IL-5
0.046 99.9 IL-6
<0.001 99.7 KC
0.003 43.6 MIP-1α
<0.001 99.2 MIP-1β
<0.001 96.0 RANTES
0.016 48.7 IL-2 10 LPS:Sal vs 10 LPS:LPS
FEMALES
0.088 29.3 IL-1β Sal:Sal vs Sal:LPS
<0.001 99.0 G-CSF
0.004 90.3 KC
0.019 55.7 RANTES
0.015 55.9 TNF-α
0.089 40.9 IL-1α 10 LPS:Sal vs 10 LPS:LPS
0.036 63.4 TNF-α
0.052 57.5 IL-2 150 LPS:Sal vs 150 LPS:LPS
0.018 68.3 RANTES
0.021 97.3 KC
0.015 67.2 MCP-1
0.028 25.8 IL-10
0.017 27.5 IL-13
0.016 42.9 (decrease)* IL-17
0.011 30.5 Eotaxin
0.017 99.3 G-CSF
0.014 78.5 MIP-1β
0.003 33.4 IL-9
0.004 59.2 IL-1β
0.001 50.0 IL-1α Sal:Sal vs Sal:LPS
MALES
P-value Change (% increase) Cytokine Treatment Group
0.066 29.5 IL-9
0.007 95.2
IL-
12p40
0.029 53.1 Eotaxin
0.001 99.4 G-CSF
0.007 96.7 MCP-1
<0.001 88.4 IL-1β
0.030 37.5 IL-5
0.046 99.9 IL-6
<0.001 99.7 KC
0.003 43.6 MIP-1α
<0.001 99.2 MIP-1β
<0.001 96.0 RANTES
0.016 48.7 IL-2 10 LPS:Sal vs 10 LPS:LPS
FEMALES
0.088 29.3 IL-1β Sal:Sal vs Sal:LPS
<0.001 99.0 G-CSF
0.004 90.3 KC
0.019 55.7 RANTES
0.015 55.9 TNF-α
0.089 40.9 IL-1α 10 LPS:Sal vs 10 LPS:LPS
0.036 63.4 TNF-α
0.052 57.5 IL-2 150 LPS:Sal vs 150 LPS:LPS
0.018 68.3 RANTES
0.021 97.3 KC
0.015 67.2 MCP-1
0.028 25.8 IL-10
0.017 27.5 IL-13
0.016 42.9 (decrease)* IL-17
0.011 30.5 Eotaxin
0.017 99.3 G-CSF
0.014 78.5 MIP-1β
0.003 33.4 IL-9
0.004 59.2 IL-1β
0.001 50.0 IL-1α Sal:Sal vs Sal:LPS
MALES
P-value Change (% increase) Cytokine Treatment Group
   154 
To summarise, the serum concentration of many cytokines was lower in saline-
injected offspring from LPS injected mothers (vs. saline-injected offspring from saline-
injected mothers; comparison 1).  Following LPS challenge, the serum concentration of 
many cytokines increased in offspring from control and 10 μg/kg LPS treated mothers, 
but did not increase in offspring from 50 and 150 μg/kg LPS treated mothers 
(comparison 3).  Often this meant that the serum concentration of many cytokines 
following LPS challenge was not different when comparing offspring from 10 μg/kg LPS 
mothers to control, but remained lower in offspring from 50 and 150 μg/kg LPS treated 
mothers (comparison 2).   
General pattern of altered and unaltered cytokines 
During analysis it became clear that, broadly, individual offspring serum cytokines 
were either affected or unaffected by maternal LPS-treatment (Table 6.6).   
•  Affected (Table 6.6):  Serum cytokines concentrations were significantly or 
trend level affected by maternal LPS treatment in saline-and/or LPS-treated 
offspring (vs offspring from saline treated control mothers).   
•  Unaffected (Table 6.6):  Serum cytokines concentrations were unaffected 
by maternal LPS treatment, whether LPS-injected or saline-injected.   
KC
TNF-α
G-CSF
GM-CSF
KC
MCP-1
MIP-1α
MIP-1β
RANTES
TNF-α
IL-17
G-CSF
IFN-γ
MCP-1
MIP-1α
MIP-1β
RANTES
IL-3
IL-4
IL-6
IL-12p70
IL-13
IL-17
IFN-γ
IL-1α
IL-1β
IL-2
IL-5
IL-9
IL-10
IL-12p40
Eotaxin
Females
IL-2
IL-4
IL-5
IL-6
IL-12p40
Eotaxin
GM-CSF
IL-1α
IL-1β
IL-3
IL-9
IL-10
IL-12p70
IL-13
Males
Cytokines unaffected by 
maternal LPS-treatment
Cytokines affected by 
maternal LPS-treatment
Offspring gender
KC
TNF-α
G-CSF
GM-CSF
KC
MCP-1
MIP-1α
MIP-1β
RANTES
TNF-α
IL-17
G-CSF
IFN-γ
MCP-1
MIP-1α
MIP-1β
RANTES
IL-3
IL-4
IL-6
IL-12p70
IL-13
IL-17
IFN-γ
IL-1α
IL-1β
IL-2
IL-5
IL-9
IL-10
IL-12p40
Eotaxin
Females
IL-2
IL-4
IL-5
IL-6
IL-12p40
Eotaxin
GM-CSF
IL-1α
IL-1β
IL-3
IL-9
IL-10
IL-12p70
IL-13
Males
Cytokines unaffected by 
maternal LPS-treatment
Cytokines affected by 
maternal LPS-treatment
Offspring gender
 
Table 6.6  Serum cytokine concentrations in offspring (saline- and/or LPS-treated) were 
either affected or unaffected by maternal LPS treatment.  Criteria for inclusion in a particular 
category were based on the presence of a statistically significant or trend level result for one or 
more treatment group when compared with control, for both LPS- and saline-injected offspring.     155 
6.3.6.2 Offspring splenocytes 
Splenocyte populations were identified from forward scatter (FSC) vs. side scatter 
(SSC) plots.  From the FSC vs. SSC plot of every mouse examined, two populations of 
splenocytes were evident (referred to here as population A and population B).  
Population A represented 10-20% of total events and consisted of small cells with a 
low degree of granularity (Fig. 6.16, top panel).  In contrast, population B represented 
35-45% of total events and consisted of larger cells with a greater degree of 
granularity (Fig. 6.16, bottom panel).  Splenocyte populations A and B were analysed 
for expression of CD19 (B lymphocytes), CD4 (T helper lymphocytes) and CD8 
(cytotoxic T lymphocytes; Fig. 6.16).     156 
 
Figure 6.16  Flow cytometry plots showing splenocyte populations and gating strategy (this 
example is representative of all mice in this study).  The forward scatter vs. side scatter (FSC vs. 
SSC) plot revealed the presence of 2 main cell populations; population A, consisting of small 
cells with a low degree of granularity, and population B, consisting of larger cells with a greater 
degree of granularity.  The percentage of cells expressing, CD19 (B lymphocytes), CD4 (T helper 
lymphocytes) and CD8 (cytotoxic T lymphocytes) were then examined in both of these cell 
populations separately.     157 
CD19
+, males:  Saline-injected male offspring from 150 μg/kg LPS mothers had 
5.7% fewer CD19
+ cells in population B than saline-injected male offspring from 
control mothers (P=0.042; Fig. 6.17b).  In addition, saline-injected male offspring 
from 10 μg/kg LPS mothers displayed a trend towards fewer CD19
+ cells in population 
B than saline-injected male offspring from control mothers (3.8% less; P=0.083; Fig. 
6.17b).  Interestingly, LPS-injected male offspring from 150 μg/kg LPS mothers also 
displayed a trend towards fewer CD19
+ cells in population B than LPS-injected male 
offspring from control mothers (5% less; P=0.077; Fig. 6.17b).  LPS-injected male 
offspring from 10 μg/kg LPS mothers displayed a trend towards more CD19
+ cells in 
population B than saline-injected male offspring from the same maternal treatment 
group (5.2% more; P=0.057; Fig. 6.17b).  There were no differences between 
treatments in the percentage of population A CD19
+ cells in males, although LPS-
injected offspring from 50 μg/kg LPS mothers displayed a trend towards fewer CD19
+ 
cells than LPS-injected male offspring from control mothers (6.8% less; P=0.091; Fig. 
6.17a).   
CD4
+, males:  Saline-injected male offspring from 150 μg/kg LPS mothers had 
4.2% more CD4
+ cells in population A than saline-injected male offspring from control 
mothers (P=0.031; Fig. 6.18a).  Interestingly, LPS-injected male offspring from 150 
μg/kg LPS mothers also displayed a trend towards more CD4
+ cells in population A 
than LPS-injected male offspring from control mothers (3.5% more; P=0.062; Fig. 
6.18a).  There were no differences between treatments in the percentage of population 
B CD4
+ cells in males, although LPS-injected offspring from 10 and 150 μg/kg LPS 
mothers displayed a trend towards more CD4
+ cells than LPS-injected male offspring 
from control mothers (2%, P=0.078 and 4.1%, P=0.057 more respectively; Fig. 
6.18b).   
CD8
+, males:  Saline-injected male offspring from 50 μg/kg LPS mothers had 3.4% 
more CD8
+ cells in population B than saline-injected male offspring from control 
mothers (P=0.008; Fig. 6.18d).  LPS-injected male offspring from 50 μg/kg LPS 
mothers displayed a trend towards more CD8
+ cells in population A than LPS-injected 
male offspring from control mothers (0.8% more; P=0.078; Fig. 6.18c).     158 
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Figure 6.17  Percentage of B lymphocytes (CD19
+) in spleens of male offspring from each 
treatment group; (a) CD19
+ cells in population A (%), (b) CD19
+ cells in population B (%).  
Values are mean±SEM; * P≤0.05; † P≤0.1 when comparing the effect of maternal treatments 
on offspring.  Bars have an open triangle (P≤0.1) when comparing the effect of offspring 
treatment within the same maternal treatment.  Differences are independent of maternal origin 
and litter size.  n=5-6 mothers per treatment group; n= 5-6 male offspring per treatment group.     159 
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Figure 6.18  Percentage of T helper (CD4
+) and cytotoxic T (CD8
+) lymphocytes  in spleens of 
male offspring; (a) CD4
+ in population A, (b) CD4
+ in population B, (c) CD8
+ in population A, 
(d) CD8
+ in population B.  Values are mean±SEM.  * P≤0.05; † P≤0.1 when comparing the 
effect of maternal treatments on offspring.  Differences are independent of maternal origin and 
litter size.  n=5-6 mothers per treatment group; n= 5-6 male offspring per treatment group.     160 
LPS-injected female offspring from 150 μg/kg LPS mothers had fewer CD8
+ cells in 
population B than saline-injected female offspring from the same maternal treatment 
group (3.3% less; P=0.040; Fig. 6.20d).  There were no differences between 
treatment groups for female offspring in the percentage of population A CD8
+ cells 
(Fig. 6.20c).  Furthermore, there were no differences between treatment groups for 
female offspring in the percentage of CD19
+ or CD4
+ cells in either population A or B 
(Fig. 6.19a,b and Fig. 6.20a,b, respectively).   
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Figure 6.19  Percentage of B lymphocytes (CD19
+) in spleens of female offspring from each 
treatment group; (a) CD19+ cells in population A (%), (b) CD19
+ cells in population B (%).  
Values are mean±SEM; n=4-6 mothers per treatment group; n= 4-6 female offspring per 
treatment group.     161 
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Figure 6.20  Percentage of T helper (CD4
+) and cytotoxic (CD8
+) T lymphocytes  in spleens of 
female offspring; (a) CD4
+ in population A, (b) CD4
+ in population B, (c) CD8
+ in population A, 
(d) CD8
+ in population B.  Values are mean±SEM.  Bars have an open star (P≤0.05) when 
comparing the effect of offspring treatment within the same maternal treatment.  Differences 
are independent of maternal origin and litter size.  n=4-6 mothers per treatment group; n= 4-6 
female offspring per treatment group.     162 
6.4  Discussion 
The evidence presented in this chapter showed for the first time that administration 
of 10, 50 and 150 μg/kg LPS to pregnant mice on GD 0.5 did not alter birth weight but 
did result in altered postnatal offspring phenotype, affecting behaviour, systolic blood 
pressure (SBP), tissue/body weight ratios, body mass index (BMI), the serum 
concentration of many cytokines and lymphocyte populations in the spleen (Table 6.7).   
- - - ↑ - -
Spleen T helper 
lymphocytes (CD4+) 
- - - ↓ - - Spleen B lymphocyes
- - - - ↑ -
Spleen cytotoxic T 
lymphocytes (CD8+) 
↓↓ ↓ ↓ ↓↓ ↓ ↓
Immune challenged 
serum cytokines 
(LPS-injected)
↓↓ ↓ ↓ ↓↓ ↓ ↓
Basal serum 
cytokines (saline-
injected)
- - - ↑ - - BMI
- - - ↑ - -
Inguinal fat/body 
weight
- - - ↑ - -
Retro-peritoneal 
fat/body weight
- ↓ - - - - Liver/body weight
- - - - - ↑ SBP
- - - ↓ - -
Locomotor and 
exploratory 
behaviour
150 50 10 150 50 10
Females (μg/kg LPS) Males (μg/kg LPS)
Offspring phenotype
- - - ↑ - -
Spleen T helper 
lymphocytes (CD4+) 
- - - ↓ - - Spleen B lymphocyes
- - - - ↑ -
Spleen cytotoxic T 
lymphocytes (CD8+) 
↓↓ ↓ ↓ ↓↓ ↓ ↓
Immune challenged 
serum cytokines 
(LPS-injected)
↓↓ ↓ ↓ ↓↓ ↓ ↓
Basal serum 
cytokines (saline-
injected)
- - - ↑ - - BMI
- - - ↑ - -
Inguinal fat/body 
weight
- - - ↑ - -
Retro-peritoneal 
fat/body weight
- ↓ - - - - Liver/body weight
- - - - - ↑ SBP
- - - ↓ - -
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Table 6.7  Summary of the phenotypic alterations seen in offspring from immune 
challenged mothers (vs. offspring from control mothers). 
In particular, male offspring from 150 μg/kg LPS treated mothers displayed reduced 
locomotor and exploratory-related behaviour, increased fat-pad mass (retro-peritoneal 
and inguinal fat/body weight ratios), increased BMI, reduced serum cytokine 
concentrations, reduced percentage of splenic B lymphocytes (CD19
+) and increased 
percentage of splenic T helper lymphocytes (CD4
+).  Male offspring from 10 and 50 
μg/kg LPS treated mothers were much less affected.  The 50 μg/kg LPS males 
displayed reduced serum cytokine concentrations and increased percentage of splenic   163 
cytotoxic T lymphocytes (CD8
+).  The 10 μg/kg LPS males displayed reduced serum 
cytokine concentrations and, unexpectedly, increased SBP.  Overall, female offspring 
were less affected than their male counterparts:  the only major alteration in 
phenotype was reduced serum cytokine concentrations and this was observed in 
female offspring from all LPS treatment mothers.  However, interestingly, liver/body 
weight ratio was significantly reduced in 50 μg/kg LPS females and to trend level in 10 
and 150 μg/kg LPS females.   
In the present study, birth weight was not altered by any of the maternally 
administered LPS doses.  This finding supports the results of the previous chapter 
(Chapter 5), where no differences in GD 17 conceptus or fetus weight were found 
following the same maternal LPS treatments as used in this chapter.  Birth weight can 
act as an indicator of an adverse prenatal environment and is thus a convenient 
parameter to use for making associations with postnatal outcomes in the offspring 
(Gluckman et al., 2007).  However, birth weight is an incomprehensive marker 
because some alterations to the prenatal environment have been shown to result in 
long term phenotypic changes in the offspring without altering fetal growth; for 
example, the offspring of women subjected to under-nutrition in early pregnancy 
during the Netherlands famine did not have reduced birth weight but did have an 
increased risk of obesity (Painter et al., 2005).  Thus, in the present study birth weight 
did not act as an indicator of alterations in other aspects of offspring phenotype, e.g. 
behavioural changes.   
Despite its unsuitability as a marker, birth weight has proven to be invaluable in 
epidemiological studies for identifying links between adverse prenatal environments 
and postnatal outcomes, identifying not only an association with cardiovascular and 
metabolic abnormalities but also those pertaining to behaviour and mental health 
(Schlotz and Phillips, 2009).  Low birth weight has been associated with a range of 
behavioural and metal health outcomes in offspring, including; low IQ, behavioural 
problems in children and adolescents (e.g. hyperactivity, inattention), antisocial 
personality disorders, stress reactivity and schizophrenia (Schlotz and Phillips, 2009).  
Schizophrenia is particularly interesting in the context of the present study because of 
the increasingly documented link between maternal immune activation and the 
occurrence of this brain disorder in the resultant offspring (Meyer et al., 2008).  
Indeed, an important mouse study demonstrated that offspring from mothers treated 
with IL-6, but not IL-1β, IFN-γ or TNF-α, during mid-gestation displayed the same   164 
postnatal behavioural phenotype as mid-gestational PolyI:C administration (Smith et 
al., 2007).  Human birth cohort studies have implicated the early stages of gestation 
as a vulnerable period.  One such study reported that maternal genital and 
reproductive infections during periconception increased the risk of schizophrenia in the 
offspring (Babulas et al., 2006).  Another of these studies indicated that the risk of 
schizophrenia in offspring was increased 7-fold after serologically documented 
influenza exposure during the first trimester of pregnancy (Brown et al., 2004).  The 
evidence presented in this chapter shows that preimplantation stage maternal immune 
activation in the mouse can result in altered behaviour in the adult offspring.  This 
finding supports the concept that prenatal environment impacts upon behavioural 
phenotype and provides evidence that maternal inflammation can induce offspring 
behavioural abnormalities by influencing the preimplantation embryo, well before the 
appearance of identifiable brain structures.   
This finding joins a selection of other studies in mice where behavioural 
abnormalities have been documented in offspring following a preimplantation stage 
challenge, e.g. in vitro embryo culture and low protein maternal diet in vivo (Ecker et 
al., 2004; Fernandez-Gonzalez et al., 2004; Watkins et al., 2008b).  Alterations in 
locomotor, exploratory and anxiety-related behaviours are a consistent feature of all of 
the studies; however, gender-specific differences are apparent and the direction of 
change in such behavioural activities also differs.  In the present study, only male 
offspring from 150 μg/kg LPS treated mothers exhibited reduced locomotor and 
exploratory-related behaviour.  Interestingly, the in vitro culture studies also showed 
effects in only male offspring, but reported increased locomotor activity and decreased 
anxiety (Ecker et al., 2004; Fernandez-Gonzalez et al., 2004).  Furthermore, increased 
locomotor and exploratory behaviour was also demonstrated following preimplantation 
low protein maternal diet in vivo, but only female offspring were affected (Watkins et 
al., 2008b).  Taken together, these findings suggest that, in the mouse, locomotor, 
exploratory and anxiety-related offspring behaviours are particularly sensitive to 
preimplantation embryo environment, and that the nature of the preimplantation 
challenge may influence the direction in which these behaviours are altered and the 
gender of the offspring in which they occur.   
In this chapter, gender and treatment group-specific alterations were also found in 
offspring BMI and adiposity.  As was seen with the behavioural alterations, only male 
offspring from 150 μg/kg LPS treated mothers were affected.  Males from 150 μg/kg   165 
LPS mothers had significantly increased BMI, despite there being no significant 
difference in raw body mass. However, to explain this discrepancy, it should be noted 
that males from 150 μg/kg LPS mothers did weigh ~2 g more than control males at 
cull, whereas there was absolutely no difference in body length (mean body lengths 
were within ~2 mm of each other).  As such, it seems the small difference in body 
weight was more influential when the relationship between body weight and body 
length (‘height’) was considered in the BMI calculation.  The increased BMI in males 
from 150 μg/kg LPS mothers appeared to be due to increased adiposity, specifically of 
the retro-peritoneal and inguinal fat-pads.  Also in the males from 150 μg/kg LPS 
mothers, body weight ratios of all organs examined seemed to be reduced, however 
this was not statistically significant for any organ except for a trend seen in the 
lung/body weight ratio.  In female offspring, there was no effect of maternal LPS 
treatment on the weight of any tissue except the liver, where liver/body weight ratio 
was reduced significantly in 50 μg/kg LPS females and to trend level in 10 and 150 
μg/kg LPS females.  Disproportionate body structure in male offspring, affecting 
particularly adipose tissue, has been observed in other studies.  Culture of 
preimplantation mouse embryos in vitro increased the body weight of only male 
offspring (Sjoblom et al., 2005).  Similar to the present study, these male offspring 
displayed central adiposity (including increased retro-peritoneal fat) and no change 
was seen in the mass of any major organ except the brain, where brain/lean body 
weight ratio was decreased (Sjoblom et al., 2005).  Disproportionate body structure 
has also been observed in male offspring following preimplantation low protein 
maternal diet in the rat (Kwong et al., 2000).  In the rat preimplantation low protein 
diet study male offspring kidney/body weight ratios were increased whereas liver/body 
weight ratios were decreased, however no information was presented regarding 
adipose tissue (Kwong et al., 2000).   
Interestingly, a disproportionate offspring body structure similar to that seen in the 
present study (where LPS was administered in early gestation) was observed in a rat 
study where mothers were challenged with LPS (790 μg/kg) during mid-gestation 
(Nilsson et al., 2001).  In this rat study, male offspring displayed increased abdominal 
adiposity (specifically of retro-peritoneal and epididymal fat-pads) but there were no 
differences in the mass of muscle or other major organs (however, no data was 
presented for kidney or liver).  Importantly, a wide range of physiological and 
endocrine parameters were investigated in this study, which allowed the authors to 
demonstrate a phenotype whereby male offspring displayed not only central obesity,   166 
but also other features relevant to the metabolic syndrome, including; insulin 
resistance, increased plasma leptin concentrations, hyperphagia, increased 17β-
estradiol and increased progesterone (Nilsson et al., 2001).  Nilsson et al (Nilsson et 
al., 2001) also found in male offspring increased hippocampal glucocorticoid receptor 
(GR) protein and reduced glucocorticoid (corticosterone) response to stress, but no 
change in hippocampal or hypothalamic leptin receptor protein and no change in blood 
pressure.  Furthermore, in another study, pregnant rats were injected with IL-6, TNF-α 
or dexamethasone (synthetic glucocorticoid) during mid-gestation and the offspring 
were examined postnatally for a range of physiological and endocrine parameters 
(Dahlgren et al., 2001).  The authors reported an overlapping but non-identical 
phenotype in the offspring following the different maternal treatments, including; 
increased body weight in all offspring that was due to increased adiposity, 
corticosterone response to stress was increased in the IL-6 group, insulin resistance 
was seen in IL-6 group males, males from the TNF-α group showed decreased 
locomotor activity whereas the IL-6 females showed increased locomotor activity and 
plasma testosterone levels were increased in females from the IL-6 and TNF-α groups 
(Dahlgren et al., 2001).  Despite a larger LPS dose being administered at a later 
gestational time point in the rat study, there are certain similarities with the results 
presented here in this chapter, namely the increase in male offspring adiposity without 
any alteration in blood pressure (males from 150 μg/kg LPS mothers).  In the present 
study no endocrine parameters or receptor expression experiments were conducted, 
therefore to see if further similarities exist, it would be interesting to conduct such 
investigations in the early gestational inflammation model used in the present study.   
The elevated systolic blood pressure (SBP) displayed by only male offspring from 10 
μg/kg LPS treated mothers was somewhat unexpected because; i) elevated SBP was 
not seen in offspring from any other treatment group, and ii) all other phenotypic 
alterations have been seen in the highest LPS group (e.g. behaviour, increased 
adiposity and BMI).  Interestingly, GD 3.5 blastocysts from 10 μg/kg LPS treated 
mothers displayed an unexpected increase in TE cell number (Chapter 5) and 
moreover, both total litter size and the number of male pups was increased in the 10 
μg/kg LPS group.  These observations suggest that maternal treatment with 10 μg/kg 
LPS may increase TE cell number in blastocysts, which may enhance their ability to 
implant and thus result in increased litter size.  In addition, there may be a preferential 
effect on male embryos because a specific increase in the number of neonatal male 
offspring was observed.  Indeed, it has been found that male embryos cleave faster   167 
than female embryos (Mittwoch, 1993); therefore male embryos could be more 
responsive to the apparent effects of the 10 μg/kg LPS maternal treatment.  I suggest 
that the elevated SBP seen only in the male offspring from 10 μg/kg LPS treated 
mothers is associated with the alterations discussed above; perhaps acting in a 
‘classical DOHaD’ manner, whereby a suboptimal in utero environment, resulting from 
decreased availability of maternal resources due to increased litter size, induces 
offspring cardiovascular abnormalities.  However, it is not possible to confirm this 
hypothesis from the results obtained in the present study.   
In the present study, serum cytokine concentrations were the only parameter 
examined where both males and females from all LPS treatment groups were affected 
to some extent.  The major finding was that serum cytokine responses were blunted in 
response to LPS-injection in offspring from LPS treated mothers, where the offspring 
from the highest treatment groups (50 and 150 μg/kg) were most affected.  
Interestingly, the basal (saline-injected) level of a larger number of the cytokines 
appeared to be blunted in female offspring than in their male counterparts; for 
example MCP-1 concentration was blunted in both saline- and LPS-injected female 
offspring whereas the same cytokine was blunted only in LPS-injected male offspring.   
A pattern appeared to exist in the type of cytokine that was ‘blunted vs. unaffected’ 
in offspring from LPS treated mothers: the classical pro-inflammatory and antigen 
presenting cell (APC; e.g. monocyte, macrophage and dendritic cell) produced 
cytokines seemed to be more affected than the T helper cell type (T H) cytokines.  For 
example, IL-1β is a typical pro-inflammatory APC produced cytokine that was blunted 
and IL-4 is typical T H cytokine that was unaffected in female and male offspring from 
LPS treated mothers (see table of main cellular sources and actions of cytokines in 
Appendix II).  It could be that this pattern of affected cytokines (i.e. ‘the APC-produced 
are affected but the T H -produced are unaffected’ idea) is seen because of the timing 
of the serum collection and/or the nature of the challenge used in this study.  It is 
possible that the kinetics of the immune response are affected by maternal LPS-
treatment, thus conducting a time course assay rather than looking at a single time 
point would be informative.  Furthermore, LPS is known to stimulate the production of 
pro-inflammatory cytokines, thus if a T H inducing challenge was given, more effect 
may have been seen in the T H cytokines e.g. IL-4.  However, if it were the nature of 
the immune challenge received by the offspring postnatally that was causing this 
pattern, then changes in the basal (saline-injected) cytokine concentrations would not   168 
have been seen.  Interestingly, upon immune-challenge offspring from 10 μg/kg LPS 
treated mothers often displayed cytokine concentrations equivalent to immune-
challenged offspring from control mothers, whereas serum cytokine concentrations of 
offspring from 50 and 150 μg/kg LPS treated mothers remained lower.  Thus, for many 
cytokines offspring from 10 μg/kg LPS treated mothers were able to mount a serum 
response comparable to offspring from control mothers, whereas offspring from higher, 
50 and 150 μg/kg LPS treated mothers did not have this capacity.   
Monocytes and APCs are cells of the innate immune system that express the LPS 
receptor, Toll-like receptor-4 (TLR4), and are the main cell type responsible for 
producing large amounts of several cytokines in response to TLR4-LPS stimulation 
(Benoit et al., 2008).  The findings in this chapter thus suggest that the APCs of 
offspring from immune challenged mothers have a reduced capacity to produce or 
secrete certain cytokines.  It is intriguing that in the offspring from 10 μg/kg LPS 
treated mothers administration of immune challenge (i.e. LPS injection) elicited a 
response that was comparable to control, even when the same cytokine was at a much 
lower concentration than control in non-immune challenged state (i.e. saline injection).  
Based on this observation, it seems likely that the effect is at the level of transcription 
or translation for many of the cytokines because upon LPS stimulation, the dampening 
effect was readily reversed and cytokine levels comparable to control were achieved 
within the same time frame.  This was the case in the offspring from 10 μg/kg LPS 
mothers whereas the blunting was pronounced even after LPS stimulation in offspring 
from 50 and 150 μg/kg LPS mothers, suggesting that more permanent changes were 
present.  Interestingly, post-transcriptional control is very important in determining the 
level of cytokine production in immune cells (Anderson, 2008).  Post-transcriptional 
control has several important features that are potentially relevant to the findings in 
the findings in this chapter; i) cytokines can be translated from stored mRNA 
molecules more rapidly than if a new transcripts had to be synthesised; ii) ‘metabolic 
economy’ because energy spent in transcribing the mRNA is not wasted because it can 
be stored and translated at a later time if the correct stimulus is applied; iii) sensors of 
microbial infection such as TLRs are linked to intracellular signalling pathways that 
regulate the translation and decay of mRNA (Anderson, 2008).   
How could these immune changes fit with the DOHaD hypothesis?  The immune 
system is very expensive in terms of energy (Lochmiller and Deerenberg, 2000; 
Newsholme and Newsholme, 1989); moreover, an immune response is extra expense   169 
in energetic terms and the sickness behaviour that arises from such a response could 
put an organism at risk, for example in terms of predation (Dantzer, 2004; Jin et al., 
1995).  Thus, if the developing fetus ‘senses’ an inflammatory external environment in 
utero via the mother, it may predict being born into a pathogen rich environment.  
Thus, to avoid excess energetic expense and risk associated with sickness behaviour, 
the offspring may make adaptations to its immune system so that it operates at a 
lower level basally and reacts minimally and only when really necessary e.g. during 
heavy infection rather than to less serious infections.  This may appear to be a great 
risk for the offspring, however despite the blunted immune status, during the course of 
my experimentation at no time did I notice any overt sign of extra burden of illness or 
disease, especially considering the animals were kept well into adult life and were not 
housed in specific pathogen free conditions (SPF).  It would be interesting to 
investigate the immune status of these offspring more fully, in terms of antibody levels 
and components of the complement system for example, and also to see what effect a 
different type of immune challenge would have, e.g. a T cell-dependent antigen such 
as SRBCs or ovalbumin.   
The spleen was examined for lymphocyte composition (T and B cells) because it is 
easily accessible, is the largest single secondary lymphoid organ of the body and 
contains up to 25% of the body’s mature lymphocytes (Fu and Chaplin, 1999).  The 
disregulated cytokine production may have contributed to the disregulated lymphoid 
homeostasis seen in the spleen of offspring from mothers treated with LPS.  However, 
unlike with the cytokines, sex-specific and treatment group specific differences were 
found in the splenic lymphocyte populations.  As was seen with many of the other 
phenotypes discussed in this chapter, only male offspring were affected and it was 
mainly those from the highest LPS treatment groups (50 and 150 μg/kg LPS).  
Interestingly, the affected offspring in the present study displayed increased T cells, 
where CD4
+ were more affected than CD8
+, and decreased B cells.   
This pattern of disregulated lymphoid homeostasis is reminiscent of that seen in a 
mouse model of X-linked severe combined immunodeficiency (XSCID) where the 
common receptor γ chain (γc; the shared component of the receptors for IL-2, IL-4, IL-
7, IL-9, IL-15) is deficient (Nakajima et al., 1997).  These mice display diminished 
numbers of bone marrow and spleen B cells, and CD4
+ T cell accumulation in the 
spleen (with no effect on CD8
+ T cells).  The CD4
+ T cells have abnormally high rates 
of proliferation and apoptosis, but the rate of proliferation is greater than the rate of   170 
apoptosis thus the cells increase in number (Nakajima et al., 1997).  Furthermore, 
these CD4
+ T cells have an activated phenotype that was shown to be T cell receptor 
(TCR) dependent (which could be specific for either self or environmental antigen).  
Indeed, >80% of such mice develop inflammatory bowel disease which the authors 
propose is consistent with the possibility of self-reactive T cells (Nakajima et al., 
1997).  Thus, the disregulated lymphoid homeostasis seen in male offspring from 150 
μg/kg LPS treated mothers could be a result of altered signalling via the γc due to the 
disregulated cytokine concentrations seen in these animals.  This aspect warrants 
further investigation in the current model because if this hypothesis is accurate, 
maternal immune activation during early gestation could predispose to auto-immune 
disease, e.g. inflammatory bowel disease, as noted above.   
In conclusion, the results presented in this chapter demonstrate that the 
preimplantation embryo is sensitive to maternal inflammation, resulting in long-term 
alterations to the structure and function of diverse body systems within the offspring, 
including, body fat and BMI, behaviour and immune status.  These findings cannot be 
directly applied to the human population; however, mouse models such as these allow 
experimentation that would be unethical to conduct in the human and provides insight 
into the areas that warrant further study in the human.   
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7  General discussion 
The preimplantation mammalian embryo is sensitive to its immediate surroundings, 
and alterations to its in vitro or in vivo environment can affect not only the immediate 
events of blastocyst formation, but can also give rise to long-term phenotypic 
consequences during fetal and/or postnatal life.  For example, rodent studies have 
shown that maternal under-nutrition during preimplantation gestation can lead to 
increased risk of cardiovascular, metabolic and behavioural abnormalities in the adult 
offspring (Kwong et al., 2000; Watkins et al., 2008b).  To date, a low protein diet is 
the only preimplantation stage maternal challenge for which short- and long-term 
offspring phenotype has been investigated.  Thus, do other types of maternal 
challenge similarly impact on the developmental programme with long-lasting 
consequences?  Infection and injury are common in everyday life and normally result 
in altered homeostasis and generation of an inflammatory response.  The aim of my 
PhD was to study the effects of an inflammatory environment during preimplantation 
development on the phenotype of the blastocyst, fetus and offspring postnatally, with 
a major focus on an in vivo mouse model of maternal systemic inflammation.   
In the initial phase of the project (Chapter 3), MF1 mouse embryos were cultured in 
the presence of IFN-γ in order to model, in vitro, cytokine changes that may occur in 
the uterine fluid, in vivo, during an inflammatory response.  IFN-γ is known to be 
produced during an inflammatory response and also that it is present in uterine fluid, 
but little is known about its effects on preimplantation embryo development.  The 
results show that select higher doses of rmIFN-γ (10 and 1000 pg/ml) increase the 
maximum percentage of cavitated embryos and reduce the ICM:TE ratio in the 
blastocyst, the latter due specifically to a reduction in ICM cell number.  Furthermore, 
a strong negative correlation was found to exist between the percentage of embryos 
cavitated and the percentage of embryos arrested, which suggested improved survival.  
Other studies have shown that IFN-γ STAT1-dependent signalling does not occur in the 
preimplantation embryo, thus it is a possibility that IFN-γ is acting via STAT1-
independent signalling pathways.  Some of the STAT1-independent signal transduction 
pathways that are activated by IFN-γ are known to be involved in preimplantation 
embryo development e.g. MAP kinase and PI3-kinase (Zhang et al., 2007).  Thus, it is 
possible that the findings presented in Chapter 3 were due to IFN-γ-mediated 
modulation of signalling pathways that are important for preimplantation development; 
for example, an effect on survival could have been mediated via PI3-K/Akt signalling   172 
and TE differentiation could have been mediated via PKC and Ras-MAPK/ERK1/2 
signalling.   
The reason for the reduced blastocyst ICM number was not investigated in the 
present study, but the degree of apoptosis could be investigated by TUNEL (terminal 
deoxynucleotidyl transferase-mediated dUTP nick end labelling) or Annexin V (detects 
the phospholipid, phosphatidylserine, that translocates from the internal to the 
external layer of the plasma membrane during early apoptosis) labelling and 
proliferation could be examined by BrdU assay.  In addition, the timing of the exposure 
to IFN-γ could be important in determining the outcome in the blastocyst.  In this 
study, IFN-γ was present in the culture media continually from the 2-cell to the 
blastocyst stage.  It would be interesting to examine the effect of IFN-γ over more 
discrete stages of preimplantation development, e.g. from 2-cells to 8-cells stage or 
from compaction to blastocyst stage.  This would give better insight into periods of 
embryo sensitivity to this cytokine.  Certain lines of evidence suggest that blastocyst 
cell number is indicative of implantation potential (Richter et al., 2001), fetal 
development (Lane and Gardner, 1997) and postnatal phenotype (Kwong et al., 2000; 
Watkins et al., 2007).  As such, the reduced ICM:TE ratio caused by exposure to IFN-γ 
suggests that implantation potential and postnatal physiology could be affect if an 
embryo was exposed to similar concentrations of IFN-γ in vivo.  Transfer of embryos 
cultured in IFN-γ into pseudopregnant females would enable implantation potential and 
postnatal offspring phenotype to be assessed.   
The remainder of this thesis (Chapters 4, 5 and 6) concerns the in vivo model of 
maternal systemic infection during preimplantation gestation and the pre- and 
postnatal consequences to the offspring.  To model maternal systemic inflammation in 
vivo, saline (control) 10, 50 or 150 μg/kg lipopolysaccharide (LPS) was administered 
intraperitoneally (i.p.) to female mice on gestational day 0.5 (GD 0.5).  The maternal 
response to LPS administration was investigated in Chapter 4.  The findings confirmed 
the induction of an inflammatory response by these doses of LPS and indicated that 
the maternal APR during very early gestation is comparable to that typically observed 
in non-pregnant mice following i.p. injection of LPS within a similar dosage range.  
Interestingly, locomotor activity at 1 hour post-injection, food consumption over the 
first 24 hours post-injection and normalised body weight at 24 hours post-injection 
were reduced by an equivalent amount in all maternal LPS treatment groups, whereas 
many of the serum cytokines examined were significantly increased only in the   173 
mothers that received the highest LPS dose, i.e. 150 μg/kg.  The latter observation 
thus placed maternal cytokines, rather than acute under-nutrition (due to the LPS-
induced anorectic effect), as potential key mediators of LPS-dose dependent 
phenotypic changes seen in later experiments.  However, when studying the effects of 
maternal challenge on offspring development, it is not the status of the mother per se 
that is important, but rather how changes in the maternal compartment alter the 
uterine environment.  Indeed, a key study highlighted that there is strict 
compartmentalisation of many cytokines in the uterine fluid compared with serum in 
the mouse during estrus, for example, the concentration of G-CSF in uterine fluid was 
173-fold greater than in serum (Orsi et al., 2007).  As such, it will be extremely 
important to determine the cytokine composition of the maternal uterine fluid following 
systemic administration of LPS.  In doing this, insight would be gained into the 
composition of the preimplantation embryo’s immediate surroundings and would thus 
help to identify more precisely potential mechanisms involved in offspring phenotype 
induction.   
The effects of maternal inflammation during early gestation on prenatal 
development are presented in Chapter 5.  The main finding in this part of the project 
was that all LPS doses resulted in significantly reduced ICM cell number and ICM:TE 
cell ratio in the GD 3.5 blastocyst.  No experiments were performed in the present 
study to determine the cause of the reduction in ICM cell number; therefore it would 
be interesting to do Annexin V labelling or TUNEL in order to assess the extent of 
apoptosis in these blastocysts.  Reduction in ICM cell number has potentially far 
reaching consequences because all fetal tissues derive from the ICM and reductions in 
this lineage deplete the available pool of stem cells, potentially resulting in delayed 
and/or reduced growth and development (Hishinuma et al., 1996; Power and Tam, 
1993; Tam, 1988).  However, it is likely that increased post-implantation cell 
proliferation was able to compensate for the earlier low blastocyst ICM cell number 
(Hishinuma et al., 1996; Power and Tam, 1993; Tam, 1988) because no gross effects 
were found in GD 17 fetal phenotype, in terms of litter size, weight of conceptus, fetus, 
placenta, yolk sac, fetal liver, fetal brain or fetal kidneys.  Other studies have indicated 
that treatments which result in altered blastocyst cell number can also result in altered 
postnatal physiology (Kwong et al., 2000; Watkins et al., 2007).  This was also true in 
the present study, as altered phenotype was evident in the offspring postnatally.     174 
The evidence presented in the final results chapter (Chapter 6) showed, for the first 
time, that maternal inflammation during early gestation can alter diverse aspects of 
postnatal offspring phenotype.  Offspring from mothers treated with 150 μg/kg LPS 
were particularly affected, and in most cases male offspring were affected to a greater 
extent than females.  The major findings were as follows:  male offspring from 150 
μg/kg LPS treated mothers displayed reduced locomotor and exploratory-related 
behaviour, increased fat-pad mass (retro-peritoneal and inguinal fat/body weight 
ratios), increased BMI, reduced serum cytokine concentrations, reduced percentage of 
splenic B lymphocytes and increased percentage of splenic T helper lymphocytes 
(CD4
+).  For female offspring the only major finding was reduced serum cytokine 
concentrations in offspring from all LPS treated mothers.  The increased mass of 
certain fat-pads hints that there may be metabolic alteration in these animals.  Thus, it 
would be interesting to investigate serum levels of leptin, insulin, glucose and 
corticosterone, and to assess glucocorticoid receptor expression in the hippocampus 
and hypothalamus.  The alterations in offspring immune status are a particularly novel 
and interesting finding, not only because the same animals also have behavioural and 
body structure abnormalities, but also because the offspring immune system has 
received very little attention in the DOHaD literature.  The immune disregulation seen 
in this study warrants further study as the reasons for the changes seen here are not 
clear at present.   
In several examples of DOHaD-related programming of offspring phenotype, 
epigenetic mechanisms have been shown to be the molecular basis underpinning 
physiological plasticity (Lillycrop et al., 2008; Lillycrop et al., 2007).  It will be 
interesting to evaluate whether the altered offspring phenotype discovered in my work 
can be explained by epigenetic processes.  Other elements that should be investigated 
(from the findings in Chapter 6) include concentrations of other cytokines (e.g. IFN-α 
and β, TGF-β), antibody levels and the complement system.  In addition, FACS analysis 
of T and B lymphocytes in blood, bone marrow, thymus and lymph nodes could be 
analysed to assess if the same patterns are observed in these tissues as have been 
seen in the spleen.  This analysis could be extended by trying to assess more precisely 
the different lymphocyte subtypes, e.g. are the increased CD4
+ T cells mainly CD25
high 
FOXP3
+ regulatory T cells (Tregs)?  Furthermore, innate immune cells (monocytes, 
macrophages, dendritic cells, natural killer cells) should be assessed further, especially 
when considering the reduced levels of cytokines seen in this study.  In addition, the 
various cell types could be isolated and studied ex vivo in order to delineate the   175 
cytokine producing abilities of each cell type separately.  By doing this it may be 
possible to pinpoint more precisely the source of the immune disregulation.  In 
addition, it would be interesting to assess the immune response to different challenges 
(e.g. PolyI:C as a viral mimic and SRBCs or ovalbumin as a T-cell-dependent stimulus) 
and at different ages (perhaps neonatally and at adolescence).  Finally, only one time 
point was examined in the present study, thus some of the observed cytokine 
differences may be due to altered kinetics.  The kinetics of the immune response could 
be examined by performing a time course assay post-immune challenge.   
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Appendix I 
Pregnant mare serum gonadotropin (PMSG; Intervet) 
1 vial contained 5000 IU PMSG in freeze-dried form. 
This was reconstituted with 20 ml of sterile 0.85% Sodium Chloride (NaCl) solution 
(saline) to give 250 IU/ml.  Aliquots of 400 µl were prepared and stored at -20°C.   
When required, one 400 µl aliquot of PMSG was defrosted and diluted with 1.6 ml of 
sterile 0.85% saline (to yield 50 IU/ml).  For superovulation, 100 µl (5 IU) of this 
PMSG solution was injected intraperitoneally. 
Human chorionic gonadotropin (hCG; Intervet) 
1 vial contained 1500 IU hCG in freeze-dried form 
This was reconstituted with 3 ml of sterile 0.85% Sodium Chloride (NaCl) solution 
(saline) to give 500 IU/ml.  Aliquots of 200 µl were prepared and stored at -20°C.   
When required, one 200 µl aliquot of hCG was defrosted and diluted with 1.8 ml of 
sterile 0.85% saline (to yield 50 IU/ml).  For superovulation, 100 µl (5 IU) of this hCG 
solution was injected intraperitoneally. 
H6-BSA 
Stock B (stored at 4-8°C for up to 2 weeks) 
Deionized  water,  sterile      10  ml 
Sodium hydrogen carbonate (NaHCO3)     0.2106  g 
Stock E (stored at 4-8°C for up to 3 months) 
Deionized  water,  sterile      50  ml 
Hepes         2.9785  g 
Stock F (stored at 4-8°C for up to 3 months) 
Sodium  chloride  (NaCl)      4.720  g 
Potassium chloride (KCl)      0.110  g 
Sodium dihydrogen orthophosphate (NaH2PO4.2H2O) 0.060  g 
Magnesium chloride (MgCl2)      0.100  g 
D-glucose        1.000  g   190 
D L - l a c t i c   a c i d         3 . 4   m l  
Deionized water, sterile          Made-up to 100 ml 
Stock G (stored at 4-8°C for up to 2 weeks) 
Deionized  water,  sterile      10  ml 
Pyruvic  acid        0.030  g 
Penicillin        0.060  g 
Streptomycin        0.050  g 
Stock H (stored at 4-8°C for up to 3 months) 
Deionized  water,  sterile      10  ml 
Calcium chloride dihydrate (CaCl2.2H2O)     0.260  g 
20% Sodium Chloride 
Deionized  water,  sterile      10  ml 
Sodium  chloride  (NaCl)      2.0  g 
To prepare 100 ml of H6-BSA: 
Deionized  water,  sterile      78  ml 
Stock  B        1.6  ml 
Stock  E       8.4  ml 
S t o c k   F        1 0   m l  
Stock  G        1.0  ml 
Stock  H        1.0  ml 
20% Sodium chloride (NaCl)      0.6  ml 
BSA (Sigma, embryo culture tested, A3311)    0.4 g 
pH adjusted to 7.4; osmolarity adjusted to 270-280 mOsm; sterile filtered (0.22 µm 
filter); aliquots stored at 4°C. 
KSOM culture medium 
2x stock KSOM 
Sodium  chloride  (NaCl)      1.110  g   191 
Potassium chloride (KCl)      0.0373  g 
Potassium dihydrogen orthophosphate (KH2PO4)   0.0095  g 
Magnesium sulphate 7-hydrate (MgSO4.7H2O)   0.0099  g 
Lactic  acid        0.362  ml 
Sodium  pyruvate       0.0044  g 
Glucose        0.0072  g 
Sodium bicarbonate (NaHCO3)     0.420  g 
Penicillin        0.01256  g 
S t r e p t o m y c i n         1   m l  
E D T A          4   m l  
Tissue culture grade water          Made-up to 100 ml 
5 ml aliquots stored at -80°C for up to 2 months. 
1x KSOM (10 ml) 
The following was added to 5 ml of thawed 2x KSOM stock: 
Calcium chloride (CaCl2; 100x stock 25 mg/ml)    100 µl 
Non-essential amino acids (100x stock; 10 mM)    50 µl 
Essential amino acids   (50x stock)        100 µl 
L-glutamine  (200  mM)      50  µl 
Deionized  water,  sterile      4.75  ml 
BSA         0.040  g 
Sterile filtered (0.2 µm filter); osmolarity adjusted to 255±5 mOsm with 20% NaCl; 
aliquots stored at 4°C for up to 1 week. 
Trinitrobenzene Sulphonic Acid (TNBS) 
TNBS is also known as Picrylsulfonic acid. 
Diluted 1:10 in PBS with 0.1% polyvinylpyrrolidone (PVP). 
pH adjusted to 7.4 with Sodium Hydroxide (NaOH); stored in the dark at 4ºC.   192 
Guinea pig complement  
Reconstituted in 1 ml of ice-cold water. 
Diluted 1:10 in cold H6-BSA; stored at -80°C. 
Propidium Iodide  
1 mg/ml in distilled water; aliquots stored in the dark at 4°C. 
Hoechst 33258 (bisBenzimide H 33258) 
2.5 mg/ml in distilled water; aliquots stored in the dark at -20°C. 
ACK buffer for lysis of red blood cells 
Deionized  water      1  L 
Ammonium Chloride (NH4Cl)     8.29  g 
Potassium Hydrogen Carbonate (KHCO3)   1  g 
Sodium-EDTA (Na2-EDTA)     37.2  mg 
pH adjusted to 7.2-7.4; sterile filtered (0.2 µm filter); stored at 4°C. 
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Appendix II 
Induces the production 
of cytokines and 
hematopoietic molecules 
from non-immune cells
T cells IL-17
Anti-inflammatory, 
upregulates IgE
production by B cells
T cells (Th2), mast cells 
and NK cells
IL-13
Induces differentiation of 
Th1 T cells, induces the 
production of IFN-γ  from 
T cells and NK cells
Monocytes, 
macrophages, DCs, B 
cells
IL-12 p70
p40 homodimer
antagonises the actions 
of IL-12 p70
Monocytes, 
macrophages, DCs, 
neutrophils, non-immune 
cells
IL-12 p40
Stimulates proliferation 
of B cells and mast cells, 
contributes to IgA
synthesis and secretion 
by B cells, antagonises
generation of Th1 cells
T cells (CD4+ Th2 and 
CD8+), B cells, 
macrophages and 
monocytes, monocytes
IL-10
Proliferation of T cells 
and erythroid precursors
T cells (Th2) IL-9
Proinflammatory, 
induces APR, B cell 
differentiation and 
antibody production, 
hematopoiesis.
Macrophages, 
monocytes, T cells and B 
cells, some non-immune 
cells
IL-6
Hematopoietic growth 
factor specifically for 
eosinophils
T cells (Th2), mast cells, 
eosinophils
IL-5
Promotes growth and 
development of T and B 
cells, immunoglobulin 
class switch to IgG1 and 
IgE.
T cells (Th2), mast cells, 
bone marrow stromal
cells
IL-4
Hematopoietic growth 
factor for myeloid 
lineage cells
T cells, mast cells, 
eosinophils
IL-3
Stimulates growth and 
differentiation of T cells, 
B cells and NK cells
T cells IL-2
As for IL-1α As for IL-1α IL-1β
Proinflammatory, 
induction of fever and 
APR, induces IL-2 
release, B cell 
maturation and 
proliferation 
Monocytes, 
macrophages, DCs, T 
and B cells, NK cells, 
some non-immune cells
IL-1α
Main Activities Main sources Cytokine
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T cells (Th2), mast cells, 
eosinophils
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Proinflammatory, growth 
and differentiation of a 
wide variety of cells, 
cytotoxic for many types 
of transformed cells 
Monocytes, 
macrophages, T cells, B 
cells, non-immune cells
TNF-α
Chemoattracts
monocytes, memory T 
cells, basophils and 
eosinophils
Activated immune and 
non-immune cells
RANTES (CCL5)
Chemoattracts and 
activates CD4+ T cells, 
NK cells, monocytes, 
macrophages, DCs, B 
cells, eosinophils
Activated immune and 
non-immune cells
MIP-1β (CCL4)
Chemoattracts and 
activates CD8+ T cells, 
NK cells, monocytes, 
macrophages, DCs, B 
cells, eosinophils
Activated immune and 
non-immune cells
MIP-1α (CCL3)
Chemoattracts and 
activate monocytes, DCs, 
basophils, NK cells and T 
cells
Activated immune and 
non-immune cells
MCP-1 (CCL2)
Chemoattracts and 
activates neutrophils and 
basohils
Monocytes, 
macrophages, DCs, non-
immune cells
KC (CXCL1)
Upregulates MHC 
expression, affects 
activation, growth and 
differentiation of T cells, 
B cells and macrophages
T cells (Th1 CD4+ and 
CD8+), NK cells
IFN-γ
Hematopoietic factor for 
growth and 
differentiation of 
granulocytic and 
monocytic cells
Monocytes, 
macrophages, T cells, 
non-immune cells
GM-CSF
Hematopoietic factor for 
growth and 
differentiation of 
neutrophils
Macrophages, bone 
marrow stromal cells, 
non-immune cells
G-CSF
Chemoattracts
eosinophils
TNF-activated 
monocytes, IFN-γ
stimulated endothelial 
cells
Eotaxin (CCL11)
Main Activities Main sources Cytokine
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